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Background: The Female Self-Advocacy in Cancer Survivorship (FSACS) Scale is a new 
measurement tool designed to address the increasing need for cancer survivors to participate in 
and lead there care in face of barriers. Pilot work has demonstrated the FSACS Scale’s content 
validity and reliability. 
Purpose: This purpose of this study was to evaluate the construct validity of the FSACS Scale. 
This instrumentation study evaluates the construct validity of the FSACS Scale as evidenced by: 
(I) Internal structure consistent with the underlying model of self-advocacy; (II) Sensitivity to 
differences between known groups; (III) Relationships between self-advocacy and key predictors 
(openness and conscientiousness; information engagement; social support) and outcomes 
(symptom distress and healthcare utilization); (IV) Relationships between FSACS subscales and 
related concepts (patient activation; self-advocacy within the HIV/AIDS population); and (V) 
Relationships between FSACS scores and criterion measures. 
Methods: A mixed-mode (online or mailed) cross-sectional survey design was used. Women 
with a history of an adult diagnosis of invasive cancer were recruited from two patient registries 
and seven advocacy organizations. Instrument selection and analyses to evaluate construct 
validity were based on the American Educational Research Association’s instrumentation 
guidelines. Analyses included an exploratory factor analysis, t-tests, and bivariate correlations.  
DEVELOPMENT OF A MEASURE OF SELF-ADVOCACY 
AMONG FEMALE CANCER SURVIVORS 
Teresa Louise Hagan, PhD, RN 
University of Pittsburgh, 2015
v 
Results: A total of N = 315 adult female cancer survivors completed the survey. Evidence from 
all five construct validity hypotheses supports the construct validity of the FSACS Scale. The 
FSACS Scale factor analysis confirmed the three underlying dimensions of self-advocacy 
resulting in a 20-item measure explaining 45.87% of the variance in responses with subscales’ 
Cronbach’s alphas between 0.791 and 0.850. While able to detect differences between women 
with low and high levels of education, the scale did not differentiate between recent and long-
term survivors. Predictor and outcome variables performed as expected. The FSACS subscales 
were more highly correlated with these outcomes than the measure of self-advocacy for 
HIV/AIDS. 
Conclusion: Results support that the FSACS Scale is a theoretically-grounded measure of self-
advocacy that can be used by clinicians and researchers to identify women at-risk for the poor 
outcomes associated with low self-advocacy.  
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Nomenclature 
The term “cancer survivor,” as defined by the National Institute of Cancer is anyone from the 
time of diagnosis until the end of life. 
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1.0  INTRODUCTION 
1.1 SPECIFIC AIMS 
Currently, more than 6.8 million adult women are living with a history of cancer in the U.S. 
(Jemal, Siegel, Xu, & Ward, 2010). Female survivors face significant barriers to achieving 
optimal, high-quality, patient-centered cancer treatment and care including disparities in 
recognition and treatment of symptoms (Cleeland et al. 1994; Donovan, Hartenbach, & Method, 
2005; Miaskowski, 2003; Paulson, Wirtalla, Armstrong, & Mahmoud, 2009; Skalla, Bakitas, 
Furstenberg, Ahles, & Henderson, 2003; Yeom & Heidrich, 2009). Survivors must invest 
significant personal involvement in order to manage the complexities of treatment decisions, 
treatment side-effects, and a fragmented healthcare system on top of facing considerable life 
disruptions, financial burdens, and long-term survivorship issues (Aranda et al., 2005; Ferrell, 
Koczywas, Borneman, Piper, & Uman, 2010; Ferrell, Smith, Cullinane, & Melancon, 2003; 
Hewitt & Simone, 1999; Pigott, Pollard, Thomson, & Aranda, 2009; Saatci, Akin, & Akipinar, 
2007; Sherwood, Donovan, Rosenzweig, Hamilton, & Bender, 2008; Stovall, Greenfield, & 
Hewitt, 2005; Wen & Gustofson, 2004). Self-advocacy is a concept uniformly encouraged by 
healthcare professionals (Clark & Stovall, 1995), cancer advocacy organizations (American 
Society of Clinical Oncology, 2012; Shapiro et al., 2009), and policy organizations (Institute of 
Medicine, 2001) as a means of addressing such barriers to quality, patient-centered cancer care. 
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However, a critical disconnect exists between the expectation and ability of female cancer 
survivors to self-advocate for their cancer care.  
Despite being roundly prescribed as a remedy for achieving quality cancer care and 
symptom management, the term self-advocacy remains largely unexamined among female 
cancer survivors. Among the HIV/AIDS, disability, and mental health populations’ self-
advocacy has been shown to be a modifiable factor associated with positive outcomes such as 
improved symptom relief, quality of life, and effective use of healthcare resources (Brashers, 
Neidig, & Goldsmith, 2004; Pickett et al., 2010; Test, Fowler, Brewer, & Wood, 2005). 
However, studies also show that women are at particular risk for poor self-advocacy 
(Mendelson & Poole, 2007; Rosenzweig, Wiehagen, Brufsky, & Arnold, 2009; Sinding, Miller, 
Hudak, Keller-Olaman, & Sussman, 2012; Wade, 2001; Wiltshire, Cronin, Sarto, & Brown, 
2006). Even with a strong basis in other populations, attempts at translating previous 
conceptualizations of self-advocacy to the cancer population have shown distinct incongruities 
(Hermansen-Kobulnicky, 2008). The PI’s pilot work studying self-advocacy in cancer 
survivorship (Hagan & Donovan, 2013a) and specifically among female survivors (Hagan & 
Donovan, 2013b) further demonstrates this population’s unique experiences of and barriers to 
self-advocacy including difficulty asserting needs to others and the additional demands of being 
a caregiver.  
One major barrier to examining self-advocacy is that no valid, reliable measurement tool 
exists specific to female cancer survivors. This lack of clear conceptualization of the construct of 
this population’s distinct form of self-advocacy and an associated measurement tool prevents the 
development and testing of evidence-based interventions to improve self-advocacy among 
female survivors and to improving quality cancer care. The Patient Self-advocacy Scale (PSAS) 
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(Brashers, Haas, & Neidig, 1999) originally developed in the context of patients with HIV, 
captures some essential dimensions, however it does not adequately capture the unique 
characteristics of self-advocacy in cancer survivors in general (Hermansen-Kobulnicky, 2008), 
and female survivors in particular (e.g. few items focus on females’ unique symptom 
experiences, propensity for social connectivity, and roles as caretakers and mothers) (DeMarco, 
Miller, Patsdaughter, Chisholm, & Grindel, 1998; Wade, 2001). Notably, the original measure 
was based on an 89% male sample.  
Following a comprehensive literature review and concept analysis of self-advocacy and a 
focus group study of ovarian cancer survivors, the candidate (Hagan) has developed an initial 
measure of self-advocacy, the Female Self-Advocacy in Cancer Survivorship (FSACS) Scale. 
The scale’s content validity has been analyzed using an 8-member expert panel of female 
survivors, clinicians, researchers, and advocates. The scale includes 3 key dimensions specific to 
cancer survivors and females: 1) the application of information, 2) mindful non-adherence, and 
3) connected strength. The FSACS Scale’s reliability has been tested among a sample of 40 adult
female cancer survivors. Initial evaluations indicate that the test-retest reliability is strong (r = 
0.94, p<.001). The scale’s internal consistency demonstrates a strong degree of common variance 
among items (Cronbach’s alpha = 0.92). Item revision and reduction based on the item and scale 
reliability findings along with cognitive interviews will be completed prior to the proposed 
construct validity study. The FSACS Scale’s validity has yet to be examined.  
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1.2 PURPOSE 
The purpose of the proposed instrumentation study is to evaluate the construct validity of the 
FSACS Scale in a diverse sample of adult female cancer survivors (N = 300). Validity will be 
evaluated based on the following hypotheses (illustrated in red in Figure 1):  
1. The internal structure of the FSACS Scale should be consistent with the three proposed
theoretical dimensions of self-advocacy;
2. FSACS Scale scores should be significantly higher for survivors who have increased time
since diagnosis and higher levels of education compared to newly diagnosed women and
women with less education, respectively;
3. FSACS Scale scores should be positively associated with survivors who are open to new
ideas, conscientious, engaged in health information, have available social support.
FSACS Scale scores should be negatively associated with symptom severity and
interference and healthcare utilization;
4. Higher scores on the FSACS Scale should scores be positively associated with scores on
a measure of patient activation. Subscale scores between the FSACS Scale and the
previous patient advocacy should vary according to the level of similarity between the
old and new subscales; and
5. FSACS Scale scores should be more highly correlated with outcome measures of
symptom severity and interference and healthcare utilization than the PSAS total score.
The proposed instrument will provide a new means to assess self-advocacy that
incorporates female-specific aspects of self-advocacy. This scale will advance the science by 
providing a means to: 1) identify key components of self-advocacy among female cancer 
survivors, 2) evaluate the impact of self-advocacy on patient outcomes including symptom 
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management and healthcare utilization, and 3) identify individuals at risk for poor outcomes 
associated with low self-advocacy.  
This study directly addresses the National Institute of Nursing Research’s focus on 
improving symptom management and patient outcomes through an innovative patient-focused 
approach. The development and validation of the FSACS Scale represents the critical first step in 
the candidate’s program of research. Data from this study will inform future research to identify 
at-risk cancer survivors and elements of self-advocacy amenable to intervention in order to 
improve patient outcomes. 
  
  6 
1.3 BACKGROUND, SIGNIFICANCE & INNOVATION 
1.3.1 Background 
The Institute of Medicine (IOM) asserted that within the new model of healthcare “control 
should reside with patients” because this has been associated with better outcomes and lower 
costs (Institute of Medicine, 2001). In cancer, momentum toward greater patient advocacy has 
resulted in interventions to improve patient self-advocacy from the LIVESTRONG Foundation 
(Shapiro et al., 2009), American Society of Clinical Oncology (2012), National Coalition for 
Cancer Survivorship (2015), and international organizations (Errico & Bowden, 2006; McNally, 
1996). Yet for all the attention paid to self-advocacy and attempts to promote it, clinicians 
continue to have difficulty fostering self-advocacy because we lack a validated instrument to 
measure changes in this concept, especially among female cancer survivors. 
Self-advocacy has been studied in other populations and shown to be an important and 
modifiable characteristic. Self-advocacy, understood at a simplistic level as “standing up for 
one’s self”, has a strong theoretical and clinical foundation in other patient populations as a 
modifiable factor important to improving health outcomes. Pickett et al. (2010) demonstrated 
that an 8-week course in self-advocacy among mental health consumers decreased symptoms, 
improved coping skills, and increased empowerment. Additional research in self-advocacy 
among disability and HIV/AIDS populations has demonstrated improved symptom management, 
quality of life, treatment adherence, and effective use of healthcare resources (Test, Fowler, 
Brewer, & Wood, 2005; Walsh-Burke & Marcusen, 1999).  
There is a lack of research in self-advocacy among cancer survivors: Self-advocacy has 
been widely adopted by oncology clinicians (Balough et al., 2011; Cartwright & Allotey, 2006; 
Clark & Stovall, 1996; Haggstrom & Doebbeling, 2011), policy makers (McCabe, Varricchio, 
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Padberg, & Simpson, 1995; Stovall, Greenfield, & Hewitt, 2005), advocacy organizations 
(O’Hair et al., 2003) and researchers (Green, Hart-Johnson, & Loeffler, 2011; LaFargue, 2010; 
Sinding et al., 2010) as a necessary part of being a cancer survivor. Complex treatment decisions 
and uncertain health outcomes place extraordinarily high demands on survivors. Nevertheless, 
while an appealing means to overcome these challenges, the implicit transfer of responsibility for 
self-advocacy to cancer survivors is not without problems. We risk demanding that patients do 
something we do not yet understand and which may actually lead to adverse outcomes (Sinding, 
Miller, Hudak, Keller-Olaman, & Sussman, 2012). One study demonstrated that when a 
measurement scale based on conceptualizations of self-advocacy in other populations was 
administered to cancer survivors, the scale’s reliability and validity fell and multiple problems 
existed within and between the scale’s dimensions (Hermansen-Kobulnicky, 2008). To meet 
IOM goals and growing demand from clinicians, it is imperative that a conceptual definition 
appropriate for cancer survivors and a corresponding measure of self-advocacy be systematically 
developed and validated for cancer survivors. Only then can we create interventions to improve 
self-advocacy and therefore address the needs of survivors at-risk for the poor outcomes 
associated with low self-advocacy.  
Female cancer survivors have unique needs and are at high risk for not being able to 
self-advocate. Despite advances in cancer survival for both genders, the 6.8 million female 
cancer survivors in the U.S. (Jemal, Siegel, Xu, & Ward, 2010) continue to encounter challenges 
in cancer care and symptom management (Cleeland et al. 1994; Paulson, Wirtalla, Armstrong, & 
Mahmoud, 2009; Seale, Ziebland, & Charteris-Black, 2006). Known gender differences in 
communication, decision-making, and engagement in healthcare may contribute to women’s 
difficulties in self-advocating (Anderson et al., 2004; Cimprich et al., 2005; Elderkin-Thompson 
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& Waitzkin, 1999; Howard, Balneaves, & Bottorff, 2007; Miaskowski, 2003; O’Brien et al., 
2008; Skalla, Bakitas, Furstenberg, Ahles, & Henderson, 2003; Sulik, Cameron, & Chamberlin, 
2012; Wade, 2001). Specific groups of females, including those of low socio-economic status 
and minority survivors, are less likely to have the tools to self-advocate, placing them at higher 
risk for poor outcomes (Deshields, Potter, Olsen, Liu, & Dye, 2011; Jones & Johnson, 2012; 
Rosenzweig, Wiehagen, Brufsky, Sillaman, & Arnold, 2009). Despite these distinct challenges 
and needs, no mechanism currently exists to quantify how these needs affect patient outcomes or 
to create profiles of women at greatest risk for poor outcomes.  
Previous measures of self-advocacy (e.g. the Patient Self-Advocacy Scale, PSAS) 
developed among individuals with HIV/AIDS were based on male conceptualizations of power, 
coping, and risk assessment (Brashers, Haas, & Neidig, 1999; Brashers, Neidig, & Goldsmith, 
2004). Two dimensions of the PSAS (“information-seeking” and “mindful non-adherence”) were 
reflected in prior work of the candidate (concept analysis, focus groups findings); however, the 
third dimension (“assertiveness”) was not. This lack of congruence between previous measures 
such as the PSAS and the experiences of female cancer survivors appears to be caused by two 
factors: 1) inability to identify gender differences in self-advocacy with a sample comprised of 
89% males; and 2) a lack of attention to factors unique to cancer survivorship. A new measure is 
required that focuses on the distinct phenomenon of self-advocacy among female cancer 
survivors.  
Self-advocacy is required in symptom management: The ability to self-advocate may 
affect myriad aspects of cancer survivorship including the ability to achieve adequate cancer 
symptom management. Cancer- and treatment-related symptoms are known to co-occur; change 
over time; influence multiple domains of patients’ lives; and require vigilance and persistence on 
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the part of the survivors to achieve symptom relief (DeFlorio & Massie, 1995; Donovan, 
Hartenbach, & Method, 2005; Ferrell, Koczywas, Borneman, Piper, & Uman, 2010). Research 
demonstrates that achieving effective symptom relief remains challenging for females. 
Significant patient- and system-level barriers exist including physiological differences in pain 
sensitivity, analgesic effectiveness, incomplete provider assessment, lack of effective treatments, 
and poor patient-provider communication (Anderson et al., 2000; Cheung, Le, Gagliese, & 
Zimmerman, 2011; Cleeland et al. 1994; Duncan, Forbes-Thompson, & Bott, 2008; Donovan, 
Hartenbach, & Method, 2005; Ferrell, Koczywas, Borneman, Piper, & Uman, 2010; Ferrell, 
Smith, Cullinane, & Melancon, 2003; Komurcu et al., 2000; Miaskowski, 2004; Shoemaker, 
Estfan, Induru, & Walsh, 2011; Yeom & Heidrich, 2009). Female subjects in Dr. Donovan’s 
study reported a mean of 14 ± 4.84 concurrent symptoms with 5.6 ± 4.35 of these rated as ≥5 (0-
10 severity scale). However, women received management recommendations for only 15-33% of 
these symptoms. These statistics are disheartening given the documented negative impact of 
symptoms on function and quality of life (Ferrell, Koczywas, Borneman, Piper, & Uman, 2010; 
National Institute of Nursing Research, 2011; U.S. Public Health Service, 2010; Yeom & 
Heidrich, 2009). Unrelieved symptoms can also lead to healthcare utilization (Sherwood, 
Donovan, Rosenszweig, Hamilton, & Bender, 2008). The goal of this study is to provide a 
theoretically-based measurement tool with the potential to identify these problems and be easily 
integrated into clinical practice.  
In summary, this study addresses a critical disconnect: self-advocacy is widely prescribed 
as a remedy for achieving quality cancer care and symptom management but the concept remains 
under-examined and difficult to quantify for female cancer survivors particularly in the area of 
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symptom management. To date, no valid, reliable scale to measure the ability of female cancer 
survivors to self-advocate exists. 
1.3.2 Significance 
A reliable, valid measure of self-advocacy in female cancer survivors (defined as any woman 
with a history of a cancer diagnosis) is urgently needed. Although self-advocacy is widely 
endorsed by healthcare providers and cancer advocacy organizations as a means of improving 
patient outcomes, the vast majority of research in self-advocacy has been completed in men, with 
an alarming paucity of conceptualization and testing in the female cancer survivor population. 
Without this information, clinicians, researchers, and advocacy organizations are creating and 
promoting self-advocacy interventions based on conceptualizations of self-advocacy that have 
been shown to be non-generalizable to cancer survivors and inconsistent with the experiences of 
self-advocacy in females, inadvertently creating the possibility of doing harm.  
The Female Self-Advocacy in Cancer Survivorship (FSACS) Scale will provide a mechanism for 
answering the role self-advocacy plays in patient outcomes for female cancer survivors by identifying:  
• Female cancer survivors at risk for poor outcomes associated with low self-advocacy; and
• Factors of self-advocacy most amenable to intervention and most capable of reducing the
poor symptom management outcomes known to be experienced by female cancer
survivors.
This study directly addresses the NINR’s goal of improving symptom management
(2011), the IOM’s call for innovative ways to involve patients in their healthcare, and the Office 
of Research on Women’s Health priority of personalized prevention based on individual 
differences in behavior (U.S. Public Health Service, 2010). 
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This study addresses a critical disconnect: self-advocacy is widely prescribed as a remedy 
for achieving quality cancer care and symptom management but the concept remains under-
examined and difficult to quantify for female cancer survivors particularly in the area of 
symptom management. To date, no valid, reliable scale to measure the ability of female cancer 
survivors to self-advocate exists. 
1.3.3 Innovation 
We challenge the idea that self-advocacy is adequately understood among female cancer 
survivors due to its non-specific definition and origin in dissimilar male patient populations. We 
caution that practice and advocacy focusing on current conceptualizations of self-advocacy may 
actually do a disservice to female cancer survivors.  
We propose a new scale of self-advocacy born out of a systematic review of the literature 
and research with female cancer survivors to identify the specific and unique aspects of self-
advocacy within this population. This is the first study to conceptualize and test self-advocacy in 
female cancer survivors and can therefore uncover the characteristics of self-advocacy that are 
important to women and provide critical information for the development of interventions to 
improve self-advocacy. The FSACS Scale has the potential to transform the current approach to 
promoting self-advocacy in clinical practice, advocacy, and research arenas.  
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1.4 PRELIMINARY STUDIES 
In collaboration with her mentoring team and consultation with multiple experts in women’s 
health, cancer survivorship, qualitative research, and instrumentation, the candidate’s prior work 
led to the creation of the FSACS Scale.  
1.4.1 Concept Analysis (Publication #1 in Chapter 3.1) 
First, the candidate conducted a systematic literature review and concept analysis of self-
advocacy to uncover the defining attributes, antecedents, and consequences of self-advocacy and 
their applicability to cancer survivorship (Hagan & Donovan, 2013a). Secondly, she led and 
analyzed focus groups to describe self-advocacy as experienced by female cancer survivors
(Hagan & Donovan, 2013b). Based on these results, key dimensions of self-advocacy were 
selected based on conceptual congruency with the concept analysis, essential and distinct factors 
found in the focus groups, and modifiability of factors for the purposes of future intervention 
studies. 
The construct of self-advocacy among female cancer survivors is defined as a woman’s 
ability to know her body and her needs, and ensuring that both are respected throughout her 
cancer care journey. This process resulted in 3 key dimensions of the FSACS Scale: “application 
of information”, “mindful non-adherence”, and “connected strength” (Table 1). “Application of 
information” refers to the ability of female cancer survivors to gather trustworthy, personally 
relevant information and apply it to their personal experiences and problems related to their 
cancer. “Mindful non-adherence” refers to the survivor’s ability to ask questions and adjust 
provider recommendations to fit her health concerns, needs, and preferences. “Connected 
strength” refers to the survivor’s ability to seek support, give support, balance personal needs 
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with others’ needs, and raise awareness. This dimension incorporates female health psychology 
and women’s experiences expressed during the focus group study (Hagan & Donovan, 2013b). 
These dimensions are distinct from the PSAS as they focus on the application rather than 
possession of information and highlight relational strength rather than individual assertiveness. 
These findings parallel previous literature uncovering the need for gender-specific considerations 
to the ways in which individuals encounter the healthcare system which may marginalize their 
needs and prevent them from receiving optimal care (Carr, 2003; Martin, 1988; Szumacher, 
2006; Sulik, 2007).  
Table 1. FSACS Scale Subscales 
FSACS Subscale # of Items 
Item 
response 
options/Level of 
Measurement 
Corresponding PSAS 
Subscale 
1. Application of information 16 6-point Likert-type Ordinal Illness education 
2. Mindful non-adherence 21 6-point Likert-type Ordinal Mindful non-adherence 
3. Connected strength 20 6-point Likert-type Ordinal Assertiveness 
1.4.2 Justification of Predictors and Outcomes of Self-Advocacy 
Key predictors established in the literature include demographic characteristics (e.g. education, 
income, race/ethnicity) (Hibbard & Cunningham, 2008; McConigley et al., 2011; Wiltshire, 
Cronin, Sarto, & Brown, 2006), openness & conscientiousness (Hagan & Donovan, 2013b; 
Osborne, Elsworth, Kissane, Burke, & Hooper, 1999; Test, Fowler, Brewer, & Wood, 2005) 
engagement in information (Clark & Stovall, 1995; Haggstrom & Doebbeling, 2011; Radina, 
Ginter, Brandt, Swaney, & Longo, 2011; Vessey & Miola, 1997) and availability of social 
support (Brashers, Neidig, & Goldsmith, 2004; Hagan & Donovan, 2013b; Lythcott, Green, & 
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Kramer Brown, 2003; Sulik, 2007). Documented outcomes of self-advocacy in other patient 
populations that are posited to be relevant to female cancer survivors include improved symptom 
management (Hagan & Donovan, 2013b; Hibbard, Greene, & Tusler, 2009; Tschopp, Frain, & 
Bishop, 2008) and decreased healthcare utilization (Hibbard & Cunningham, 2008; Hibbard, 
Greene, & Tusler, 2009; Mutchler et al., 2011). 
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Figure 1. Measurement Model of the Female Self-Advocacy in Cancer Survivorship Scale with Hypotheses for 
Validity Testing 
While other outcomes of self-advocacy are likely to exist, these outcomes were selected 
because they are proximal, significant, defined, and specific to cancer symptom management. 
The measurement model of self-advocacy (Figure 1) illustrates how the 3 dimensions are related 
to key predictors and outcomes from the literature and pilot work. 
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1.4.3 Initial Item Creation & Evidence of Validity Based on Instrument 
Content (Unpublished Manuscript #3 in Chapter 3.3) 
A large set of items was developed to encompass the breadth and depth of each dimension of 
self-advocacy using items specific to cancer survivorship (see Appendix A for all items). Item 
wording was based on the overall measurement model, content analysis, focus groups, and 
content validity experts’ opinions.  
Likert-type scaling was used to form a continuum ranging from 1 (strongly disagree), 2 
(disagree), 3 (somewhat disagree), 4 (somewhat agree), 5 (agree), to 6 (strongly agree). Six 
response options were selected in order to capture variability and discriminate meaningfully 
between respondents. Negatively worded items and reverse coded items were included. Varying 
levels of difficulty (or how hard the action or belief described in an item would be for a survivor) 
were included to differentiate between levels of self-advocacy. An even number of response 
options was selected to avoid a neutral response option and require directionality of response 
(agree or disagree). 
Content validity of this scale was evaluated using 8 experts including 3 female cancer 
survivors, 2 clinicians, 2 researchers, and 1 patient advocate. Each expert panelist was sent a 
copy of the preliminary FSACS Scales and asked to review each item and the scale as a whole. 
Each item was rated for relevancy and clarity using a 4-point Likert-type scale (1 = not 
relevant/clear to 4 = very relevant/clear) and space was given for comments. Lynn’s (1986) 
methodology was used to calculate the Content Validity Index (CVI). The CVI was determined 
for each scale item and the entire scale. Based on Lynn’s criteria, a CVI of 0.78 (or 7 of the 9 
panelists) indicates adequate endorsement of an item or the instrument beyond the 0.05 level of 
significance.  
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Based on panelist feedback, 22 items had ≥ 3 panelists rate relevancy as a 1 or 2. 
Interestingly, 5 items from the previous self-advocacy measure (PSAS) received low-rankings 
from the panelists. Fourteen items were deleted due to low CVI, redundancy of items, and 
inclusion of items that were determined to be outcomes of self-advocacy rather than behaviors of 
self-advocacy. Thirteen items were reworded, mainly to soften adversarial language, improve 
specificity, and include action-orientation. Also of note, 3 items were preserved despite low 
ratings because of disagreement between researchers and survivors. For example, the item “I 
don’t know enough to make decisions about my cancer and treatment” (reverse scored) was 
endorsed by survivors but not researchers. 
Table 2 reports the CVI statistics for the revised FSACS Scale. The CVI was calculated 
in multiple ways to account for the item-level and scale-level variations in expert ratings of 
the FSACS Scale’s relevancy. The Average Scale-CVI (S-CVI/Ave) was calculated by averaging 
the proportion of experts rating each individual item as relevant (rating of 3 or 4). In other words, 
the S-CVI/Ave is equal to the average of each of the individual item CVIs (I-CVI). The 
Scale-CVI/Universal Agreement (S-CVI/UA) was calculated as the proportion of items 
rated as relevant (rating of 3 or 4) by all 8 experts (Polit & Beck, 2006). Both the S-CVI/Ave 
(0.81) and S-CVI/UA (0.83) were above the recommended cut-off level of 0.78. 
Table 2. CVI Statistics of FSACS Scale 
Type of CVI Statistic Calculation 
Average Scale-CVI (S-
CVI/Ave) 0.81 
Average proportion experts rating each item as 
relevant (rating of 3 or 4). 
Scale-CVI Universal 
Agreement (S-CVI/UA) 0.83 
Proportion of total items judged by all experts as 
relevant (rating of 3 or 4) 
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Pilot testing of the final 57 items was conducted with a group of masters-prepared nurses, 
research staff, and staff at the University of Pittsburgh School of Nursing as final check for 
readability, grammar, spelling, and formatting.  
1.4.4 Evaluation of Reliability (Unpublished Manuscript #3 in Chapter 3.3) 
Reliability testing was performed in order to 1) evaluate internal consistency and test-retest 
reliability of the FSACS Scale; 2) evaluate the feasibility of assessing self-advocacy and related 
measures necessary for instrument validation; and 3) produce a parsimonious scale to be 
validated in the candidate’s dissertation.  
Design: A repeated measure design with baseline and 2-week measures was used. Time 
points were chosen to test the scale’s consistency (test-retest reliability) within a time period in 
which little variation is thought to occur (DeVillis, 2012).  
Sample: Subjects (N = 40) were recruited from three cancer clinics (two at Magee 
Women’s Hospital of UPMC and Passavant Hospital) and members of four advocacy and cancer 
organizations (Gilda’s Club of Western PA, National Ovarian Cancer Coalition of Pittsburgh, 
Urban League of Greater Pittsburgh, and the African American Women Speaker’s Bureau). Two 
women who were approached at the clinics refused to participate, both due to time constraints 
while at the clinic.  
Inclusion Criteria: 1) female, 2) at least 18 years old, and 3) have a history of a cancer 
diagnosis at age 18 or older (younger cancer survivors are likely to differ in their responses).  
Exclusion Criteria: 1) unable to complete questionnaires in English (only English 
version) or 2) have a diagnosis of basal cell carcinoma or cervical intraepithelial neoplasia stage 
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1 (these survivors have inherently different treatment and symptom experiences than other 
cancer survivors).  
Procedures: Directors at clinics and organizations identified potential participants and 
introduced the study to them. Potential subjects who expressed interest in participating were 
introduced to the candidate who then carried out screening and informed consent procedures.  
On Day 1, the candidate screened potential subjects for eligibility. If the inclusion criteria 
were met and the potential participant was interested in participating in the study, written consent 
was obtained. Participants completed all baseline study measures in a private room within the 
clinic or office. The candidate handed all measures to the participant, instructed the participant to 
complete the survey independently, asking the candidate for clarifications or assistance as 
needed. Following completion of the FSACS Scale, the candidate conducted cognitive 
interviews with the participant to review any problems or issues with the items or survey and to 
assess the feasibility of completing the survey. 
After all surveys were complete, the candidate provided the participant with an envelope 
containing the follow-up survey, instructions to complete the survey in 2 weeks (14 days), and a 
pre-addressed, pre-stamped envelope to mail the survey to the candidate. The candidate called 
each participant 2 days before the follow-up survey was to be completed and sent reminder 
postcards 3 and 5 days after the due date if the survey was not received. Participants were sent 
thank you cards with payment after receipt of the follow-up survey. 
Measures (See Table 4 for full description of measures):  
Baseline: a) Demographic questionnaire; b) FSACS Scale; and c) related measures. 
Two-week follow-up: a) FSACS Scale.  
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Analysis: Internal consistency reliability was measured using Cronbach’s alpha for 
summary scores (total scale and proposed subscales), item-total correlations, and the influence of 
each item on total scale and relevant subscale reliability. Test-retest reliability was calculated 
using Pearson’s Product-Moment Correlation. Criteria for reliability were based on standards set 
by Nunnally (1978).  
Results: The sample had a mean age of 57.28 years (SD = 13.16, Observed Range = 25-
89) and 53.8% were married. Considering racial and ethnic background, 12.8% identified as
Black or African American and one woman identified as Hispanic. For education and 
employment status, 20.5% of women had a high school degree or less and only 35.9% were 
working full-time. About 20% (n = 8) of women had a household gross annual income less than 
$30,000. 
Most women (n = 17, 42.5%) had a diagnosis of ovarian cancer, followed by breast 
cancer (n = 15, 37.5%). The remaining eight women reported a variety of six additional cancer 
sites. Almost half of the women were within one year of their cancer diagnosis (n = 19, 47.5%). 
The remaining women were either between 1 and 5 years since diagnosis (n = 11, 27.5%) or 
greater than 5 years since diagnosis (n = 10, 25%). Most women (n = 26, 65%) were receiving 
treatment at the time of survey completion. Seven (12.5%) women had experienced at least one 
recurrence. 
Preliminary evaluations show that the test-retest reliability is strong (r = 0.94), 
indicating that the scale is stable across time points. The scale’s internal consistency 
demonstrates a strong degree of common variance (internal consistency) among items 
(Cronbach’s alpha = 0.92 for the full scale). The three dimensions had Cronbach’s alpha’s of 
0.88, 0.81, and 0.90, respectively. 
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Feasibility and acceptability of completing the FSACS Scale was reported to be high by 
participants. 
Transition to Proposed Study: Based on the findings from reliability testing and cognitive 
interviews, adjustments will made based on Nunnally’s standards of reliability including a 
reduced number of items. Considerations for item deletion include: 1) low item-to-total score 
correlations (<0.30), 2) improved Cronbach’s alphas if item deleted, 3) poor clarity or ease of 
understand from the feasibility data, and 4) large amounts of user-defined missing data (refusal 
or confusion on how to respond). 
1.5 RESEARCH DESIGN & METHODS 
1.5.1 Research Design & Setting 
A cross-sectional design with a sample will be used to evaluate the validity of the FSACS Scale. 
The primary sampling strategy is random sampling followed by purposive sampling based on a 
review of completed questionnaires to ensure adequate representation of important sub-groups. 
All data will be collected through web-based or mailed self-report surveys. 
1.5.2 Population & Sample 
Potential subjects will be identified through 1) cancer and research registries and 2) advocacy 
organization databases.  
1.5.2.1 Sample Size Adequacy No gold standard exists to determine the necessary sample size 
when conducting an instrument validation study. Rather, sample size determination must 
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consider the proposed use of data in the study. Major considerations used to determine the ideal 
sample size for this study include: 1) performing an exploratory factor analysis (Hypothesis 1), 
2) comparing groups of survivors by stage of diagnosis and educational achievement (Hypothesis
2), and 3) evaluating relationships between the FSACS Scale/Subscales and related concepts. 
(Hypotheses 3-5). 
Sample Size for Exploratory Factor Analysis Various ideal sample sizes have been 
suggested for drawing valid conclusions during factor analysis. Table 3 summarizes the most 
commonly cited sample size justifications. 
Table 3. Suggestions for Exploratory Factor Analysis Sample Size 
Author(s) Sample Size Suggestions 
Comrey & Lee (1992) 300 subjects as “good” 
DeVellis (2012) 300 for pilot samples 
Rouquette (2011) generally need 300; for EFA with 3 constructs and >30 items 
Tabachnick & Fidell 
(2001) 300 subjects as rule of thumb 
MacCallum, Widaman, 
Zhang, and Hong (2001) 
difficult to estimate sample size a priori; required sample size needs 
depends in large part to obtained data (i.e. large communalities 
<0.60 and several items for each factor, can reduce the necessary 
sample size) 
Munro (2001) >5 subjects per variable; minimum required in order to perform a factor analysis 
Stevens (2002) 5-20 participants per variable; fewer when component saturation is high 
Based on these suggestions, a sample size of 300 appears adequate given the FSCACS 
Scale’s 3 subscales and 57 items. Even if communalities (the squared multiple correlation among 
items) are low, 300 individuals is adequate to provide reliable correlation coefficients in the 
factor analysis. 
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Sample Size for Group Comparisons and Relationship to Other Concepts The 
sample size must be large enough to perform hypothesis testing for Hypotheses 2-5. These 
hypothesis-driven comparisons will establish construct validity and also be used as pilot data in 
future studies testing the FSACS Scale. For two-tailed t-tests between groups (Hypothesis 2), 
desired confidence level of 95% and 80% power, and anticipated Cohen’s D effect size of 0.45 
(Stevens, 2002) (based on the patient activation literature) a sample size of N = 158 and 
subgroup sample size of n = 79 is needed. Because the sample size of each subgroup (time since 
survival and educational level) will be used in targeted recruitment and checked regularly during 
recruitment, this sample size will be easily reached with the overall goal of N = 300 for the factor 
analysis. For bivariate correlations between scales and subscales (Hypotheses 3-5) using two-
tailed test of significance set at α = 0.05, a correlation coefficient with an acceptable absolute 
error rate of 0.15 (the difference between different scales’/subscales’ correlations) a sample size 
of 223 is needed. A sample size goal of N = 300 will be able to tolerate an absolute error rate of 
0.13. In conclusion, a sample size of N = 300 is large enough to both perform the construct 
validity testing and group comparisons. 
Using a conservative response rate of 30-50% (based on Dillman’s estimate of 74% 
(2002)), an estimated 600 to 1,000 women will be contacted with equal numbers from registries 
and organizational databases.  
1.5.2.2 Inclusion Criteria Identical to the reliability testing study, participants will meet 
inclusion criteria if they are: 1) female, 2) over the age of 18, and 3) have a history of a cancer 
diagnosis after the age of 18. This sample is purposefully broad in order to include of a wide 
variety of cancer sites, survivorship stages, health statuses, ethnicities, socioeconomic status, and 
current disease status (a key principle of instrument development necessary to ensure potential
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 generalizability). Exclusion Criteria: Participants will be considered ineligible if they are 1) 
unable to complete questionnaires in English or 2) have a diagnosis of basal cell carcinoma or 
cervical intraepithelial neoplasia stage 1 because these survivors are expected to have inherently 
different experiences than other female cancer survivors. 
Sampling procedures are designed to limit the risk of coverage error and sampling error. 
Coverage error (or failure to randomly sample from the population of interest) and sampling 
error (or obtaining responses from too few people representative of the population) are addressed 
by recruiting from national and local registries and databases, regular recruitment checks, and 
minority recruitment plans. 
1.5.2.3 Sampling Procedures Emailed or mailed letters of invitation will be sent to 
approximately 600 to 1,000 women in order to meet the target sample size of 300. If data is 
available from the registries or organizational databases regarding socio-demographic 
information of interest (time since diagnosis, cancer type, minority status, and/or 
educational level), then that information will be used to help target specific groups of potential 
participants. 
Potential participants will be identified through cancer and research registries and 
advocacy organization databases.  
• Cancer and research registries: Participants will be recruited from two research
registries: 1) a research registry (the Clinical and Translational Research Institute Patient
Research Registry and 2) tumor registry (the Pennsylvania Tumor Registry). Participants
included in the CTSI Registry have previously participated in research studies and have
agreed to be contacted by researchers. A convenience sample of the Patient Research
Registry will be obtained by members of the registry responding to an email from the
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registry notifying them of their potential eligibility in this study. A random sample of the 
Pennsylvania Tumor Registry members from specific years between 1985 and 2013 will 
be created. Letters of introduction will be emailed to participants who may be eligible for 
the proposed study. If no email address is provided in the registry, letters of introduction 
will be mailed to the address provided by potential participants.  
• Advocacy organization databases: Participants will be recruited from the American
Cancer Society, National Ovarian Cancer Coalition, the African American Women’s
Speaker’s Bureau, the Urban League of Greater Pittsburgh, and the Cancer Caring
Center. The organizations’ databases contain names and information about the
organization’s members. Directors at these organizations have agreed to introduce the
candidate and the proposed study to potential participants. A random sample of the
organization’s members will be selected. If an email address is available, organization
directors will email the letter of introduction to potential participants. If no email address
is provided in the organization’s database, letters of introduction will be mailed by the
directors of the organizations to the address provided by potential participants.
• Both registries and organization databases: After 150 participants have completed
questionnaires, the candidate will review the cumulative proportion of participants with
different times since diagnoses, cancer sites, years since education, and racial and ethnic
backgrounds. Based on these findings, purposive sampling will be used in both registries
and organization databases containing this information to target under-represented sub-
groups.
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1.5.3 Instruments 
Appendix A includes a paper copy of all survey instruments given to participants. The Qualtrics 
online survey mirrored the format of these surveys. The construct of self-advocacy among 
female cancer survivors is defined as a woman’s ability to know her body and her needs, and 
insuring that both are respected throughout her cancer care journey. The FSACS Scale is a 57-
item (will be reduced) 6-point Likert-type self-report scale. Likert-type scaling was used to form 
a continuum ranging from 1 (strongly disagree), 2 (disagree), 3 (somewhat disagree), 4 
(somewhat agree), 5 (agree), to 6 (strongly agree). The number of items will be reduced after 
reliability analysis is complete. Six response options were selected in order to capture variability 
and discriminate meaningfully between respondents. Negatively worded items and reverse coded 
items were included. Varying levels of difficulty (or how hard an item would be) were included 
to differentiate between levels of self-advocacy. An even number of response options was 
selected to avoid a neutral response option and require directionality of response (agree or 
disagree). Content validity has demonstrated strong internal consistency (Cronbach’s α = 0.92) 
and test-retest reliability (r = 0.94) among a sample of 40 women with a history of a cancer 
diagnosis. 
During reliability testing, the average time to complete the 57-item FSACS Scale was 17 
minutes, and 49 minutes for the complete set of questionnaires. The Flesch Reading ease score is 
69.5 (ideal range for patient information and questionnaires is 60-70 on a 100-point scale). The 
Flesch-Kincaid reading level is 6.4 (ideal level of 7 or 8, though less to include a broader range 
of educational backgrounds). Acceptability was high among women in the reliability study. No 
special requirements, such as looking up health information or performing tasks, are required 
while completing the measurement. 
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The 3 key dimensions of the FSACS Scale are “application of information”, “mindful 
non-adherence”, and “connected strength” (Table 1). “Application of information” refers to the 
ability of female cancer survivors to gather trustworthy, personally relevant information and 
apply it to their personal experiences and problems related to their cancer. “Mindful non-
adherence” refers to the survivor’s ability to ask questions and adjust provider recommendations 
to fit their health concerns, needs, and preferences. “Connected strength” refers to survivor’s 
ability to seek support, give support, balance personal needs with others’ needs, and raise 
awareness. 
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Table 4. Predictors, Outcomes, and Related Measures to Self-Advocacy 
Construct Citation Measure # of Items 
Item 
response 
options 
# of 
Subscales % Female 
Cronbach’s
α 
Predictors 
Demographic 
Characteristics 
(Sereika & Engberg, 
2006) 
CRCD 
Sociodemogra-
phic Survey - R 
25 Variable n/a 100 n/a 
Disease 
Characteristics n/a 
Investigator-
developed 7 
Single 
response n/a n/a n/a 
Openness and 
conscientiousness 
(Goldberg et al., 
1999; Goldberg, 
2006) 
IPIP 20 5-point Likert-type 2 
Not
reported .81-.82
Information 
engagement 
(DuBenske et al., 
2009) HIOS 8 
5-point 
Likert-type 1 63.6 .65 
Perceived availability 
of social support (Cohen et al., 1985) ISEL 12 
4-point 
Likert-type 3 74.4 .31-.81 
Outcomes 
Symptom severity & 
interference with life 
(Cleeland et al., 
2000) MDASI 24 
11-point 
Likert-type 2 57 .91-.94 
Healthcare utilization (Given & Given,2013) 
Adapted 
questionnaire 4 
Single 
response 4 
Not
reported n/a
Related Measures 
Patient activation (Hibbard et al., 2004) PAM 13 
5-point 
Likert-type 1 63 .91 
Patient self-advocacy  (Brashers, Haas, &Neidig, 1999) PSAS 12 
5-point 
Likert-type 3 9.2 .60-.82 
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Valid, reliable measures were selected to capture the hypothesized predictors, outcomes, 
and related concepts in the literature (Table 4). Measures were selected based on their conceptual 
congruence with the literature and focus groups, number of items to reduce patient burden, the 
percent of female participants in the original scale development, and reliability. Measures with 
low reliability (ISEL) were kept based on the strength of other criteria. 
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1.5.3.1 Predictors Specific socio-demographic characteristics such as age, level of education, 
and income are measured using the Center for Research in Chronic Disorders (CRCD) 
Sociodemographic Survey. The personality traits of openness and conscientiousness are 
measured using the International Personality Inventory Pool (IPIP). Information engagement is 
measured using the Health Information Orientation Scale (HIOS). Perceived availability of social 
support is measured by the Interpersonal Support Evaluation List (ISEL). 
1.5.3.2 Outcomes Symptom severity and interference, measured by the MD Anderson Symptom 
Inventory (MDASI), captures the symptoms commonly experienced by individuals with cancer 
and how symptoms interfere with their daily life. The adapted healthcare utilization 
questionnaire tracks the number of primary care visits, emergency department visits, hospital 
admissions, and home health care visits individuals had within past 3 months and whether or not 
these were related to cancer. 
1.5.3.3 Related Concepts Patient activation, measured by the Patient Activation Measure 
(PAM), assesses the knowledge, confidence, and skills individuals have in managing their health. 
A previous measure of self-advocacy, the Patient Self-Advocacy Scale (PSAS), measures patient 
involvement in decision-making and was developed among a mostly male population of 
individuals with HIV/AIDS. 
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1.5.4 Data Collection Procedure
The finalized FSACS Scale will be developed into web-based and paper-pencil formats. Both 
approaches will use Dillman’s Tailored Design Method to increase internet and mailed survey 
response rates through personalized, systematic design and implementation strategies (Dillman, 
2002). The Research Electronic Data Capture (REDCap) application will be used for web-based 
questionnaires, and mailed questionnaire responses will be manually entered into REDCap. The 
following will occur after receipt of participant information from the registry and organization 
databases. A mixed mode data system will be used including both web-based and mailed surveys. 
1.5.4.1 Web-based A) Initial Email and Survey Delivery (Day 0): For web-based questionnaires, 
emails will be sent to potential participants containing information about 1) the purpose of the 
research study; 2) amount of time involved; 3) description of voluntariness of participation, 
minimal risks, and lack of personal benefit involved; 4) candidate’s contact information for any 
questions about the research; and 5) contact information for the IRB regarding questions about 
rights as a research participant. A link to the study website containing all questionnaires will be 
included. Potential participants will be given the choice to opt out of further contact in the email. 
Even if they do not opt out, no potential participant will be contacted more than twice (initial and 
follow-up invitation).  
On the website, all information on informed consent will be included as a required page 
for reading prior to beginning the web-based survey and that can be printed for their records. A 
question asking for voluntary consent to participate in the research study will be required. The 
website will include explicit statements that no identifiable information is being collected in the 
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surveys, that responses will not be linked to participants’ emails (after the data collection phase), 
and that completion of the surveys implies that participants are consenting to be a part of this 
research study.  
B) Reminder Emails (Days 5 and 10): Reminders will be emailed to the participant
including a link to the survey if the candidate has not received the returned survey. 
C) Final Reminder Email (Day 21): A final reminder will be emailed to the participant
including a link to the survey if the candidate has not received the returned survey with a note 
that this is the final notice to participate.  
1.5.4.2 Mailed A) Initial Letter and Survey Delivery (Day 0): For mailed questionnaires, an 
initial letter will be mailed to the participant’s address provided by the registry or advocacy 
organization. It will include the same introduction and consent information as the emailed survey 
along with a pre-stamped postcard to allow women to opt out of participation.  
B) First Questionnaire Delivery (Day 7) If no postcard is received by the in 1 week, the
candidate will mail a packet of information to the participant including all the information 
emailed in the web-based questionnaire (see above), a written consent form indicating that 
completion and return of the questionnaires indicates agreement to participate in the research 
study, instructions to complete the questionnaires, a copy of the questionnaires, and instructions 
to return all items in the pre-addressed, pre-stamped envelope to the candidate at the participants’ 
earliest convenience.  
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C) Reminder Post-card (Days 14): A reminder post-card will be mailed if the candidate
has not received the returned survey. 
D) Replacement Questionnaire Delivery (Day 21): If the survey has not be returned, the
study will send a replacement questionnaire along with a reminder letter and replacement 
consent form. A pre-addressed, pre-stamped return envelope will also be included. 
1.5.4.3 Both Web-based and Mailed Emailed and mailed questionnaire items and formatting 
will be identical and use standardized methodology for constructing questionnaires to decrease 
patient burden and increase response rate (Dillman, 2002). This mixed-mode use of a web-based 
survey with the option for a paper-and-pencil version with reminders has demonstrated 
equivalency of scale measurements, has minimal confounding effects, and will compensate for 
the differences in response rate and data completeness known to exist in each delivery method 
(Kongsved, Basnov, Holm-Christensen, & Hjollund, 2007). This approach does not exclude 
those without internet access, decreases need for resources and funds, is appropriate for all age 
groups (Edwards et al., 2009; van den Berg, et al., 2011). 
Participants will be paid $8 after successfully completing and returning questionnaires. 
Participants completing web-based questionnaires will receive Amazon.com gift codes in an 
email from the candidate. Participants completing mailed questionnaires will receive WePay pre-
paid credit cards in the mail. 
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1.5.5 Data Analysis Procedures 
This study evaluates the validity of the FSACS Scale in a sample of 300 female cancer survivors. 
The proposed psychometric testing in this study will focus on reducing total items to the most 
parsimonious set of items in order to achieve optimal reliability and validity. 
1.5.5.1 Descriptive Statistics Descriptive statistics will be collected and analyzed on all scales 
through a collection of methods. These statistics serve to describe the sample, examine 
distributions for each variable, and examine relationships among variables before completing the 
primary analyses. 
Frequency distributions will provide numerical comparisons within and between 
categorical variables. Graphs such as bar graphs and bivariate scatterplots will provide pictorial 
comparisons between variables and help identify outliers. Variable distributions (along with 
FSACS Scale item distributions) will be summarized through plots. Box and whisker 
(percentiles), histograms (number or percent of cases for ranges of values), and stem-and-leaf 
plots (all data values but group similar data values) will be analyzed for each variable.  
Summary statistics will calculate the distribution of observed data values for each 
variable. For nominally-scaled categorical data, mode and range will be reported for individual 
items. For all ratio scales and intervally-treated Likert-type scales (due to large number of 
response options with meaningful variation in responses), the mean, standard deviation, and 
standard errors will be reported along with appropriate subscale scores. For the FSACS Scale, 
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mean, standard deviation, standard error, range, and minimum/maximum values will be analyzed 
as appropriate for the total scale, item means, item variances, and inter-item correlations. 
1.5.5.2 Data Screening Procedures Patterns of missing data will be examined to detect the type 
of missingness for variables and cases. Nonrandom missing data will be explored for patterns 
between variables. A t-test for variables missing completely at random will be performed to 
examine differences between sub-groups (select socio-demographic, disease, and site variables). 
If greater than 5%, missing data will be handled using Expectation Maximization (EM) 
algorithm because this method uses observed values and current estimates of relationships 
between variables in order to substitute an expectation for missing data. This iterative method is 
considered more desirable than mean substitution or last observation carried forward methods. 
Regression methods and multiple imputation methods will also be considered and compared to 
EM using a sensitivity analysis to ensure the strongest method incorporating available data is 
used. 
Assumptions of validity testing and factor analysis will be tested prior to analysis. All 
variables will be examined for violations of normality (histograms, Shapiro-Wilk, and 
Kolmogorov–Smirnov testing), independence of observations (inherent in design), linear 
relationships between variables (scatterplots), and homogeneity of variance (boxplots and 
Levene test). Variables exhibiting significant skewness and/or kurtosis will be adjusted in order 
to satisfy the assumptions and produce stable results. Violations of assumptions will be reported, 
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and if egregious, transformations will be performed. Prior to analyses between known groups, 
these same assumptions will be checked and corrected for each sub-group. 
Additional assumptions for conducting an Exploratory Factor Analysis will be tested. 
Factorability will be tested to ensure an adequate degree of intercorrelation between FSACS 
Scale items so that coherent factors can be named. This assumption will be tested with the inter-
item correlations, anti-image correlation matrix diagonals, and measures of sampling adequacy 
(Kaiser-Myer-Olkin greater than 0.5 and Bartlett’s test in which the sphericity should be 
statistically significant). Sample size adequacy will be tested to ensure reliable estimates of 
correlations between items can be made. In addition to the sample size estimates provided in 
Section 1.5.2.1, this assumption will also be tested post hoc by checking sample distribution for 
each group and estimating sample size as described in Section 1.5.2.1.  
Instrument development requires variability in response rates among participants. Item 
distributions of the FSACS Scale will be examined by reviewing frequency distributions and 
means/standard deviations for all questionnaire items. Items that are highly skewed and have 
unbalanced distributions will be identified because these items convey little information. Items 
reflecting a broad range of distribution will be retained because these items discriminate between 
individuals and are desirable during factor analysis and psychometric evaluation. Item 
performance across different sub-groups (cancer site, time since diagnosis, active treatment) will 
be examined and chi-square statistics of association produced in order to check assumptions 
prior to analysis. Tukey’s test of non-additivity will be performed to test the assumption that 
there is no evidence of multiplicative interaction among FSACS Scale items. 
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Categorical data will be examined for univariate and bivariate outliers by examining 
frequency distributions and cross-tabulations. Continuous data will be examined for univariate 
and bivariate outliers by creating standardized scores and reviewing cases with z-scores above 3 
or below -3, examining box-and-whisker plots, bivariate scatterplots, and Mahalanobis’ 
distances. Any atypical values will be considered for transformation or deletion depending on 
their influence on hypothesis testing. Winsorizing, or score alteration, will be considered for 
extreme values. 
Data transformations will be conducted for highly skewed or non-normal data 
distributions. Positively skewed data will be considered for square-root or logarithmic (Log 10) 
transformations, depending on the extent of the skewness. Negatively skewed data will be 
considered for square-root or logarithmic (Log 10) transformations following a reflection of the 
variable, depending on the extent of the skewness. 
1.5.5.3 Data Analysis Procedures Validity refers to the extent to which an instrument is capable 
of producing inferences that actually capture the underlying construct it intends to measure. If 
valid, the interpretation of a measurement’s scores should be able to be used in making 
inferences about an individual’s scores on the measure. Unlike previous decades in which 
validity was measured as static and discrete forms (i.e. content, criterion, and construct 
breakdown), validity is now recognized as a unitary quality of a measurement. Validity involves 
“an overall evaluation of the plausibility of the intended interpretations” (Kane, 1994) of a 
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measure. Validity evidence requires multiple, diverse types of bodies of evidence and arguments 
that are substantiated with evidence collected over time. 
According to the American Educational Research Association’s (AERA) Standards for 
Educational and Psychological Testing, in the absence of a gold standard against which to 
measure convergent validity, establishing construct validity is a process of gathering evidence on 
the extent to which a measure performs as expected in relevant situations (1999). To establish 
construct validity, an investigator must generate a set of propositions that guide interpretation of 
the measure’s performance.  
For the FSACS Scale, validity will be based on evaluation of the hypotheses testing 
validity (in red in Figure 1): 
• H1) Internal structure: the internal structure of the FSACS Scale should be consistent
with the three proposed theoretical dimensions of self-advocacy;
• H2) Sensitivity to differences between known groups: Total and subscale FSACS scores
should be significantly higher for: 1) Experienced survivors (≥ 5 years since diagnosis)
compared to newly diagnosed women (≤ 6 months); and 2) Women with high levels of
education (≥ master’s degree) compared to those with low levels of education (≤ a high
school education);
• H3) Relationships between self-advocacy and key predictors and outcomes: FSACS
Scale total score and subscale scores should be positively associated with the personal
attribute of openness and conscientiousness (IPIP), the learned skill of information
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engagement (HIOS), social support (ISEL) and negatively associated with symptom 
severity and interference (MDASI) and healthcare utilization;  
• H4) Concurrence with related concepts (formerly convergent validity): Higher scores on
the FSACS Scale should be positively associated with scores on the Patient Activation
Measures (PAM). Subscale score correlations between the FSACS Scale and the previous
patient advocacy measure (PSAS) are expected to vary according to the level of
similarity between the old and new subscales: 1) the two “mindful non-adherence”
subscales should be strongly positively correlated (r>0.70); 2); the “illness education”
(PSAS) and “application of information” (FSACS) subscales are expected to be
moderately correlated (r=0.30-0.70); and 3) the “assertiveness” (PSAS) and “connected
strength” (FSACS) subscales are expected to be weekly correlated (r<.30), and finally;
• H5) Criterion measures (formerly criterion validity): The FSACS Scale total score
should be more highly correlated with outcome measures of symptom severity and
interference and healthcare utilization than the PSAS total score.
Psychometric evaluation of the FSACS Scale will be based on the propositions defined
above. 
H1: Exploratory Factor Analysis will be performed using maximum likelihood (ML) 
method with the goal of reducing items and producing a parsimonious scale. Oblique rotation 
will be used to allow for correlation between factors. A chi-square goodness-of-fit statistic will 
evaluate the degree of congruence between data and the proposed model. In the event that the 
assumptions of ML method are not met, Principal Axis Factoring will be used along with an 
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examination of the residual correlation matrix instead to determine goodness-of-fit. Scree plots 
and percent of variance explained will be used to help identify how many factors to extract. The 
pattern matrix will be used to examine the partial standardized regression coefficients and 
determine if a simple solution has been achieved. Items will be considered for deletion based on 
item-to-total correlations ≤ 0.35, inter-item correlations < 0.20, and factor loadings < .40 and 
>.90 in order to ensure items contribute to the total variance explained without being redundant. 
Items that cross-load onto more than one factor will be individually reviewed in consideration for 
their congruency with factors and the overall construct and retained if loading higher on the 
intended factor. Ultimately, a parsimonious scale should be created based on the above criteria 
that considers the theoretical underpinnings, distinguishability, simplicity, internal consistency, 
and interpretability of factor scores. 
H2: T-tests will be used to compare FSACS Scale scores between experienced and newly 
diagnosed cancer survivors and survivors with high and low levels of education. 
H3: Bivariate correlations and t-tests as appropriate will be conducted between FSACS 
Scale scores and scores on designated measures of predictors (IPIP, HIOS, and ISEL) and 
outcomes (MDASI, Healthcare Utilization). 
H4: Bivariate correlations will be conducted between the FSACS Scale scores and 
subscale scores of related concepts from the literature (PAM and PSAS) to evaluate concurrent 
validity. 
H5: Bivariate correlations will be calculated between the PSAS scale scores and outcome 
variables (MDASI, Healthcare Utilization) and compared with the strength of association 
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between the FSACS and outcomes to evaluate whether the FSACS performs better among 
female cancer survivors compared to the PSAS. Pearson correlations between the both the PSAS 
and FSACS Scale will be respective outcome measures will be compared.  
All tests will be conducted at the α =0.05 significance level. Data analysis will be 
conducted using SPSS (version 21, SPSS, Inc., Chicago, IL). 
1.6 DISSERTATION TIMELINE 
Table 5 outlines the dissertation timeline originally presented by the candidate during her 
Comprehensive Exam and Overview in May 2015. As of late June 2015, all anticipated deadlines 
and times were met except that participants were recruited through March 2015. 
42 
Table 5. Dissertation Timeline 
May -
June 
2014 
July–
Sept. 
2014 
Oct.–Dec. 
2014 
Jan.–
Feb. 
2015 
March-
May 
2015 
June-Aug. 
2015 
Dissertation Proposal X 
Dissertation Approval X 
Recruitment (minority 
recruitment strategy 
implemented at 50% & 
75% recruitment) 
X X X 
Analysis 
-Developing syntax 
Performing planned 
analyses 
Consulting research team 
members 
X X X 
Manuscript Preparation X X 
Dissemination X 
Post-doctoral Award 
Preparation 
X X X 
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1.7 DATA INTERPRETATION 
Validity of the interpretation of FSACS Scale scores will be evaluated based on the five 
hypotheses listed in Section 1.5.5.3. Since each hypothesis could be rejected or retained, the 
argument for validity testing will be based on the extent each hypothesis is or is not retained. 
If these hypotheses are substantiated in this study’s results, then the interpretation of high 
FSACS Scale scores will be indicative of an adult woman with cancer with a high ability to self-
advocate.  
Item reduction of the FSACS Scale will occur by looking at the performance of the new 
instrument based on scale-, factor-, and item-level statistics. Criteria for exclusion will include 1) 
low item-item correlations (<0.30), 2) poor fit into the factor structures within the Exploratory 
Factory Analysis, and 3) large amounts of user-defined missing data (refusal or confusion on 
how to respond). 
1.8 STUDY LIMITATIONS 
Survey research inherently includes errors of observation and non-observation. Furthermore, 
using a self-reported administration method introduces respondent recall and bias error which 
can impact external validity of score interpretations. Particularly in the current study, bias is 
introduced because of the social desirability of self-advocacy. Concerns of observation and bias 
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were addressed by including a large number of items behaviors varying in difficulty that reflect 
the depth and breadth of self-advocacy as defined in previous work.  
Another limitation to this study includes not including more types of validity evidence. 
Given the lack of an alternate measure of self-advocacy for female cancer survivors, item 
responses cannot be compared to a gold standard. Responsiveness, or a measurement’s 
sensitivity to detect change, is not measured given the cross-sectional design of the study. Future 
studies collecting longitudinal data will measure changes in outcomes based on individuals’ 
responses to the FSACS Scale. 
1.9 POTENTIAL PROBLEMS 
1.9.1 Reducing Survey Error 
Survey development research must be concerned with error in estimating the true score of the 
surveys being administered. In order to produce accurate information about self-advocacy in 
female cancer survivors, four types of survey error all pose potential problems with this study: 
coverage error, sampling error, nonresponse error, and measurement error (Dillman, 2002). Each 
of these types will be systematically addressed: 
• Coverage error, or the risk of not all members of the population have a known, nonzero
chance of being included in the sample, will be addressed by using broad sample frames
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(particularly the Pennsylvania Tumor Registry) and regularly scheduled recruitment 
checks.  
• Sampling error, or error in precision due to not all members of the population being
sampled, is addressed by randomly sampling a high enough proportion of the portion
based on sample size estimations.
• Nonresponse error, or error due to systematic differences between participants receiving
the survey who do and do not return completed surveys, is addressed by sending
personalized, tailored instructions intended to motivate all women receiving
questionnaires.
• Measurement error, or inaccurate or imprecise survey responses, is addressed through
extensive pilot testing of survey questions to ensure clarity of instructions and wording
along with survey design and construction.
1.9.2 Achieving Sample Size 
One of the major potential problems in this study is not achieving the desired sample of 300 
adult female cancer survivors. To address this problem, special attention will be made to include 
culturally sensitive statements in the recruitment flyers/paperwork, survey paperwork, FSACS 
scale, and consent forms. Recruitment activities during will include personalized, culturally 
sensitive language according to Dillman’s methods of formatting web-based and paper surveys 
according to social exchange theory. Minority female survivors were included within the eight-
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member expert panel during the creation of the FSACS Scale items and assisted in assuring the 
FSACS Scale represents minority female cancer survivors’ experiences.  
Table 6 illustrates the intended recruitment by site and racial status. To ensure inclusion 
of a wide variety of cancer sites, survivorship stages, health statuses, ethnicities, socioeconomic 
statuses, and current disease statuses (a key principle of instrument development necessary to 
ensure potential generalizability), these factors will be evaluated by the research team after 
accrual is 50% and 75% complete. If necessary, the candidate will increase efforts to recruit a 
diverse sample including targeted selection of clinics and direct requests to clinical staff.  
less than a high school education and 20% being non-Caucasian.  
Table 6. Numbers of Potentially Eligible Participants by Recruitment Site 
White 
(n) 
Black 
(n) 
Asian/PI 
(n) 
Other 
(n) TOTAL 
PA Cancer Tumor Registry* 52 16 3 1 72 
CTSI Participant Research 
Registry 70 4 1 3 78 
TOTAL Registries 122 20 4 4 150 
American Cancer Society 80 1 0 5 86 
Urban League of Greater 
Pittsburgh 0 9 0 0 9 
National Ovarian Cancer 
Coalition (Pittsburgh and 
National) 
30 1 0 4 35 
African American Women’s 
Speakers’ Bureau 0 10 0 0 10 
Cancer Caring Center 10 0 0 0 10 
TOTAL Cancer and Advocacy 
Organizations 120 21 0 9 150 
TOTAL 242 41 4 13 N=300 
*These data were provided by the Bureau of Health Statistics and Research, Pennsylvania
Department of Health. The Department specifically disclaims responsibility for any analyses, 
interpretations or conclusions. 
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Our goal is to ensure diversity in education and race by achieving the pre-set goals of 
10% having Based on demographic information from the individual recruitment sites, we believe 
this enrollment strategy is feasible. 
Minority recruitment will be discussed at the weekly research team meetings and monthly 
meetings. Low minority recruitment at specific clinics and organizations will be addressed 
through a detailed recruitment plan with Dr. Rosenzweig. These contingency minority 
recruitment plans are detailed below:  
• A panel of minority recruitment experts including Dr. Rosenzweig, the Center for Minority
Health (CMH), and the directors of the African American Women’s Speakers’ Bureau and
Urban League of Greater Pittsburgh plan to meet for consultation and formation of a detailed
plan including: 1) targeting minority female survivors within cancer clinics and cancer
registries, 2) developing culturally-sensitive recruitment flyers and literature, and 3) working
directly with clinic and advocacy organization staff to direct efforts at minority women.
• The candidate has registered with an additional cancer advocacy organization, the Army of
Women, and will be able to recruit from the women included in this registry who have
indicated interest in participating in cancer trials and research projects. The registry currently
includes 12,297 Black of African American women, 12,000 Hispanic or Latina women,
3,897 Asian women, 1,665 Native American women, and 19,806 women of other racial and
ethnic groups.
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1.10 ALTERNATIVE APPROACHES 
Alternate methods exist to empirically validate new measurement tools. Different modes of 
survey delivery could be used including telephone or face-to-face survey delivery modes. 
Alternatively, a single mode of web-based or mailed questionnaires could be used. However, 
these alternate survey delivery modes reduce external validity and generalizability for future use 
of the FSACS Scale in clinical or research settings. Likewise, using a single mode would 
significantly increase the cost of implementation (mailed) or increase sampling error if not 
including women without reliable access to the internet (web-based). 
Additional alternative approaches include consideration of additional hypotheses to 
establish validity based on the AERA guidelines. However, the five hypotheses currently 
included consider both the structural dimensions of the FSACS Scale and external relationships 
of the FSACS Scale with other measures, both of which are based on previous literature 
surrounding self-advocacy and female cancer survivorship literature. Content validity has 
previously been reviewed and found to be adequate. Future research can explore additional 
hypotheses regarding the interpretation of the FSACS Scale scores with additional measures, 
samples, and settings. 
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1.11 PROTECTION OF HUMAN SUBJECTS 
Approvals have been achieved to secure the safety of research participants, access to 
participants, and instrument use: 
• Institutional Review Board
o University of Pittsburgh Institutional Review Board (PRO12110062)
• Access to Participants
o CTSI Participant Research Registry
o Pennsylvania Department of Health for the Cancer Registry
o National Ovarian Cancer Coalition (National)
o African American Women Speaker’s Bureau (Pittsburgh)
o Cancer Caring Center (Pittsburgh)
o *American Cancer Society (National) (currently being developed)
• Instrument Use for paper- and web-based questionnaires from the owners or creators of
each instrument.
Consents will be obtained from all participants. Mailed questionnaires will include a
consent form stating “By completing and returning the completed questionnaire you agree to 
participate in this research study”. Web-based questionnaires will include a typed copy of the 
consent form and ask participants to indicate their voluntary consent by responding “Yes” to the 
item “By clicking “YES” you agree to participate in this research study.” 
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Potential Risks and Risk Reduction: The major risks of 1) subject burden and 2) breach of 
confidentiality will be systematically addressed.  
1) Subject Burden: To reduce the risk of subject burden, shortened versions of scales and
select subscales of larger measures were used when valid/reliable and appropriate to minimize 
patient burden. Participants will be given written instructions in their formal introduction to the 
survey to take time to rest and return to questionnaires at a later time if they begin to experience 
fatigue and/or distress during questionnaire completion. These instructions will be provided for 
both web-based and mailed questionnaires.  
2) Breach of Confidentiality: To reduce the likelihood of a breach of confidentiality,
questionnaire data will be assigned a code number and stored in a locked file cabinet separate 
from the file identifying participants by code number. Internet surveys will be designed to assure 
confidentiality in responses. Internet surveys will be delivered on a secure website (REDCap) 
which uses the Secure Sockets Layer (SSL) encryption. The REDCap website ensures that data 
are maximally secured and in accord with the Health Information Portability and Accountability 
Act. Data is stored behind the University of Pittsburgh firewall. Unique identification numbers 
will be assigned to each participant. No identifying information will be collected on the web-
based survey. Survey responses will be stored on a secure server at the University of Pittsburgh. 
The candidate has established plans with clinic and organization directors to assure protection of 
all participants including confidentiality of all identifiable information, minimization of any risk, 
use of informed consent materials, and description of risks and benefits. 
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Data and safety monitoring will be conducted during monthly meetings with Drs. 
Donovan and Cohen during which data quality, management and any adverse events arising from 
the study will be reviewed. A summary of these reviews will be provided to the IRB at the time 
of the yearly renewal. Any unanticipated adverse events will be reported immediately to the IRB. 
1.12 INCLUSION OF WOMEN, MINORITIES, AND CHILDREN 
This study specifically addresses a research question relevant to female cancer survivors. All 
adult women with a history of a cancer diagnosis ages ≥ 18 years old are included in this study 
independent of cancer stage. Women with a previous diagnosis only of basal cell carcinoma or 
cervical intraepithelial neoplasia stage 1 are excluded because these survivors are expected to 
have inherently different experiences than other female cancer survivors.  
We plan to ensure that 10% of the sample has less than a high school education and 20% 
be non-Caucasian. Tables 7 and 8 describe the racial and ethnic make-up of the recruitment sites. 
We anticipate that adult women at various stages of cancer survivorship share experiences and 
situations in which self-advocacy and symptom management are likely to occur and significantly 
impact their lives. These statements are supported by the candidate’s focus group study in which 
female survivors’ experiences consistently expressed the same central themes of self-advocacy 
independent of individual disease state, age, number of recurrences, years since diagnosis, racial 
background, and years of education (Hagan & Donovan, 2013b). 
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Table 7. Demographics of Registries 
 
By Race By Ethnicity 
 
White Black Asian/ PI 
Undiscl
osed/ 
Other 
TOTAL 
Non-
Hispa
nic 
Hisp
anic 
Und
isclo
sed 
TOTAL 
Allegheny 
County 81.5% 13.2% 2.8% 2.5% 100% 98.4% 1.6% n/a 100% 
CTSI 
Participant 
Research 
RegistryA 
6,974 74 49 954 8,451 7,426 9 1 7,976 
82.5% 5.6% 0.6% 11.3% 100% 93.1% 0.1% 6.8% 100% 
PA Cancer 
Tumor 
RegistryB 
697,25
1 9,990 4,683 82,102 844,026 
358,17
7 
3,86
8C 
Not 
avail
able 
62,045 
82.6% 7.1% 0.6% 9.7% 100% 
Not 
availa
ble 
Not 
avail
able 
Not 
avail
able 
Not 
availabl
e 
TOTAL 92% 7% 0.001% 1.6% 100% 97% 3% n/a 100% 
A: Females ≥ 18 years old in with history of cancer diagnosis as of February 2014.  
B: Females ≥ 20 years old with previous diagnosis of cancer in registry (1990-2010 data 
available for statistical review. These data were provided by the Bureau of Health Statistics and 
Research, Pennsylvania Department of Health. The Department specifically disclaims 
responsibility for any analyses, interpretations or conclusions. 
C: Data from 2002-2010. The Pennsylvania Department of Health began tracking ethnic data in 
2002. 
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Table 8. Demographics of Advocacy and Cancer Organizations 
Total % Female % Minority 
American Cancer Society TBD* TBD* TBD* 
Urban League of  Greater Pittsburgh 20,000** 75%** 85% 
National Ovarian Cancer Coalition (Pittsburgh) 400** 85%** Not known 
National Ovarian Cancer Coalition (National) 5,000** 85%** Not known 
African American Women’s Speakers Bureau 20*** 100% 100% 
Cancer Caring Center 7,000*** 90% Not known 
TOTAL Advocacy and Cancer Organizations 32,420 75-100% 
*Information from the American Cancer Society will be given to the candidate prior to study
implementation. 
**Estimate from advocacy organization director. Because organizations’ records vary, directors 
estimates of total membership and what proportion is female and minority are described to 
represent the large sample from which eligible women can be recruited. 
***The African American Women’s Speakers Bureau includes 20 African American women. 
This organization sponsors regular educational series, health forums, and events that are widely 
advertised to African American women throughout western Pennsylvania. Dr. Rosenzweig has 
high success in recruiting minority cancer survivors through this organization. 
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1.13 RESEARCH PARTICIPATION RISK & RISK REDUCTION 
Human participants will be protected from risks associated with participating in this research 
study. 
1.13.1 Involvement 
Three hundred female adult cancer survivors will participate in this study by completing paper- 
or web-based surveys at one time point. Inclusion Criteria: 1) female, 2) at least 18 years old, 
and 3) have a history of a cancer diagnosis at age 18 or older (younger cancer survivors are likely 
to differ in their responses). Exclusion Criteria: 1) unable to complete questionnaires in English 
(only English version) or 2) have a diagnosis of basal cell carcinoma or cervical intraepithelial 
neoplasia stage 1 (these survivors have inherently different treatment and symptom experiences 
than other cancer survivors).  
1.13.2 Sources of Data 
All data will be collected in the paper- or web-based surveys completed by participants. 
1.13.3 Recruitment and Retention 
Recruitment strategies have been developed with each recruitment site to identify email listservs 
and databases from which the candidate can contact potential participants. 
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Dillman’s Tailored Design Method (2002) will be utilized to maximize recruitment and 
return of paper- and web-based surveys by reducing the burden of participation. Dillman’s 
survey procedures are based on social exchange theory in which the survey request and 
motivation to complete the surveys is based on establishing trust and increasing the perceived 
benefits of completing the survey while decreasing the expected costs of participation. 
Trust will be established by 1) providing written endorsement from the leaders of the 
organizations from which the participants are recruited, 2) stressing the importance of the 
knowledge to be gained in this study, and 3) ensuring confidentiality of all participant 
information. Participants’ perceived benefits of participation will be highlighted by providing 
background information about the survey, asking for help and advice, showing respect for 
individuals, and providing social validation. Participants’ expected costs of participation will be 
decreased by making participation convenient, used abbreviated versions of questionnaires, 
requesting minimal private information and no sensitive information, and avoiding any 
subordinating language. 
Scheduled recruitment checks will occur after 50% and 75% of the total sample has been 
recruited. If it low participation among women with low educational status and minority status is 
discovered, then targeted recruitment strategies will be developed and implemented if with 
consultation with Dr. Rosenzweig and her research team. Surveys are completed at one time 
point, so retention strategies are not included. 
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1.13.4 Potential Risks & Risk Reduction 
1) Subject Burden: To reduce the risk of subject burden, shortened versions of scales and select
subscales of larger measures were used when valid/reliable and appropriate to minimize patient 
burden. Participants will be given written instructions in their formal introduction to the survey 
to take time to rest and return to questionnaires at a later time if they begin to experience fatigue 
and/or distress during questionnaire completion. These instructions will be provided for both 
web-based and mailed questionnaires. 
2) Breach of Confidentiality: To reduce the likelihood of a breach of confidentiality,
questionnaire data will be assigned a code number and stored in a locked file cabinet separate 
from the file identifying participants by code number. Internet surveys will be delivered on a 
secure website (REDCap) which uses the Secure Sockets Layer (SSL) encryption. Data is stored 
behind the University of Pittsburgh firewall. Surveys are designed to assure confidentiality in 
responses. Unique identification numbers will be assigned to each participant. No identifying 
information will be collected on the web-based survey. 
Survey responses will be stored on a secure private server with the assistance of Dr. 
Donovan’s research team’s web-design experts and information science specialist who will be 
available to assist the candidate for the duration of the study. The candidate has established plans 
with clinic and organization directors to assure protection of all participants including 
confidentiality of all identifiable information, minimization of any risk, use of informed consent 
materials, and description of risks and benefits. 
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1.13.5 Risk-Benefit Ratio 
This study has minimal risk. The benefit of creating a valid, reliable measure of self-advocacy 
among female cancer survivors constitutes a significant and innovative research methodology 
capable of being used in future research to address the needs of female cancer survivors. 
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2.0  SUMMARY OF STUDIES 
2.1 FINAL SAMPLE 
We originally planned to compare FSACS Scale scores of women within 6 months of their 
diagnosis and over 5 years (Hypothesis 2). In order to ensure more equal distribution 
during planned analyses, participants’ times since diagnosed with classified as 0-1 year, 1-5 
years, and over 5 five years. Given that most women within 1 year of diagnosis had 
received or were currently receiving some type of ongoing treatment (e.g. radiation 
(40.0%), chemotherapy (70.5%), or adjuvant treatment(18.8%)), it is likely that between 6 
months and 12 months these women were still acutely impacted by their cancer and its 
treatment. 
2.2 RECRUITMENT 
2.2.1 Registries 
The Pennsylvania Tumor Registry contained the names, street addresses at time of diagnosis, 
racial and ethnic categories, date of birth, and ICD-9 codes of all adult females diagnosed 
with cancer from 1985-2013. Concerns arose with the registry including: 
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• Outdated addresses caused many initial letters to be returned.
• The registry was not checked against the Social Security Death Index.
• In situ cancers were included with invasive cancers; some ICD-9 coded that were of 
unclear invasiveness and malignancy. Several women called or mailed the researcher to 
indicate that they had never received a cancer diagnosis.
• The registry contained more years for women who would be > 5 years since diagnosis
(1985 – 2009) than 1 – 5 years (2009 – 2013) or < 1 year (some 2013) although the
planned hypotheses of the study required roughly equally numbers from these three
groups.
To address these concerns, the candidate used a random number generator to randomly
identify women from specific years and checked each randomly selected woman against: (1) a 
publically available website with addresses (whitepages.com), (2) the Social Security Death 
Index, (3) online obituary searches particularly for women diagnosed within the past two years, 
and (4) a list of ICD-9 codes. Years from the original list of registry participants were 
weighted toward 2009-2013 in order to achieve equal numbers participants from the three 
groups of times since diagnosis. 
Initial letters sent through the Pennsylvania Tumor Registry were not cross-
checked against the ICD-9 manual to ensure all potential participants had invasive cancers. 
Even after cross-checking occurred, some participants still indicated having been diagnosed 
with an in situ or non-invasive cancer. As a result, 19 participants (6.1%) in the final sample 
had a non-invasive cancer diagnosis. These participants remain in the analyses because 
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the treatment and psychological adjustment for this population has been shown to reflect 
that of individuals diagnosed at later stages. 
While the response rate of 17.3% from the Pennsylvania Tumor Registry is low 
compared with other studies having used this registry, this study randomly selected potential 
participants from the entire registry. Individuals who are older, non-White, and have more 
advanced disease are known to have lower response rates when recruited through state tumor 
registries (Kelly, Fraze, & Hornik, 2010), but it was important to the study design and 
hypotheses to select a variety of ages, ethnicities, and times since diagnosis. 
2.2.2 Advocacy Organizations 
Difficulties recruiting occurred at several sites. At the Urban League, personnel changes 
and problems accessing eligible participants greatly impeded recruitment. To address these 
barriers to recruitment, the candidate instead attended events sponsored by the Urban League 
and brought copies of the survey study, consent form, return envelopes with postage, and 
business cards to recruit potential participants face-to-face at these events.  
At the American Cancer Society (ACS), both national and local recruitment strategies 
were undertaken. Originally, the ACS’s online website for their Cancer Support Network 
posted a study announcement on their website (http://csn.cancer.org/announcements). However, 
given the limited visibility of this advertisement, very few participants were recruited 
despite bi-monthly updates to put the study at the top of the Announcement webpage. Several 
suspicious emails were sent to the study’s email address requesting to participate 
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referencing this announcement. While the first few requesters were given access to the survey, a 
distinct pattern of email addresses, email text, and abnormal survey responses raised 
concerns which the candidate brought to her Committee and determined that emails fitting 
this pattern could be ignored in order to preserve the integrity of the data. While the 
announcement remained on the ACS website, the candidate decided to also recruit from the 
local ACS Pittsburgh Chapter by speaking at local volunteer meetings. 
The African American Women’s Speakers Bureau leadership helped recruit participants 
at events they were organizing or attending. Researchers from this study were not present at 
those events. Few potential participants elected to participate in the study. 
Due to the low recruitment from the Urban League of Greater Pittsburgh and the African 
American Women’s Speakers Bureau (both of which were assumed to help ensure diversity of 
the sample), the candidate used available racial and ethnic data through the Pennsylvania Tumor 
Registry to target minority women. 
Additional sites were included including the LiveWell Survivorship Program at 
Hillman Cancer Center (October 2014), cancer support groups at Hillman Cancer Center 
(November 2014), and Magee Women’s Hospital newsletters and clinic flyers (October 2014). 
All of these sites were able to recruit several eligible to complete online and paper surveys. 
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2.3 DATA COLLECTION PROCEDURES 
Prior to the start date of the study, the decision was made to use Qualtrics rather than REDCap 
for web-based survey dissemination, data collection and management. Qualtrics’ 
superior survey-building capabilities, export options, and usability drove this decision. 
Blocks of individual questionnaires were randomly presented to participants in order to 
prevent order effect. 
The Pennsylvania Tumor Registry had guidelines for using their registry that altered 
the data collection procedures. Prior to any participant research activity, the participant 
needed to return a signed consent form. Originally, no reminders were sent to participants after 
sending the questionnaire packet. Later, after clarification with the directors of the registry, 
replacement questionnaires were sent to participants who had not yet returned the 
questionnaires. 
Participants were given $10.00 Amazon.com gift cards instead of WePay cards. This was 
done to avoid collecting participants’ Social Security numbers and to make the experience 
as easy as possible for all participants in accordance with Dillman’s Tailored Design Method. 
2.4 ASSUMPTIONS FOR DATA ANALYSIS 
Prior to any analyses, all data was cleaned, recoded, and assumptions were checked. For the 
factor analysis, item performance was checked. Item-to-total correlations and inter-item 
correlations were examined. While some correlations were less than 0.35 and 0.20, respectively, 
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these items were determined to be poor performers during earlier testing and throughout future 
factor analysis stages. 
Almost all assumptions for the factor analysis (Hypothesis 1) and additional hypotheses 
(Hypotheses 2 – 4) were met for all scales except for the FSACS Scale and the MDASI. The 
MDASI symptom severity and symptom interference subscales had significant floor effects. One 
hundred and ten women did not report any symptoms. The 205 women who did report any 
symptom being above 0 had a mean symptom severity score of 1.37 (SD = 1.38) and 
mean symptom interference of 1.16 (SD = 1.83) indicating low overall symptom burden 
among this sample. 
For the final 20-item FSACS Scale, several univariate and multivariate outliers existed 
and several items demonstrated high skewness and kurtosis. Six participants were univariate 
and/or multivariate outliers on the FSACS and other scales. The factor analysis and 
additional analyses were run with and without these 6 participants, and the number of factors 
and factor loadings did not significantly differ. Eleven of the final 20 items in the FSACS 
Scale had skewness and/or kurtosis +/- 1.00 mostly due to ceiling effects in which most 
respondents scored items as a 4, 5, or 6 on the 6-point Likert scale. After collapsing response 
options 1 and 2 into option 3, the problems of skewness and kurtosis were resolved. 
All scales had less than 4.1% missing data save for the FSACS Scale which had 8.0% 
missing data. Although the pattern of missingness was determined to be random (MCAR: 
chi-square = 790.754, df = 1317, p = 1.000), the decision was made to use estimation 
maximization (EM) to input missing data in order to provide the largest sample size for the 
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factor analysis. After missing data was imputed using EM, factor analyses results were 
compared to results without the EM imputation, regression, regression with residuals, and 
multiple imputation techniques for addressing missing data. Factor analysis results did not vary 
between methods. 
The six univariate and multivariate outliers were deleted from analyses for 
Hypotheses 2-5. Results of hypotheses testing did not change when these outliers were 
eliminated. 
2.5 ITEM REDUCTION PROCESS 
The original 57 items used during reliability testing were included in the construct 
validity testing. Online surveys had random ordering of the 57 items. Paper surveys had 
the same ordering.  
Decisions about what items to keep or delete must incorporate multiple sources of 
information regarding item performance. While the data analysis plan inferred that results of 
factor analysis statistics (item-to-total correlations, inter-item correlations, factor loadings, 
cross-loading items) would be the primary determinants of item deletion while considering 
theoretical underpinnings, reliability, interpretability, and simplicity.  
During the process of determining the final set of items for a theoretically-
consistent, psychometrically robust, parsimonious, and clinically useful measurement, we also 
considered item’s previous performance during content validity, cognitive interview, and 
reliability testing. For example, during content validity testing the experts were asked to rank 
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the five items they found most important and the five items they found least important to self-
advocacy. These items were noted and kept in the analyses despite low communalities and 
factor loadings in order to increase the face validity of the final measure. Responses of the 
cancer survivors on the expert panel were given extra weight during this process. 
In order to track decisions to delete or retained items in the FSACS Scale, a table was 
used to track item performance across several psychometric criteria (Table 9). As noted in the 
table, items were reworded after content validity testing, therefore complicating cross-
evaluations with reliability and construct validity testing results. While there was no one 
formula or rule by which items were deleted or retained, this table provides evidence and/or 
explanations behind the choices we made in deciding on the final items measure. Future 
research will investigate items that performed differently than expected based on the original 
theory or which may be performing poorly due to lack of clarity or poor wording choice.  
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Table 9. Item Reduction Criteria and Elimination from 57 to 20 Item Scale 
Item 
Content 
Validity: # 
of experts 
ranking 
item as 
Most and 
Least 
Important* 
Problems 
Identified 
during 
Cognitive 
Interview
s 
Low 
Content 
Validity 
Index 
Score 
Poor 
Initial 
Reliabil
ity 
Low 
Commu
nalities 
(<0.30) 
Low 
Factor 
Loading 
(<0.40) 
Notes** 
Delete 
or 
Keep 
BEING AN INFORMED DECISION MAKER  
(FORMERLY APPLICATION OF INFORMATION) 
1. I seek out information to help me
improve my life as a cancer survivor. Most: 2 
(1 cancer 
survivor) 
Poor 
conceptual 
clarity with 
factor; 
Low 
variability 
Delete 
2. I make sure the health information I get is
trustworthy. Most: 1 (cancer survivor) 
Item confusing to 
others including 
survivors 
Poor 
conceptual 
clarity with 
factor; 
Low 
variability 
Delete 
3. I can tell the difference between health
information that does and does not apply
to me.
Most: 1 
Least: 1 X X Delete 
4. Health information gives me more control
as a cancer survivor.
Most: 1 
Many experts 
disagree with 
concept of 
“control” 
Low 
variability Delete 
5. I ignore questionable health information. X X Delete 
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Table 10 (continued) 
6. I try new things to improve my life as a
cancer survivor.
Most: 1 (cancer 
survivor) 
Least: 1 
Cross-
loading Delete 
7. I don’t know enough to help make
decisions about my cancer care. Least: 1 X X X Delete 
8. I use my skills to solve the problems I
face as a cancer survivor. Most: 3 X Keep 
9. I gather information before making
decisions about my cancer care.
Most: 1 (cancer 
survivor) Keep 
10. If I had problems with my job or other
responsibilities, I would know where to
look for help.
Least: 1 X X X X Delete 
11. I weigh my options carefully before
making important decisions about my
cancer care.
X Keep 
12. I prepare myself to make decisions about
my cancer care. Most: 1 Keep 
13. When it comes to making decisions about
my cancer care, I know what my priorities
are.
Most: 2 Keep 
14. Having information helps me to make
decisions about my cancer care.
Most: 3 (1 cancer 
survivor) 
Confusing item 
to many; hard to 
disagree with 
item 
Lowest 
variability Delete 
15. If a health problem doesn’t go away, I
look for different ways to manage it. Least: 2 X X X X X Delete 
16. If I had problems covering the costs of
my cancer care, I would know where to
look for help.
Least: 1 X X X X Delete 
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Table 10 (continued) 
COMMUNICATING WITH MY HEALTH CARE PROVIDERS 
(FORMERLY LEADING MY HEALTH CARE) 
17. Sometimes I adjust my provider’s
recommendations to better fit with my
life.
Most: 1 
Least: 2 (1 
cancer survivor) 
X X X X Delete 
18. If a treatment is not working, I wait for
my provider to make a change. X X X Delete 
19. I ask questions when I don’t understand
what my provider is telling me. Most: 5 (1 
cancer survivor) X 
Cross-
loading 
between 
factors 1 
and 3 
Keep 
20. My provider knows what is best for me. Most: 1 X X X X Delete 
21. Sometimes I decide not to follow the
advice of my provider.
Most: 1 
Least: 1 X X X X Delete 
22. I don’t want my provider to think I am a
difficult patient. Least: 1 X X X Delete 
23. If I don’t do what my provider asks me to
do, I have a good reason. Least: 1 X X X X Delete 
24. I feel like I can disagree with my
provider.
Most: 1 
Least: 1 X X X Delete 
25. If a medication is not working, I tell my
provider.
Most: 1 (cancer 
survivor) 
Confusion if 
person not 
taking 
medication; 
confusion about 
chemotherapy 
vs. medication 
X X Very low variability Delete 
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Table 10 (continued) 
26. I question my provider if I don’t agree
with his or her recommendations.
Most: 1 X X 
Cross-
loading 
between 
Factors 1 
and 3; Kept 
in due to 
Content 
Expert 
approval 
Keep 
27. I don’t talk about a health concern with
my provider unless I think there is a
solution.
X Keep 
28. I rarely tell my provider about the
problems I am having. Keep 
29. I know where to get an answer if my
provider can’t give me one. Most: 3 X X 
Kept in due 
to Content 
Expert 
approval 
Keep 
30. I ask my provider to explain his or her
recommendations. Most: 4 (2 
cancer 
survivors) 
X 
Cross-
loading 
between 
Factors 1 
and 3 
Keep 
31. I am not sure where I would go if my
provider is not able to answer the
questions I have. Not included 
Removed 
due to 
redundancy 
with #29 
Delete 
32. I am comfortable asking for a second
opinion. Most: 2 X X 
Kept in due 
to Content 
Expert 
approval 
Keep 
33. Not following the advice of my provider
bothers me. X X X X X Delete 
34. I know what’s best for me medically. X X X X X Delete 
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Table 10 (continued) 
35. I seek other help for my needs that are not 
being met by my provider.  
Most: 1 
Least: 1 X  X X X 
Initially 
kept in 
initially 
due to 
Content 
Expert 
approval, 
but 
ultimately 
poor fit 
Delete 
36. I worry that asking for a second opinion 
would hurt my relationship with my 
provider.  
      Duplicate of Item 32 Delete 
37. I have a hard time voicing my preferences 
to my provider.  
Most: 2 (2 
cancer 
survivors) 
      Keep 
CONNECTED STRENGTH 
38. I seek out support from other cancer 
survivors. Most: 1       Keep 
39. I seek out support from friends and 
family. Most: 1 X  X X X  Delete 
40. Helping other cancer survivors also helps 
me. Most: 1       Keep 
41. I don’t like asking my friends and family 
for help. 
Most: 1 
Least: 1 (cancer 
survivor) 
   X X  Delete 
42. Many of my decisions are based on 
what’s best for my family.     X X  Delete 
43. Being there for other cancer survivors is 
an important part of being a cancer 
survivor. 
Most: 1      Redundant with #44 Delete 
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Table 10 (continued) 
44. When I hear someone has cancer, I try to
reach out to them. Keep 
45. It helps me to know that other cancer
survivors have gone through what I am
going through.
Most: 1 X Keep 
46. My friends and family motivate me to get
better.
Most: 1 (cancer 
survivor) X X X 
Kept in 
initially 
due to 
Content 
Expert 
approval 
Delete 
47. I can balance my needs with the needs of
others who depend on me. X X X Delete 
48. I am comfortable telling my friends and
family what I need. Most: 1 X X X Delete 
49. I protect my family and friends from my
health problems. Least: 1 X X 
Cross-
loaded 
onto 
Factor 3 
Delete 
50. Sometimes I have to put myself first. X X Delete 
51. I feel connected to other cancer survivors. Poor 
conceptual 
clarity 
with factor 
Delete 
52. I support other cancer survivors. Poor 
conceptual 
clarity 
with factor 
Delete 
53. Telling other people my story makes me
feel good. Keep 
54. I prefer to deal with my cancer on my
own.
Most: 1 
Least: 1 (cancer 
survivor) 
X Cross-loading Delete 
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Table 10 (continued) 
55. I want to give back by helping other 
cancer survivors. Least: 1      
Poor 
conceptual 
clarity 
with factor 
Delete 
56. I try to raise awareness about cancer. 
      
Cross-
loaded 
onto 
Factor 3 
Keep 
57. I am comfortable sharing my cancer 
experience with others. Least: 1       Keep 
*Many items during content expert review were worded differently from the items in the 57-item scale included in the Reliability and Validity testing. 
**This category was only considered in the last rounds of item deletion if there was acceptable item performance on all previous measures. 
Underlined X’s indicate that poor communalities and/or factor loadings occurred after the first set of items was deleted. 
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Several items loaded or cross-loaded on unexpected factors. Two items (Item 19: “I ask 
questions when I don't understand what my provider is telling me.”; Item 26: “I question my 
provider if I don’t agree with his or her recommendations.”; and Item 30: “I ask my provider to 
explain his or her recommendations.”) were originally included in the “Leading my Health Care” 
dimension but cross-loaded slightly more strongly on the “Application of Information” 
dimension. This was assumed to be because all three questions included aspects of 
communication (e.g. “I ask…” and “I question…”) and decision-making (e.g. seeking 
clarification and explanations). Due to the original intent for the items to be in the “Leading 
my Health Care” dimension, lack of impact on factor correlations, and difference of < 0.25 
factor loading between dimensions, the decision was made to keep Items 19 and 30 on the 
“Leading my Health Care” factor which would later be named “Communicating with My 
Health Care Providers.” 
One item, (Item 32: “I am comfortable asking for a second opinion.”) clearly and solely 
loaded onto the “Application of Information” factor rather than the “Leading my Health 
Care” dimension for which it was originally intended. While the intent of the item was 
intended to tap into patients who fear speaking up to their provider or being rude at the expense 
of their pursuing more diagnosis and treatment options, the item also includes aspects of 
seeking out information and going to a new provider to ask for a recommendation. Due to 
the clear loading and conceptual congruence with patients seeking out information this item 
was moved to the factor on which it loaded. 
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2.6 RENAMING FSACS SCALE DIMENSIONS 
In accordance with scale development procedures, the FSACS Scale dimensions were renamed 
after the final item set was determined. First, the three factors from the factor analysis were 
selected. For each factor, the items were ranked from highest to lowest factor loadings. Items that 
cross-loaded onto other factors (e.g. Items 19 and 30) were ranked at the bottom. Items were 
reviewed by three researchers (T. L. H., S. M. C., and H. S. D.) to identify common attributes 
or themes between a factor’s items. A new dimension name was agreed upon by the 
three researchers that encompassed all items within the factor. 
The original dimension “Application of Information” was updated to “Being an 
Informed Decision Maker” after reviewing factor loadings. Not only was the word “decision” 
used in 4 of the 6 items, but the terms “prepare,” “weigh my options,” “asking,” and “use 
my skills,” and “gather information” all demonstrate the work necessary to being informed 
decision makers and participants in their health care. This factor explained the most amount of 
variance in participant responses.  
The original dimension “Connected Strength” remained the same after reviewing the 
factor loadings. This factor explained the second most variance in participant responses. Items 
reflect the ways in which female cancer survivors benefit from  giving and receiving support..  
The original dimension “Mindful Non-adherence” had been updated to “Leading my 
Health Care” prior to construct validity testing and was finally updated to “Communicating 
with My Health Care Providers” after reviewing the factor items. Many items within this 
dimension had significant problems throughout all stages of psychometric testing. The items 
that remained strong during most or all of the content validity, reliability, and factor analysis 
testing centered on the ability of participants to communicate their questions, problems, 
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misunderstandings, and preferences to their healthcare providers. The verbs “tell,” 
“ask,” “voicing,” “talk,” and “question” were included in these items. Due to this emphasis 
on communication, the dimension was named to emphasize the ability or inability of some 
participants to communicate their needs to their providers. This factor explained the least 
amount of variance in participant responses. 
The final 20-item FSACS Scale is reported in Appendix B. 
2.7 ADDITIONAL FSACS SCALE DETAILS 
After the final FSACS Scale item set was determined, reliability statistics were reanalyzed for 
the total scale and three dimensions. Internal consistency was measured using Cronbach alpha as 
a coefficient of consistency for the 20-item set. The Cronbach’s alpha for the total FSACS Scale 
was α = 0.880 and α =  0.817, 0.791, and 0.850 for the “Being an Informed Decision Maker,” 
“Connected Strength,” and “Communicating with My Health Care Providers” dimensions, 
respectively. 
Test-retest reliability was also calculated for the final FSACS Scale. Using data from the 
previous reliability study, test-retest reliability for the final 20-item scale was calculated. The 
Pearson Product Moment Correlation for the total FSACS Scale was r = 0.926 (p ≤ 0.001) and r 
= 0.982, 0.980, and 0.888 for the “Being an Informed Decision Maker,” “Connected Strength,” 
and “Communicating with My Health Care Providers” dimensions, respectively, all at a 
significance level below p = 0.01. 
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3.0  MANUSCRIPTS 
The candidate has 2 published, 1 submitted, and 1 submission-pending manuscripts documenting 
her research team’s linear process of creating, testing, and validating the FSACS Scale.  
Manuscript 1: First, the candidate conducted a systematic literature review and concept 
analysis of self-advocacy to uncover the defining attributes, antecedents, and consequences of 
self-advocacy and their applicability to cancer survivorship. The focus group manuscript is 
published in the Journal of Advanced Nursing in October 2013. 
Manuscript 2: The candidate then led and analyzed focus groups to describe self-
advocacy as experienced by female cancer survivors. The focus group manuscript is published in 
the Oncology Nursing Forum in March 2013. 
Manuscript 3: Next, the candidate tested the content validity and initial reliability of the 
FSACS Scale in order to endure the face validity and consistency of item response. The content 
validity and reliability manuscript has been submitted to the Journal of Nursing Measurement in 
June 2015. 
Manuscript 4: Finally, the candidate will submit the construct validity manuscript to 
Cancer in August 2015. 
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3.1 CONCEPT ANALYSIS 
See Attachment 1.
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3.2 FOCUS GROUP TESTING 
See Attachment 2.
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3.3 CONTENT VALIDITY AND RELIABILITY TESTING MANUSCRIPT 
Theoretical to Tangible: Creating a Measure of Self-Advocacy 
3.3.1 Abstract 
Background & Purpose: Abstract concepts are difficult to measure. This article reports the 
process of creating a measurement of self-advocacy among female cancer survivors.  
Methods: The development of the Female Self-Advocacy in Cancer Survivorship 
(FSACS) Scale’s theoretical underpinnings and item development led to evaluations of the 
measure’s content validity and reliability.  
Results: The construct of self-advocacy contains 3 sub-dimensions with a total of 57 
Likert-type self-report items. Content validity results (S-CVI = 0.81 and S-CVI/UA = 0.83) 
indicated strong relevancy of items. Reliability results supported the consistency of the FSACS 
Scale scores, with strong internal consistency (Cronbach’s alpha = 0.92) and test-retest reliability 
(PPMC r = 0.94). 
Conclusions: Translating constructs like self-advocacy into quantifiable measures takes 
substantial effort, but is crucial to developing psychometrically strong, relevant measurements. 
3.3.2 Background & Conceptual Framework 
Self-advocacy has been identified as a critical component of improving health outcomes because 
it underlies individuals’ ability to understand and lead their own care (Clark & Stovall, 1996; 
Ferrell, McCabe, & Levit, 2013; Walsh-Burke & Marcusen, 1999). A patient’s ability to 
advocate for her health, social, and personal needs not only has the potential to make her a 
proactive and engaged health care consumer, but also affords her the ability to ensure her health 
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and care promote her self-worth and identity. Yet a dearth of research leaves researchers and 
clinicians unable to measure survivors’ ability to self-advocate and therefore provide evidence-
based interventions (Hermansen-Kobulnicky, 2008). Moreover, differences between and within 
genders are known to exist in how cancer survivors self-advocate (Sinding et al., 2010; Wiltshire 
et al., 2006). In order for self-advocacy to be an accurate, effective variable for use in research 
and practice, a new measurement tool must be created specific to the phenomena of self-
advocacy in this population.  
The purpose of this study is to report the content validity and reliability of a measurement 
of self-advocacy among female cancer survivors, the Female Self-Advocacy in Cancer 
Survivorship (FSACS) Scale. We aim to 1) report the conceptual and empirical steps included in 
our process and 2) evaluate the initial content validity and reliability of the FSACS Scale. 
Conceptual challenges and key decisions will be discussed along with their implications for 
clinical and research use of the final instruments. The process of compiling quantitative 
(deductive) and qualitative (inductive) sources of information to form the domains of a construct, 
developing items within each domain, and then testing the content validity and reliability of the 
instrument will be described.  
3.3.3 Procedures for Instrument Development 
Concepts and constructs are the basic building blocks of scientific theory and represent our 
verbal representations of “real world” phenomena (Watt & van den Berg, 1995). Some of these 
phenomena are directly observable; others are more abstract. Regardless of the level of 
abstraction, concepts and constructs must be unambiguously defined in order to operationalize 
the construct into reliable and valid instruments. As Shadish, Cook, & Campbell (2002) caution, 
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“To the extent that experiments contain construct errors, they risk misleading both theory and 
practice.” Ensuring that measures of these subjective phenomena accurately and meaningfully 
detect the presence of these concepts allows inferences to be made regarding the presence of the 
construct based on the measurement. 
The process of creating valid and reliable measures of abstract constructs such as 
behaviors, attitudes, personal characteristics, and quality of life is a complex, time-consuming, 
but essential task in behavioral research. Few articles provide practical advice and 
methodological directions about how to operationalize abstract behavioral concepts into 
psychometrically sound, parsimonious instruments. Similarly, most manuals and textbooks 
provide broad guidelines without describing the contextual nuances of item and scale 
development. This article, which describes the progression from concept to tool can provide an 
exemplar for researchers endeavoring to develop measures that accurately operationalize abstract 
constructs. 
Establishing the initial FSACS Scale was performed in multiple steps using established 
methods for psychometric and instrument development (American Educational Research 
Association, 1999; Food and Drug Administration, 2009): 1) Developing the initial instrument: 
Quantitative and qualitative findings from the literature and qualitative data from focus groups 
was analyzed and synthesized into a construct definition, three dimensions, and 57 items. 2) 
Content validity testing: The initial instrument was tested for face value approval among a group 
of professional and lay experts in self-advocacy to evaluate relevancy and clarity. 3) Reliability 
testing: A revised instrument was tested among a pilot sample of 40 adult female cancer 
survivors for consistency in item responses over a two week time period. 
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3.3.3.1 Intent The first step in instrument development is defining the intent of the instrument. 
We wanted to measure adult female cancer survivor’s abilities to advocate for their health, well-
being, and self-worth during their cancer journey. Self-advocacy was assumed to be a state, or 
transient characteristic, rather than a trait, or enduring, characteristic. 
3.3.3.2 Construct Definition Constructs link theories to experiments, and therefore how we 
define constructs is crucial to ensuring that inferences from measurement to theory can be made 
within and across concepts, theories, and uses (Shadish, Cook & Campbell, 2002). During a two-
year period, we collected and analyzed multiple sources of evidence and reduced all of our data 
into clearly defined, essential attributes of self-advocacy. The goal was to operationalize the 
concept of self-advocacy using its distinguishing features as revealed by previous research and 
patient experience. This iterative process included several revisions before deciding on a set of 
items. Conceptual domains were created using both deductive and inductive methods.  
Deductive methods included a concept analysis and literature review of self-advocacy 
within cancer survivorship (Hagan & Donovan, 2013a). An in-depth review of the literature and 
patient experiences were absolutely critical to uncovering the full range and breadth of the 
phenomena. Research was included from oncology, HIV/AIDS, mental health, disability, 
empowerment, engagement, and female health psychology fields. After reviewing this broad 
literature, theoretical clarity came through conceptually differentiating the predictors, outcomes, 
and defining characteristics of self-advocacy within oncology according to Walker and Avant’s 
methodology (2005). 
During the literature review, an existing measure of self-advocacy, the Patient Self-
Advocacy Scale (PSAS; Brashers, Haas, & Neidig, 1999), was identified. While both the PSAS 
and the FSACS attempt to capture the construct of “self-advocacy,” the populations of interest 
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are categorically distinct. The PSAS was developed among individuals with HIV and a primarily 
male population. Because of the significant disease and gender differences and existing evidence 
for inadequacy of the PSAS when tested among cancer survivors (Hermansen-Kobulnicky, 
2008), we chose not to adapt the previous measure but to create a new measure with 
consideration for the behavioral aspects that may overlap between patient and gender 
populations.  
Inductive methods included a focus group of cancer survivors (n = 14) in order to elicit 
patient perspectives on and experiences of self- advocacy (Hagan & Donovan, 2013b). The 
results corroborated several of the findings from the concept analysis, but also revealed new 
attitudes about self-advocacy particular to the female cancer population that had not yet been 
discussed in the literature. 
3.3.3.3 Construct The construct of self-advocacy was ultimately defined as how patients stand 
up for themselves during their cancer experience. When faced with any of the myriad challenges 
that cancer diagnosis, treatment, and survivorship presents, how is a woman able to get her 
needs, priorities, and preferences met? Beyond just being proactive and engaged, self-advocacy 
defines the ability to face problems that come as a result of the cancer. Many of these problems 
may concern treatment and working with the medical team, but other problems may concern 
accessing and utilizing information or maintaining relationships with family members, friends, 
and other cancer survivors.  
While historically advocacy has been used as a means of addressing social inequalities 
and power hegemony within the medical institution (Brashers, Haas, Neidig, & Rintamaki, 
2002), the construct of self-advocacy does not promote adversarial relationships between patients 
and their health care providers or institutions. Rather, the degree to which a patient is able to 
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self-advocate is the degree to which she can productively participate as an equal member of her 
health care team and social support network even in the face of difficult situations. 
3.3.3.4 Challenges Conceptual challenges arose while developing the definition of self-
advocacy. This has consequences not only for the measurement tool but also in how the tool 1) 
will be applied to and translated into intervention research and 2) can support broader theory 
development. As discovered while conducting the concept analysis (deductive method), theories 
of self-advocacy within cancer are largely immature and non-parsimonious, creating confusion 
regarding the defining features of self-advocacy and differentiation with its antecedents or 
consequences. Definitions encompassed both attitudinal and behavioral components; inter- and 
intrapersonal applications; and situational and policy spheres of action. Different disciplines 
made different assumptions about the intent of advocacy varying from collective groups 
changing national or state policies to groups of individual survivors for improving their personal 
health, well-being, and autonomy. Ultimately, we decided to define self-advocacy in terms most 
relevant to cancer survivors which had scientific evidence in the literature and would ensure that 
the application of the tool would be meaningful given the needs of this population. 
Difficulties also occurred during the inductive derivation of item content. The focus 
groups uncovered the real-life behaviors and attitudes of how women define “self-advocacy” in 
their contextually situated cancer experiences. The initial analysis of the results provided rich 
descriptive data identifying a multitude of themes and subthemes. However, consistent with 
traditional focus group analysis, analyses focused on reaching theoretical saturation and not 
generalizability to other populations. In order for instrument development to encompass the full 
breadth of the participants’ conversations, a fresh reading of the focus group transcripts was 
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required to assure all possible behavioral indicators of self-advocacy would be captured in the 
measurement’s items and dimensions. 
Combining the results from the use of the deductive and inductive methods was a third 
challenge, and the most conceptually demanding. Our aim was to have subscales that were 
similar enough to have a shared relationship with the overall construct yet different enough to 
provide unique information about the full conceptual breadth of self-advocacy. After consulting 
with instrumentation experts, it was decided to focus on three dimensions of self-advocacy 
supported by both deductive and inductive methods which together would be able to define self-
advocacy, discriminate between women who do and do not self-advocate, and potentially be the 
most modifiable characteristics. This meant that some findings from the concept analysis and 
focus group study were not directly included in the scale’s dimensions. These findings were 
considered outside the scope of the measurement model and scale building because they did not 
focus on actions but remain significant aspects of self-advocacy to be integrated into future 
research. Figure 2 illustrates the synthesis and refinement of the focus group and concept 
analysis results into the dimensions of the FSACS Scale. 
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Figure 2. Derivation of Female Self-Advocacy in Cancer Survivorship Scale’s Dimensions Based on Deductive and Inductive Pilot Work
Concept Analysis (Deductive) 
Defining Characteristic 1: Thoughts and 
Cognitions 
• Prioritization of needs, wants 
• Sense of empowerment 
• Creation of ‘new normal’ 
Defining Characteristic 2: Actions for Self 
• Make informed decisions 
• Navigation of healthcare system 
• Teamwork with healthcare providers 
• Mindful non-adherence 
Defining Characteristic 3: Utilization of 
Resources 
• Seeking and providing support 
• Membership in cancer-related groups 
• Advancing cancer awareness, policy, and 
research 
FSACS Scale 
Dimension 1: 
Application of 
Information 
Dimension 2: 
Leading My 
Health Care 
Dimension 3: 
Connected 
Strength 
Focus Groups (Inductive) 
Theme 1: Knowing Who I Am and 
Keeping My Psyche Intact 
• Having a strong will 
• Keeping a positive attitude 
• Being on the tipping point 
Theme 2: Knowing What I Need 
and How to Get It 
• Knowing how and when to seek 
information 
• Being pro-active to manage my 
healthcare team 
• Taking advantage of my support 
network 
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3.3.4 Description, Administration, and Scoring of the Instrument 
3.3.4.1 Operationalization and Item Development After each of the three dimensions was 
defined, self-report items were created according to the domain sampling model (DeVellis, 
2012). An exhaustive list of items from a hypothetical universe of items relating to the defining 
characteristics of self-advocacy among female cancer survivors resulting in 20-30 items for each 
dimension with a total of 71 items. This was considered enough to provide sufficient breadth of 
items per domain. Redundancy was encouraged at this stage with the goal of capturing the full 
breadth of the construct.  
Response options included a 6-point Likert-type (1 = strongly disagree and 6 = strongly 
agree) response scale to avoid over-selection of a neutral response option that is often observed 
in response bipolar scales with a midpoint. Positive and negative stems were included. Varying 
levels of intensity or difficulty were included to ensure response variance and scale sensitivity to 
differences in self-advocacy. 
Central to our consideration of writing items was ensuring that the items were specific 
and concrete enough to inform future research to support women who struggle to self-advocate. 
By selecting reflective indicators of the construct as opposed to unobservable precursors that 
give rise to self-advocacy, items are more likely to be modifiable and translated into intervention. 
Items asking for respondents to indicate their beliefs or react to hypothetical situations were 
therefore avoided and preference given to actions and behaviors. 
3.3.4.2 Administration & Scoring The FSACS Scale is intended to be a self-administered 
measurement tool to be used in both research and practice settings as a means of identifying 
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female cancer survivors who struggle to advocate for themselves. A total score will be used to 
measure a woman’s overall ability to self-advocate, while sub-dimension scale scores will 
provide more specific information about areas in which they may struggle. 
3.3.5 Content Validity Testing & Results Content validity is “the degree to which elements 
of an assessment instrument are relevant to and representative of the targeted construct for a 
particular assessment purpose” (Haynes, Richard, & Kubany, 1995). Testing content validity 
assesses the degree to which the content of the instrument reflects the construct of self-advocacy 
among female cancer survivors. Employing both population and content experts was critical to 
establishing a valid measure (Vogt, King, & King, 2004). The expert panel, described in Table 
10, included 9 representatives (N = 9): 3 females with cancer, 1 nurse practitioner, 1 physician, 2 
researchers, 1 social worker, and 1 patient advocate. One of the survivors was an African 
American female. All professionals on the panel specialized in working with female cancer 
survivors. Qualifications of experts were evaluated by their professional and personal experience 
with female cancer survivors and identification by peers as promoting patient self-advocacy 
(Grant & Davis, 1997). 
Table 10. Expert Panelists for Content Validity 
Member Number Gender 
Years in 
Role 
Cancer 
Survivor 
Cancer Survivors 3 Female 9, 10, & 18 
Breast, Ovarian, 
& Brain 
Nurse Practitioner 1 Female 18 No 
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Table 10 (continued) 
Physician 1 Male 30 No 
Researcher 2 Female 14, 25, &35 No 
Social Worker 1 Female 30 No 
Patient Advocate 1 Male 10 Melanoma 
We personally contacted each panel member to explain the instrument development 
process, the definition of self-advocacy, and the value of their experiential expertise in self-
advocacy to critiquing our instrument. All contacted experts agreed to participate. Each expert 
panel member was sent the initial FSACS Scale, a written introduction to the concept of self-
advocacy, a content validity questionnaire, and a copy of the preliminary FSACS Scale. The 
experts reviewed each item and the scale as a whole. Each item was rated separately for 
relevancy and clarity using 4-point Likert-type scales ranging from 1 (not relevant/clear) to 4 
(very relevant/clear) and space was given for comments. We also asked questions regarding the 
overall scale, suggestions for additions and revisions to the measure, and any other comments. 
Completed packets were returned and analyzed. 
Lynn’s (1986) methodology was used to calculate the Content Validity Index (CVI) for 
each scale item and the entire scale. Based on Lynn’s criteria, a CVI of 0.78 (or 7 of the 9 
panelists) indicates adequate endorsement of an item or the instrument beyond the α = 0.05 level 
of significance.  
In total, 14 items were deleted due to low CVI, redundancy of items, or for being 
outcomes rather than behaviors of self-advocacy. Thirteen items were reworded, mainly to soften 
any confrontational language, improve specificity, and include action-orientation. Based on 
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panelist feedback, 22 items had ≥ 3 panelists rating its relevancy as a 1 or 2. Five of the twelve 
items from the previous self-advocacy measure received low-rankings from the panelists. Of 
note, 3 items were preserved despite low ratings because of discrepancies between researchers’ 
and survivors’ ratings with preference given to survivors’ ratings. For example, the item “I don’t 
know enough to make decisions about my cancer and treatment” (reverse scored) was endorsed 
by survivors but not researchers. 
Content validity statistics of the 57-item scale are reported in Table 11. The Average 
Scale-CVI (S-CVI/Ave) was calculated by averaging the proportion of experts rating each 
individual item as relevant (rating of 3 or 4). In other words, the S-CVI/Ave is equal to the 
average of each of the individual item CVIs (I-CVI). The Scale-CVI/Universal Agreement (S-
CVI/UA) was calculated as the proportion of items rated as relevant (rating of 3 or 4) by all 8 
experts (Polit & Beck, 2006). Both the S-CVI/Ave (0.81) and S-CVI/UA (0.83) were above the 
recommended cut-off level of 0.78. 
Table 11. Content Validity Statistics 
3.3.6 Reliability Testing & Results 
Reliability testing was performed in order to 1) evaluate internal consistency (the degree of 
consistency among items in the instrument) and test-retest reliability (the stability of the 
observed scores over time) of the FSACS Scale; 2) evaluate the feasibility of assessing self-
Type of CVI Statistic Calculation 
Average Scale-CVI (S-
CVI/Ave) 0.81 
Average proportion experts rating each item as 
relevant (rating of 3 or 4) 
Scale-CVI Universal 
Agreement (S-CVI/UA) 0.83
Proportion of total items judged by all experts as 
relevant (rating of 3 or 4) 
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advocacy and related measures necessary for instrument validation; and 3) produce a 
parsimonious scale to be validated in a large sample study. Note that prior to reliability testing, 
pilot testing of the final 57 items was conducted with a group of masters-prepared nurses, 
research staff, and staff at the University of Pittsburgh School of Nursing as final check for 
readability, grammar, spelling, and formatting. 
Evaluation was completed with a sample of female adult cancer survivors. To estimate 
test-retest reliability, a repeated measure design with baseline and 2-week measures was used. 
Time points were chosen to test the scale’s consistency within a time period in which little 
variation is expected (DeVillis, 2012).  
Recruitment of N =40 participants was conducted at four cancer and advocacy 
organizations and three cancer clinics in Pittsburgh, PA. Inclusion criteria included: 1) female, 2) 
≥ 18 years old, 3) history of a cancer diagnosis at ≥ 18 years old, and 4) a cancer diagnosis other 
than basal cell carcinoma or cervical intraepithelial neoplasia stage 1 (these survivors have 
inherently different treatment and symptom experiences than other cancer survivors). Equal 
numbers of participants were recruited through clinics and organizations. Directors at clinics and 
organizations identified potential participants and introduced the study to them. Potential 
subjects who expressed interest in participating were introduced to the researcher (T. H.) who 
then carried out screening and informed consent procedures.  
On Day 1, the researcher screened potential subjects for eligibility. If the potential 
participant met the inclusion criteria and was interested in participating in the study, written 
consent was obtained. Participants completed all baseline study measures in a private room at the 
clinic or office. Individual measures were randomly ordered to avoid an order effect. The 
researcher (T. H.) handed all measures to the participant, instructed the participant to complete 
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the survey independently, asking the candidate for clarifications or assistance as needed. 
Following completion of the FSACS Scale, the researcher conducted cognitive interviews with 
the participant to review any problems or issues with the items or survey and to assess the 
feasibility of completing the survey. 
After all surveys were complete, the researcher provided the participant with an envelope 
containing the follow-up survey, instructions to complete the survey in 2 weeks (14 days), and a 
pre-addressed, pre-stamped envelope to mail the survey to the candidate. The researcher called 
each participant 2 days before the follow-up survey was to be completed and sent reminder 
postcards 3 and 5 days after the due date if the survey was not received. Participants were sent 
thank you cards with a $20 pre-paid debit card after receipt of the follow-up survey. 
Sample characteristics and health histories for the reliability study are described in Table 
12 and Figure 3. The sample had a mean age of 57.28 years (SD = 13.16, Observed Range = 25-
89) and 53.8% were married. Women represented a diverse population with 12.8% of
participants identifying as Black or African American and one identifying as Hispanic. Twenty-
one percent of women had a high school degree or less, and only 35.9% were working full-time. 
About 20% (n = 8) of women had a household gross annual income less than $30,000. Most 
women (n = 17, 42.5%) had a diagnosis of ovarian cancer, followed by breast cancer (n = 15, 
37.5%). Almost half of the women were within one year of their cancer diagnosis (n = 19, 
47.5%). The remaining women were either between 1 and 5 years since diagnosis (n = 11, 
27.5%) or greater than 5 years since diagnosis (n = 10, 25%). Most women (n = 26, 65%) were 
receiving treatment at the time of survey completion. Seven (12.5%) women had experienced at 
least one recurrence. 
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Table 12. Demographic and Health Information for Reliability Study Sample 
n % M SD 
Demographic Information 
Age 57.5 13.1 
Years of education 14.6 4.2 
Race and Ethnicity 
White 32 84.2 
African American/Black 5 13.2 
Other 1 2.6 
Latina 1 2.6 
Employment status 
Working ≥ 35 hours/week 14 35.9 
Retired 10 25.6 
Working < 35 hours/week 9 23.1 
Disabled 4 10.3 
Laid off/unemployed 1 2.6 
Relationship status 
Currently married 21 53.8 
Divorced/separated 7 18.0 
Never married 4 10.3 
Widowed 4 10.3 
Living with partner 3 7.7 
Household annual income 
< $30,000 7 20.6 
$30,000 - $59,999 8 23.5 
$60,000 - $99,999 9 26.5 
≥ $100,000 9 26.5 
Cancer History 
Time since diagnosis 
<1 year 19 47.5 
1 -5 years 11 27.5 
> 5 years 10 25.0 
Cancer recurrence (M and SD 
if any recurrence) 7 17.5 3.4 4.4 
Multiple cancer diagnoses 5 12.5 
Currently on treatment 26 65.0 
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Figure 3. Cancer Diagnoses of Reliability Study Sample 
Two measures of reliability were estimated: 1) internal consistency as measured by 
Cronbach’s alphas based on N = 40 and 2) test-retest reliability or item response stability as 
measured by Pearson’s Product Moment Correlations based on n = 39. Participant feedback was 
reviewed using content analysis to identify recurring themes. Internal consistency for the FSACS 
was strong (alpha = 0.92). The three dimensions had Cronbach’s alpha’s of 0.88, 0.81, and 0.90, 
respectively. 
Preliminary evaluation of test-retest reliability indicates that the scale is highly stable 
across time points (Pearson Product Moment Correlation of r = 0.94). The three dimensions also 
showed strong test-retest reliability (Application of Information: r = 0.85; Leading My Health 
Care: r = 0.97; Connected Strength: r = 0.88). Feasibility and acceptability of completing the 
FSACS Scale was reported to be high by participants though several participants noted that the 
number of items in the FSACS Scale would need to be greatly reduced to reduce response 
burden. 
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Cognitive interviews identified participant concerns about specific questionnaire items. 
The most common concerns reported by participants included difficulty responding to items that 
implied that they have control over their cancer, have an adversarial relationship with their 
provider, or suggested a need to actively reach out to other survivors or tell their story to others. 
Future iterations of the survey instructions and final item selection will consider these patient 
concerns. 
Figure 4 illustrates the FSACS Scale used during reliability testing. Indications are made 
to highlight items that performed poorly during content validity testing, reliability testing, and 
cognitive interviewing. Items listed in this figure do not represent the final FSACS Scale; 
construct validity testing will further test this measurement model and result in a parsimonious 
scale with a significantly reduced number of items. Figure 4 is meant to be a useful template for 
instrument developers who are looking to take a construct and clarify its dimensions, sub-
dimensions (if any), and items while ensuring consistency between these varying levels of 
abstraction. 
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Construct Self-Advocacy Among Female Cancer Survivors 
   
Dimension Application of 
Information 
Leading My 
Health Care 
Connected 
Strength 
   
Sub-dimension 1 
Using information related to 
problems related to cancer 
(7 items) 
Voicing needs/preferences 
to provider 
(7 items) 
Seeking/giving support 
(8 items) 
-Know how to address problems 
related to job/responsibilities+* 
-Know how to cover costs of 
cancer* # 
-Weigh options before making 
decision* 
-Prepare to make decisions 
-Know priorities before making 
decision 
-Feel information helps make 
decisions 
-Look for alternative ways to 
manage problems+ * # 
-Hard to voice my 
preferences R  
-Wait for provider to make 
changes R #
-Tell provider if 
medication is not working 
-Don’t discuss problems 
unless solution* 
-Rarely tell provider about 
problems R 
-I know what is best for me 
P+ * #
-Provider knows what is 
best R + # 
-Seek support from other 
survivors 
-Seek support from 
friends/family+ # 
-Helping others helps me 
-Being there for other cancer 
survivors is important 
-Reach out to other survivors 
-Knowing others gave gone 
through this helps me* 
-Feel connected to other 
survivors 
-Support other survivors 
Sub-dimension 2 
Applying information to 
problems related to cancer 
(4 items) 
Asking questions 
(2 items) 
Feeling comfortable asking 
for help 
(2 items) 
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-Try new ways to improve life 
-Don’t know enough to make 
decisions R* # 
-Use skills to solve problems+ 
-Gather information prior to 
making decisions 
-Ask questions if I don’t 
understand P # 
-Ask provider to clarify 
recommendations P 
-Comfortable telling 
friends/family what I need# 
-Don’t like asking for helpR 
Sub-dimension 3 
Finding trustworthy, relevant 
information 
(5 items) 
Seeking additional support 
beyond that of provider 
(5 items) 
Balancing needs of self with 
needs of others 
(6 items) 
-Seek out information P 
-Make sure information is 
trustworthy 
-Distinguish if information is 
applicable or not 
-Feel control from information 
-Ignore questionable information 
-Know other places to get 
answers to my questions* 
-Don’t know where to go if 
provider can’t help me R 
-Feel comfortable asking 
for second opinion 
-Worry that second opinion 
would hurt relationship 
-Seek help for other needs+ 
#
-Make decisions based on 
family 
-Friends and family motivate 
me# 
-Balance my needs with 
others’ needs* 
-Able to put self first 
-Prefer to deal with cancer by 
myself*
-Protect friends/family from 
health problems R 
Sub-dimension 4 
Adjusting providers 
recommendations 
(3 items) 
Raising awareness and 
support for cancer causes 
(4 items) 
-Adjust recommendations 
to fit my life P+ *
-Decide not to follow 
recommendations P*# 
-Have reason for not 
-Feel good telling my story 
-Want to give back to 
survivors 
-Try to raise awareness 
-Feel comfortable sharing my 
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following 
recommendations* # 
experience 
Sub-dimension 5 
Feeling comfortable 
disagreeing with provider 
(4 items) 
-Feel I can disagree with 
provider# 
-Don’t want to be seen as 
difficult R#
-Question provider if I 
disagree with him or herP
-Bothered by not following 
provider+ * # 
P = In previous measure of self-advocacy for HIV/AIDS population  
R = Reverse-scored item 
+ = Cognitive Interviews: Negative verbal feedback from at least 3 participants 
* = CVI score: Low score measured by at least 3 content experts rating item a 1 or 2 for relevancy or clarity
# = Reliability: Low internal consistency measure by item-total correlations <0.30  
Italicized = Considered for deletion in future testing based on ≥ 1 negative reliability and content validity testing 
(+,*, or #) 
Figure 4. Initial Female Self-Advocacy in Cancer Survivorship Measurement Model with Results of 
Content Validity, Reliability, and Cognitive Interview Testing 
3.3.7 Discussion 
Self-advocacy is a process that precedes and promotes many positive healthcare behaviors and 
attitudes. Only by measuring self-advocacy through scientifically-discovered indicators of the 
construct can we as researchers and practitioners aim to improve it. The FSACS Scale, which 
operationalizes the latent variable of self-advocacy, should provide the means by which to 
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measure self-advocacy. In this study, we moved the construct of “self-advocacy” from a well-
appreciated but under-defined part of the cancer lexicon into a concrete, measurable construct. 
Using both deductive and inductive reasoning in a conjoint, purposeful manner we formed and 
tested the FSACS Scale for content validity and reliability. By rigorously developing and testing 
the initial content validity and reliability of the measure, users can have increased confidence in 
the ability to make inferences about patients’ abilities to self-advocate based on their FSACS 
Scale scores.  
A S-CVI of 0.81 and S-CVI/UA of 0.83 and strong reliability results provide promising 
evidence that the content is 1) representative of the targeted construct, 2) item responses are 
stable over time, and 3) items have a high degree of consistency with each other. Cronbach’s 
alpha is a function of scale length and may be overinflated, so internal consistency will be 
retested in future construct validity testing with the final set of scale items. 
While the methodology of clarifying the dimensions of self-advocacy was time-
consuming and required reading multiple sources of literature to understand the historical uses 
and intentions of self-advocacy, we believe this detailed attention resulted in a clear tool capable 
of being retested and reapplied in future patient populations. By paying attention to previous 
research, patient experiences, expert opinion, and thorough analysis of the initial tool, future 
applications of the tool should be easier to understand and interpret because it reflects the best 
understanding of the phenomena of self-advocacy among female cancer survivors. 
The version of the FSACS Scale discussed in this analysis is not the final scale. 
Currently, in-depth construct validity testing of the FSACS Scale is underway in a large-sample 
study. Hypotheses will be tested related to the extent to which the factor structure of the scale is 
congruent with the conceptual dimensions of self-advocacy and how the FSACS Scale scores 
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should compare to scores on other measures including, 1) predictors and outcomes of self-
advocacy and 2) constructs that are similar but distinct from self-advocacy (e.g. PSAS, patient 
activation). Our goal is to validate a parsimonious measure of self-advocacy that is specific to 
self-advocacy in female cancer survivors, sensitive to changes in self-advocacy over time, and 
specific enough to distinguish between women who struggle to self-advocate and those who do 
not. 
Finally, this study has limitations. Survey research inherently includes errors of 
observation and non-observation that impact the precision of a measure. Participant responses 
may not be accurate (observational error), the sample may not represent the population to which 
the instrument is to be made generalizable (coverage error), and people who are approached do 
not always complete the study (response error). Self-reported administration methods introduce 
respondent recall, bias error, and social desirability error which can impact external validity of 
score interpretations. Concerns of observation and bias were addressed by instructing 
participants that little is known about the benefits or harms of self-advocacy, including a large 
number of items, and targeting behaviors varying in level of difficulty. Despite these limitations, 
the initial FSACS Scale meets most of Lohr et al.’s (1996) attributes for high-quality, health 
outcome measurement tools. 
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3.4 CONSTRUCT VALIDITY TESTING MANUSCRIPT 
3.4.1 Abstract 
Background: The Female Self-Advocacy in Cancer Survivorship (FSACS) Scale is a new 
measurement tool designed to address the increasing need for cancer survivors to participate in 
and lead there care in face of barriers. Pilot work has demonstrated the FSACS Scale’s content 
validity and reliability. 
Purpose: This purpose of this study was to evaluate the construct validity of the FSACS 
Scale. This instrumentation study evaluates the construct validity of the FSACS Scale as 
evidenced by: (I) Internal structure consistent with the underlying model of self-advocacy; (II) 
Sensitivity to differences between known groups; (III) Relationships between self-advocacy and 
key predictors (openness and conscientiousness; information engagement; social support) and 
outcomes (symptom distress and healthcare utilization); (IV) Relationships between FSACS 
subscales and related concepts (patient activation; self-advocacy within the HIV/AIDS 
population); and (V) Relationships between FSACS scores and criterion measures. 
Methods: A mixed-mode (online or mailed) cross-sectional survey design was used. 
Women with a history of an adult diagnosis of invasive cancer were recruited from two patient 
registries and seven advocacy organizations. Instrument selection and analyses to evaluate 
construct validity were based on the American Educational Research Association’s 
instrumentation guidelines. Analyses included an exploratory factor analysis, t-tests, and 
bivariate correlations.  
Results: A total of N = 315 adult female cancer survivors completed the survey. 
Evidence from all five construct validity hypotheses supports the construct validity of the 
FSACS Scale. The FSACS Scale factor analysis confirmed the three underlying dimensions of 
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self-advocacy resulting in a 20-item measure explaining 45.87% of the variance in 
responses with subscales’ Cronbach’s alphas between 0.791 and 0.850. While able to detect 
differences between women with low and high levels of education, the scale did not 
differentiate between recent and long-term survivors. Predictor and outcome variables 
performed as expected. The FSACS subscales were more highly correlated with these 
outcomes than the measure of self-advocacy for HIV/AIDS. 
Conclusion: Results support that the FSACS Scale is a theoretically-grounded measure 
of self-advocacy that can be used by clinicians and researchers to identify women at-risk for the 
poor outcomes associated with low self-advocacy.  
3.4.2 Introduction 
Individuals with cancer benefit from being engaged, active members in their care. A united 
group of patients, providers, advocacy organizations, and government agencies (American 
Society of Clinical Oncology, 2012; Clark & Stovall, 1995; Institute of Medicine, 2001; Shapiro 
et al., 2009) extols the benefit of cancer patients advocating for their needs, preferences, and 
desires. Self-advocacy is a concept similar to concepts of self-management and engagement, but 
distinct in its focus on situations in which a challenge or problem occurs. Despite this call for 
increased patient involvement, little research has guided providers, patients, or researchers on 
how to support patient self-advocacy. 
Existing theories and measurements of self-advocacy have been shown to inadequately 
represent the unique needs of individuals with cancer, especially those of women who face 
different problems of communication, symptom management, and quality of life compared to 
male cancer survivors (Anderson et al., 2004; Cleeland et al. 1994; Cimprich et al., 2005; 
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Elderkin-Thompson & Waitzkin, 1999; Howard, Balneaves, & Bottorff, 2007; Miaskowski, 
2003; O’Brien et al., 2008; Paulson, Wirtalla, Armstrong, & Mahmoud, 2009; Seale, Ziebland, 
& Charteris-Black, 2006). Over 7.6 million U.S. adult women had a history of a cancer diagnosis 
in 2013 (American Cancer Society, 2014). Women face physical, psychological, social, and 
financial challenges during their diagnosis, treatment, and survivorship. From the time of 
diagnosis through to long term survivorship, survivors must overcome barriers and negotiate to 
ensure they receive quality care that is concordant with their priorities (Sheppard, Adams, 
Lamdan, & Taylor, 2011). Gender differences in symptom prevalence and severity, patient care 
delivery, and communication place female cancer survivors at risk for poor health outcomes such 
as increased symptom distress and healthcare utilization (Bertakis & Azari, 2011; Bertakis & 
Azari, 2012; Keogh, 2014; Miaskowski, 2003). The degree to which these challenges can be 
addressed in a way that supports women’s needs, preferences, and priorities is a defining feature 
of providing patient-centered care.  
To fill this gap, a multi-phase instrument development process beginning with a literature 
review (Hagan & Donovan, 2013a), focus groups (Hagan & Donovan, 2013b), content validity 
(Hagan, Cohen, Stone & Donovan, 2015), and initial reliability (Hagan, Cohen, Stone & 
Donovan, 2015) studies resulted in a novel measure of self-advocacy for female cancer survivors 
that established the face validity and consistency of participant responses. The purpose of the 
current study is to evaluate the construct validity of the Female Self-Advocacy in Cancer 
Survivorship (FSACS) Scale in order to test the accuracy with which researchers and clinicians 
can use the FSACS Scale to make inferences about women’s abilities to self-advocate. 
The FSACS Scale is intended to measure the ability of female cancer survivors to get 
their needs, priorities, and desires met in the context of their cancer care. The construct consists 
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of three conceptual dimensions: (a) Application of Information, (b) Leading my Healthcare, and 
(c) Connected Strength. Application of information captures a woman’s ability to find 
trustworthy information and apply it to herself. Leading my healthcare exemplifies how a woman 
can build productive, respectful relationships with her health care team. Connected strength 
refers to a woman’s ability to both give and receive support, balance her needs with the needs of 
others, and gain strength through relationships. 
According to the American Educational Research Association (1999), establishing the 
construct validity of a measure is a process of developing and testing hypotheses about how the 
interpretation of a measurement’s scores should perform if it truly captures the intended 
construct. For example, by constructing proposed relationships between the interpreted scores of 
a new measure and scores of validated measures, a researcher can build an argument that the new 
measure’s scores accurately predict the presence of a latent concept.  
In order to test the FSACS Scale’s conceptual accuracy, the researchers tested a series of 
hypotheses including self-advocacy’s relationship with theoretical predictors, outcomes, related 
measures, and known differences between survivors. Predictors (personality traits of being open 
and conscientious, engaging in health information, and having social support) and outcomes 
(symptom distress and using healthcare resources) were selected based on findings from the 
concept analysis and focus group studies. Related measures were selected based on their 
conceptual similarity to self-advocacy and included patient activation and the previous measure 
of self-advocacy developed within the HIV/AIDS patient population. Evidence for construct 
validity will be determined by the failure to reject these five hypotheses. Figure 5 illustrates the 
measurement model relating all measures and hypotheses for construct validity testing. 
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Figure 5. Measurement Model of the Female Self-Advocacy in Cancer Survivorship Scale with Hypotheses for 
Validity Testing 
3.4.3 Methods 
3.4.3.1 Design A cross-sectional mixed-mode survey study design with a mixture of random and 
convenience sampling was used. A sample of 315 adult female cancer survivors was justified 
based on Tinsely and Tinsley (1987) and Comrey’s (1973) recommendations for factor analyses. 
Inclusion criteria included: 1) female, 2) being diagnosed with cancer after the age of 18, 3) 
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ability to read and write in English, and 4) a diagnosis of an invasive cancer (e.g. not basal cell 
carcinoma, squamous cell carcinoma, or cervical intraepithelial neoplasia Stage I). 
Women were recruited from 2 patient registries and 7 advocacy organizations. Figure 6 
lists each recruitment site and strategy. For the advocacy organizations and cancer clinics, 
leaders notified their members about the study through email, newsletters, and in-person 
meetings based on the preferences and feasibility of each site. Interested women contacted the 
principle investigator who screened the potential participants and mailed online or paper-based 
questionnaires to all eligible participants based on their preference.  
Members of the University of Pittsburgh Clinical and Translational Science Institute 
(CTSI) Patient Research Registry were alerted about the study, contacted the CTSI, and referred 
to the principal investigator if they screened as eligible for the study. Members of the 
Pennsylvania Tumor Registry (34.0% of the total study sample) were randomly selected from a 
list of women diagnosed with any type of cancer in the state for 15 selected years between 1985 
and 2013.  
3.4.3.2 Procedure Surveys were completed either on paper through the mail or online according 
to participant preference between July 2014 and March 2015. Dillman’s (2002) Tailored Design 
Method (e.g. personalization, ease of participation, and building a relationship with the 
participants) guided the design and delivery of both mailed and online surveys in order to build 
trust with participants and increase response rates and data quality. To further reduce sources of 
sample and respondent bias, refusal forms were given in the initial mailing to members of the 
Pennsylvania Tumor Registry if they did not want to participate.  
Paper surveys were mailed with a pre-addressed, pre-stamped return envelope. Online 
surveys were sent through Qualtrics, a secure web-based data management system. If 
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questionnaires were not returned, then reminder postcards or emails were sent on 5, 10, and 21 
days after the initial survey. Participants received a $10 gift certificate after returning the survey. 
The study was approved by the University of Pittsburgh’s Institutional Review Board. 
3.4.3.3 Measures The previously developed FSACS Scale is a 57-item 6-point Likert-type self-
report scale capturing 3 dimensions of how women with a history of cancer advocate (or stand up 
for) their needs, priorities, and wants in the face of an obstacle. Valid, reliable measures were 
selected to capture the hypothesized predictors, outcomes, and related concepts in the literature. 
Shortened versions were selected when available to reduce participant burden. Table 13 
describes each construct’s selected measure including number of items, response options, percent 
of female participants in the original study population, and reliability data. Predictors and 
outcomes were derived from the literature and previous qualitative work. Related measures were 
selected to compare and contrast the FSACS Scale with patient activation and the previous 
measure of self-advocacy derived from an HIV/AIDS population of mostly male patients 
(Brashers, Haas, & Neidig, 1999). 
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Table 13. Predictor, Outcome, and Related Measures 
Construct Citation Measure # of Items 
Item 
response 
options 
# of 
Subscales % Female 
Cronbach’s
α 
Predictors 
Demographic 
Characteristics 
(Sereika & Engberg, 
2006) 
CRCD 
Sociodemogra-
phic Survey - R 
25 Variable n/a 100 n/a 
Disease 
Characteristics n/a 
Investigator-
developed 7 
Single 
response n/a n/a n/a 
Openness and 
conscientiousness 
(Goldberg et al., 
1999; Goldberg, 
2006) 
IPIP 20 5-point Likert-type 2 
Not
reported .81-.82
Information 
engagement 
(DuBenske et al., 
2009) HIOS 8 
5-point 
Likert-type 1 63.6 .65 
Perceived availability 
of social support (Cohen et al., 1985) ISEL 12 
4-point 
Likert-type 3 74.4 .31-.81 
Outcomes 
Symptom severity & 
interference with life 
(Cleeland et al., 
2000) MDASI 24 
11-point 
Likert-type 2 57 .91-.94 
Healthcare utilization (Given & Given,2013) 
Adapted 
questionnaire 4 
Single 
response 4 
Not
reported n/a
Related Measures 
Patient activation (Hibbard et al., 2004) PAM 13 
5-point 
Likert-type 1 63 .91 
Patient self-advocacy  (Brashers, Haas, &Neidig, 1999) PSAS 12 
5-point 
Likert-type 3 9.2 .60-.82 
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3.4.3.4 Data Analysis 
Hypothesis 1: Internal Structure To test if the internal structure of the FSACS Scale 
reflected its theoretical underpinnings, an Exploratory Factor Analysis was performed using 
maximum likelihood (ML) method, oblique rotation, and scree plots. For comparison, Principal 
Axis Factoring and Principle Components extraction methods, orthogonal rotation, and 
eigenvalues were used to extract factors, and found to provide weaker explanations of item 
variance and factor structure. A goodness-of-fit statistic was evaluated the degree of congruence 
between data and the proposed model. 
Hypothesis 2: Sensitivity to Known Groups Comparisons were made between groups 
of women known to differ in their abilities to self-advocate to assure that the FSACS Scale is 
sensitive enough to detect differences between these groups. FSACS subscale scores should be 
significantly higher among (a) women with 5 or more years since their diagnosis compared to 
women within 1 year of their diagnosis and (b) women with more than a bachelor’s degree 
compared to women with a high school degree or less. Student t-tests were used to make these 
comparisons. 
Hypothesis 3: Relationships to Key Predictors and Outcomes FSACS total and 
subscale scores should be positively correlated to key predictors: participant’s personality traits 
of being open to new experiences and conscientiousness (IPIP), comfort and engagement in 
health information (HIOS), and perceived availability of social support (ISEL). Scores should 
also be negatively correlated to key outcomes: symptom severity and interference (MDASI) and 
healthcare utilization (HCU). Bi-variate correlations and t-tests as appropriate were conducted 
between FSACS Scale scores and other scale scores. 
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Hypothesis 4: Concurrence with Related Concepts Convergent validity was tested 
by comparing FSACS Scale scores with measures of patient activation and a previous measure of 
self-advocacy. Higher scores on the FSACS Scale should be positively associated with scores on 
the Patient Activation Measures (PAM). Subscale score correlations between the FSACS Scale 
and the previous patient advocacy measure (PSAS) are expected to vary according to the level of 
similarity between the old and new subscales: 1) the “Mindful Non-adherence” and “Leading My 
Health Care” subscales should be strongly positively correlated (r > 0.70); 2); the “Illness 
Education” (PSAS) and “Application of Information” (FSACS) subscales are expected to be 
moderately correlated (r = 0.30-0.70); and 3) the “Assertiveness” (PSAS) and “Connected 
Strength” (FSACS) subscales are expected to be weekly correlated (r < 0.30). Bi-variate 
correlations were conducted between the FSACS Scale scores of related concepts from the 
literature (PAM and PSAS) to evaluate concurrent validity. 
Hypothesis 5: Criterion Measures Criterion validity was tested by comparing FSACS 
Scale scores and PSAS total scores on outcome measures. FSACS Scale scores should be more 
highly correlated with outcome measures of symptom severity and interference (MDASI) and 
healthcare utilization (HCU) than the PSAS total score. Bi-variate correlations were calculated 
between the PSAS scores and outcome variables and compared with the strength of association 
between the FSACS Scale and outcomes to evaluate whether the FSACS Scale performs better 
among female cancer survivors compared to the PSAS. All data analyses were conducted using 
SPSS (Version 22, SPSS, Inc., Chicago, IL). 
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3.4.4 Results 
A total of N = 315 adult female cancer survivors completed the study. Recruitment site 
information and enrollment are listed in Figure 6. Women who refused to participate were 
significantly older (χ² (4, N = 409) = 93.6, p < .001), further from their time of diagnosis (χ² (2, N = 
403) = 8.3, p = .015), more racially diverse (χ² (6, N = 405) = 14.8, p = .022), and less educated (χ² (4, N 
= 400) = 79879.9, p < .001) than women who did participate in the study. 
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Key: 
∞ = Online invitation 
§ = Paper invitation
¥ = In-person invitation 
¢ = Local 
£ = National 
Random Sampling 
§ £ Pennsylvania Tumor Registry
• Assessed for eligibility (n = 1,201)
• Sent introductory packet (n = 896)
Completed (n = 208) 
• CTSI Patient Research Registry (n = 53)
• National Ovarian Cancer Coalition (n = 42)
• American Cancer Society (n = 27)
• Cancer Caring Center (n = 32)
• Urban League of Greater Pittsburgh (n = 5)
• African American Women’s Speakers Bureau (n = 8)
• LiveWell Survivorship Program (n = 15)
• Magee Women’s Research Hospital (n = 27)
Excluded (n = 210) 
• Envelopes returned as
undeliverable (n = 110) 
• Declined to participate (n = 100)
Analyzed (n= 315) 
• Paper (n = 129)
• Online (n = 186)
Convenience & Simple Random Sampling (estimated total 
female membership*) 
• ∞ ¢CTSI Patient Research Registry (n = )
• ∞ ¢ £National Ovarian Cancer Coalition (n = 4,250)
• ∞ ¥ ¢£American Cancer Society (n = 1,000)
• ∞ ¢ Cancer Caring Center (n = 6,300)
• ¥ ¢ Urban League of Greater Pittsburgh (n = 15,000)
• ¥ ¢ African American Women’s Speakers Bureau (n = 20)
• ∞ ¢ LiveWell Survivorship Program (n = 100)
• ∞ ¢ £ Magee Women’s Research Hospital (n = 21,000)
Enrolled (n = 136) 
• Signed and returned consent form
Completed (n = 107) 
• Returned questionnaires
Lost to follow-up (n = 29) 
Lost to follow-up (n = 26) 
Sent questionnaire (n = 234) 
Figure 6. CONSORT Flowchart of Site Recruitment, Sample Enrollment, and 
Data Collection 
113 
Sociodemographic and health information of the sample are reported in Table 14. Among 
the total sample, participants had a mean age of 58.4 (observed range = 21 – 95). Most women 
were white (n = 280, 89.7%), married (n = 194, 62.2%), earned at least a bachelor’s degree (n = 
166, 53.4%), and had a median household income of at least $50,000 (n = 164, 54.7%). Forty-
one women (13.0%) reported that their current household income did not meet their basic needs.  
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Table 14. Sample Demographics 
 n % 
Age (Mean, Standard deviation) 58.4 13.5 
Highest Degree Earned 
Less than high school 2 0.6 
High school 70 22.5 
Associates  72 23.2 
Bachelor’s  83 26.7 
More than bachelor’s  83 26.7 
Household Annual Income 
< $20,000 33 11.0 
$20 – 49,999 65 21.7 
$50 – 79,999 70 23.3 
$80 – 150,000 74 24.7 
> $150,000 20 6.7 
Unknown/decline 53 16.8 
Marital Status   
Currently married 194 62.2 
Separated/Divorced 41 13.1 
Never married 30 9.6 
Living with partner/ 
significant other 
22 7.1 
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Table 14 (continued)   
Widowed 22 7.1 
Other 3 1.0 
Race   
White 280 89.7 
African American/Black 24 7.7 
American Indian 1 0.3 
Alaska Native 1 0.3 
Asian 3 1.0 
Other 3 1.0 
Ethnicity   
Hispanic or Latino 7 2.2 
Types of Health Insurance 
Private  242 76.8 
Medicare 121 38.4 
Medicaid 25 7.9 
Disability 14 4.4 
Other 30 9.5 
 
Figure 7 lists the frequencies and percentages of all cancer diagnoses reported by 
participants. While most women reported having breast (n = 148, 47%) or ovarian (n = 68, 
21.6%) cancer, women listed over twenty different types of cancer. Figure 8 reports participants’ 
stages at diagnosis. Almost half of the participants were diagnosed at Stage I or II (n = 153, 
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48.7%). Figure 9 illustrates participants’ times since diagnosis. The sample included 63 (20.0%) 
women within one year, 109 (34.6%) women between one and five years, and 140 (44.4%) 
women over five years since their cancer diagnosis. Fifty-three (16.9%) women had more than 
one cancer diagnosis, and 73 (23.4%) women reported a recurrence of a cancer. Seventy women 
(45.5%) had previous illness experiences related to cancer outside of their own diagnosis. 
 
Figure 7. Types of Cancer Diagnoses in Sample 
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Figure 8. Cancer Stage at Time of Diagnosis 
 
 
Figure 9. Time Since Diagnosis in a Three-group Split 
Assumptions for maximum likelihood factor analysis, sub-group analyses, and planned 
comparisons were tested prior to data analyses. Estimation maximization was used to address 
missing data (8.0%) in the FSACS Scale responses; all other measures had <4% missing data. 
All assumptions for scales and subscales were upheld save for the FSACS Scale, which had 
skewness and kurtosis concerns which were managed by collapsing item response categories into 
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4 rather than 6 point scales. Also, both subscales of the MDASI were negatively skewed which 
was expected for this broad population of all cancer survivors. Descriptive statistics for all 
measures are reported in Table 15. 
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Table 15. Descriptive Statistics for All Measures 
 Measure Mean SD SE 
FSACS Scales 
Being an 
Informed 
Decision Maker 
FSACS Scale 34.55 4.67 0.26 
Connected 
Strength FSACS Scale 33.11 5.96 0.34 
Communicating 
with My Health 
Care Providers 
FSACS Scale 29.80 4.40 0.25 
Predictors 
Openness and 
Conscientiousness IPIP 76.45 9.58 0.03 
Health 
Information 
Orientation 
HIOS 23.57 4.18 0.03 
Social Support ISEL 43.45 5.66 0.03 
Outcomes 
Symptom 
Burden* 
MDASI – 
Severity 11.97 16.90 0.10 
 MDASI – 
Interference 5.06 10.02 0.13 
Utilization (n, %) 
in past 3 months 
Hospitalized 39 12.5%  
 Visited 
Emergency 
Department 
36 11.5%  
 Visited 
Primary Care 
Provider 
187 59.9%  
 Visited by 
Home Care 12 3.9%  
Related Measures 
Patient self-
advocacy PSAS 43.59 6.26 0.03 
Patient activation PAM 43.31 5.02 0.02 
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3.4.4.1 Hypothesis 1: Internal structure The factor analysis of the 57-item FSACS Scale 
resulted in a 20-item, 3-factor structure consistent with theoretical dimensions of self-advocacy. 
The three factors were named based on the content and themes of retained items within each 
dimension: 1) “Application of Information” was changed to “Being an Informed Decision 
Maker” (6 items); “Leading My Health Care” was changed to “Communicating with My Health 
Care Providers” (7 items); and “Connected Strength” remained the same (7 items). Reliability 
testing using Cronbach’s alpha and test-retest reliability data from the previous study (Hagan, 
Cohen, Stone, & Donovan, Submitted) was performed on the final measure and was strong 
across the FSACS Scale total and subscale scores (Table 16). 
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Table 16. Hypothesis 1: Factor Analysis with Oblique Rotation 
 Communality Factor 1 Factor 2 Factor 3 
Being an Informed Decision Maker (α = 
0.817; r= = 0.980**) 
    
I gather information before making 
decisions about my cancer care. 
0.569 0.822 -0.036 -0.131 
I weigh my options carefully before 
making important decisions about my 
cancer care. 
0.646 0.793 0.036 -0.005 
I prepare myself to make decisions 
about my cancer care 
0.575 0.768 -0.058 0.017 
I use my skills to solve the problems I 
face as a cancer survivor. 
0.418 0.638 0.152 -0.133 
When it comes to making decisions 
about my cancer care, I know what my 
priorities are. 
0.450 0.632 -0.065 0.109 
I am comfortable asking for a second 
opinion. 
0.249 0.437 0.031 0.088 
I know where to get an answer if my 
provider can't give me one. 
0.164 0.395 0.049 -0.021 
Connected Strength (α = 0.791; r = 
0.888**) 
    
I try to raise awareness about cancer. 0.561 -0.050 0.758 0.020 
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Table 16 (continued)     
Helping other cancer survivors also 
helps me. 
0.598 0.139 0.722 -0.023 
Telling other people my story makes me 
feel good. 
0.507 -0.150 0.717 0.106 
I seek out support from other cancer 
survivors. 
0.449 0.161 0.655 -0.197 
I am comfortable sharing my cancer 
experience with others. 
0.492 -0.173 0.641 0.253 
When I hear that someone has cancer, I 
try to reach out to them. 
0.403 0.027 0.633 -0.024 
It helps me to know that other cancer 
survivors have gone through what I am 
going through. 
0.342 0.101 0.574 -0.097 
Communicating with My Health Care 
Providers (α = 0.850; r = 0.980**) 
    
I don’t talk about a health concern with 
my provider unless I think there is a 
solution. (Reverse) 
0.562 -0.068 -0.033 0.791 
I rarely tell my provider about problems 
I am having related to cancer. (Reverse) 
0.552 -0.031 0.052 0.739 
I have a hard time voicing my 
preferences to my provider. (Reverse) 
0.343 0.178 -0.051 0.495 
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Table 16 (continued)     
I question my provider if I don't agree 
with his or her recommendations. 
0.299 0.416 -0.103 0.247 
I ask my provider to explain his or her 
recommendations. 
0.518 0.404 0.089 0.381 
I ask questions when I don't understand 
what my provider is telling me. 
0.474 0.420 0.003 0.373 
Primary factor loadings for each item are indicated in bold text. 
Reliability statistics are in parentheses following each dimension’s name (Total Internal 
Consistency: Cronbach’s α = 0.880; Total Pearson Product Moment Correlation: r = 0.926**) 
* indicates correlation is significant at a level below p = 0.01) 
** indicates correlation is significant at a level below p = 0.001) 
The chi-square goodness of fit test statistic tested the adequacy of the number of extracted 
factors. At χ² (133, N = 315) = 272.42, p < 0.01. To protect against a Type II error of rejecting 
additional factors due to the conservative p-value of 0.05, additional numbers of factors were 
tested. The chi-square statistics for the 4-factor solution also resulted in significant chi square 
statistics. While the 5-factor solution resulted in a non-significant chi square statistic, the pattern 
matrix did not result in conceptually understandable factors based on the underlying theory. 
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Thirty-seven items were deleted based on their individual communalities, inter-item 
correlations, item-to-total correlations, factor loadings, previous input from content validity 
experts, and conceptual meaningfulness. The alternative extraction methods did not result in 
significantly different item-total correlations, extracted factors, or explanation of variance in item 
responses. The Kaiser-Meyer-Olkin measure of sampling adequacy of 0.902 and Bartlett’s test of 
sphericity was significant  (X2 (190) = 2,583, p  < 0.001), indicating adequate sampling size.  
Table 16 shows the factor loadings for all three dimensions, which in total explained 
45.87% of the variance in participant responses (Table 17). The three factors were significantly 
correlated with each other but had weak to moderately-high correlations (Table 18). Due to this 
empirical evidence of distinct subscales, the decision to report FSACS subscale scores rather 
than total scores was made.  
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Table 17. FSACS Scale Variance Explained 
 
Initial Eigenvalues 
 
Extracted Sums of Squared 
Loadings 
 Rotated 
Sums of 
Squared 
Loadings 
Factor Total 
% of 
Variance 
Cumulative 
% 
 
Total 
% of 
Variance 
Cumulative 
% 
 
Total 
Being an 
Informed 
Decision Maker 
6.32 31.61 31.61  5.80 29.00 29.00 4.87 
Connected 
Strength 
2.78 13.88 45.49  2.25 11.27 40.27 4.03 
Communicating 
with My Health 
Care Providers 
1.61 8.03 53.52  1.12 5.60 45.87 3.50 
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Table 18. FSACS Subscale Correlation Matrix 
 Being an 
Informed 
Decision Maker 
Connected 
Strength 
Communicating 
with My Health 
Care Providers 
Being an 
Informed 
Decision Maker 
1.00 - - 
Connected 
Strength 
0.452** 1.00 - 
Communicating 
with My Health 
Care Providers 
0.628** 0.279** 1.00 
*p ≤ 0.05 
**p ≤ 0.01 
   
3.4.4.2 Hypothesis 2: Sensitivity to Known Groups Table 19 compares FSACS subscale scores 
of women with varying educational levels and times since diagnosis. As hypothesized, women 
with higher levels of education scored significantly higher on all three FSACS total scale and 
subscale scores compared to women with lower levels of education. However, experienced 
survivors did not have significantly different scores than women within a year of cancer 
diagnosis.  
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Table 19. Hypothesis 2: Group Comparisons 
Being an 
Informed 
Decision Maker 
Connected 
Strength 
Communicating 
with My Health 
Care Providers 
M 
(SD) 
t (p-
value) 
M (SD) 
t (p-
value) 
M (SD) 
t (p-
value) 
Time Since Diagnosis 
Within 1 
year  
(n = 63) 
33.52 
(5.21) 
-1.82 
(0.07) 
32.95 
(5.65) 
-0.98 
(0.33) 
29.43 
(5.06) 
-0.87 
(0.39) 
Greater than 
5 years  
(n = 140) 
34.76 
(4.10) 
33.78 
(5.50) 
29.99 
(3.91) 
Highest Level of Education 
High school 
or less  
(n = 72) 
33.34 
(4.15) 
-4.25 
(<.001)** 
33.04 
(5.58) 
-0.18 
(0.38) 
28.35 
(4.46) 
-4.39 
(<.001)** 
More than a 
bachelor’s 
degree  
(n = 83) 
36.00 
(3.62) 
33.87 
(6.16) 
31.22 
(3.67) 
*p ≤ 0.05 two-tailed significance
**p ≤ 0.01 two-tailed significance 
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3.4.4.3 Hypothesis 3: Relationships to Key Predictors and Outcomes Table 20 shows 
correlations between FSACS subscale scores and those of predictors and outcomes of self-
advocacy. Predictors: FSACS subscale scores were significantly positively correlated with all 
predictors (openness and conscientiousness, information engagement, and social support). The 
only predictor that did not perform as expected was information engagement which was 
significantly positively correlated with “Connected Strength” but significantly negatively 
correlated with “Communicating with My Health Care Providers.” 
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Table 20. Hypotheses 3 and 4 : FSACS Subscale Scores Compared  to Predictors, Outcomes, and 
Related Concepts 
 Being an 
Informed 
Decision Maker 
Connected 
Strength 
Communicating 
with My Health 
Care Providers 
Predictor Variable    
Openness and conscientiousness 
(IPIP) 
0.460** 0.245** 0.438** 
Information engagement (HIOS) 0.047 0.127* -0.127* 
Social support (ISEL) 0.243** 0.199** 0.227** 
Outcome Variable    
Symptom severity (MDASI) -0.076 0.032 -0.130* 
Symptom interference (MDASI) -0.167** -0.044 -0.260** 
Hospitalization 0.210** 0.030 0.130* 
Emergency Department Visit 0.153** -0.058 0.117* 
Primary Care Visit 0.008 0.035 -0.113 
Home Health Visit -0.146** -0.150** -0.097 
Related Concepts    
Patient Activation (PAM) 0.553** 0.272** 0.498** 
Patient Self-Advocacy (PSAS) 0.501** 0.237** 0.342** 
*p ≤ 0.05 
**p ≤ 0.01 
 
Outcomes: FSACS subscale scores showed mixed evidence for the hypothesized 
relationships between FSACS subscale scores and symptom distress and healthcare utilization. 
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The “Being an Informed Decision Maker” subscale was significantly negatively correlated with 
symptom interference only. The “Connected Strength” subscale was not related to either 
symptom distress subscale. The “Communicating with My Health Care Providers” subscale was 
significantly negatively correlated with both symptom severity and symptom interference.  
For healthcare utilization, the “Being an Informed Decision Maker” subscale was 
significantly negatively correlated with having had a home health visits and significantly 
positively correlated with being hospitalized and emergency department visits. The “Connected 
Strength” subscale was significantly negatively correlated only with home health visits. The 
“Communicating with My Health Care Providers” subscale was significantly positively 
correlated with both being hospitalized and emergency department visits. 
3.4.4.4 Hypothesis 4: Concurrence with Related Concepts Table 21 reports correlations 
between the FSACS subscale scores and related concepts. As hypothesized, patient activation 
scores were significantly positively correlated with each of the FSACS subscale scores. 
Compared to the self-advocacy scale created for individuals with HIV/AIDS, the FSACS 
subscales demonstrated similarities and differences (Table 22). “Being an Informed Decision 
Maker” was significantly positively correlated with “Illness Education.” “Connected Strength” 
was weakly, but significantly positively correlated with “Assertiveness.” However, the 
“Communicating with My Health Care Providers” was not correlated with “Mindful Non-
Adherence.” 
131 
Table 21. Hypothesis 4: FSACS and PSAS Subscale Correlations 
FSACS Subscales 
PSAS Subscale 
Being an 
Informed 
Decision Maker 
Connected 
Strength 
Communicating 
with My Health 
Care Providers 
Illness Education 0.517** 
Assertiveness 0.373** 
Mindful Non-
Adherence 
-0.042 
*p ≤ 0.05
**p ≤ 0.01 
3.4.4.5 Hypothesis 5: Criterion Measures The FSACS Subscales were more highly correlated 
with the outcomes of symptom distress and healthcare utilization than the PSAS total score 
(Table 22). The PSAS scores were only significantly and positively related to hospitalizations. 
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Table 22. Hypothesis 5: FSACS Subscale Scores vs. PSAS Scores on Outcome Measures 
 FSACS Scale 
PSAS Total 
 
Being an 
Informed 
Decision 
Maker 
Connected 
Strength 
Communicating 
with My Health 
Care Providers 
Symptom Distress     
Symptom severity (MDASI) -0.076 0.032 -0.130* -0.100 
Symptom interference 
(MDASI) 
-0.167** -0.044 -0.260** -0.023 
Healthcare Utilization     
Hospitalization 0.210** 0.030 0.130* 0.155** 
Emergency Department Visit 0.153** -0.058 0.117* -0.010 
Primary Care Visit 0.008 0.035 -0.113 0.074 
Home Health Visit -0.146** -0.150** -0.097 0.042 
*p ≤ 0.05 
**p ≤ 0.01 
  
3.4.5 Discussion 
Results of the five a priori hypotheses larges supported the accuracy of the FSACS as a measure 
of self-advocacy. The internal structure of the FSACS Scale is consistent with the theoretical 
underpinnings of self-advocacy among female cancer survivors and provides a parsimonious set 
of 20 items tapping into three distinct dimensions of self-advocacy.  
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In this model of self-advocacy, women’s self-advocacy is defined as (a) preparing and 
making informed decisions consistent with a woman’s priorities, (b) finding strength through 
mutually supporting and being supported by other cancer survivors, friends, and family, and (c) 
openly and confidently voicing concerns, problems, and confusions with health care providers 
and working with them to find solutions. The more a woman is able to be an informed decision 
maker in her health care, communicate her concerns and questions to her health care provider, 
and both get and give receive support, the more she is able to advocate for herself. Like similar 
self-care concepts, self-advocacy promotes patient engagement and empowerment (Richard & 
Shea, 2011), but unlike these other concepts incorporates specific behaviors of how survivors 
perform when faced with a challenge or problem in their experience. 
The FSACS Scale adeptly detected differences between women with high and low levels 
of education. The lack of difference between women at different times since diagnosis may 
reflect the long-term survivors’ distance from the health-related problems and the paucity of 
recently diagnosed women in the sample. If women further from diagnosis and treatment 
experience fewer challenges related to being a cancer survivor, then their need for self-advocacy 
may naturally decrease over time. The lack of difference may also reflect the current lack of 
training in self-advocacy skills for cancer survivors, leaving all survivors at risk for poor self-
advocacy. Given that both informed decision making and communication are amenable to 
intervention (Au et al., 2012; Meropol et al., 2013), self-advocacy may also be capable of 
increasing if directly taught through a targeted intervention. 
The FSACS subscale scores largely performed as expected with the predictors of self-
advocacy. Openness and conscientiousness (IPIP) were the most strongly correlated with all 
three self-advocacy subscales as was perceived availability of social support (ISEL). The health 
  134 
information engagement measure (HIOS) was positively correlated with “Connected Strength” 
but negatively correlated with “Communicating with My Health Care Providers.” While the 
association between health information seeking and Connected Strength was expected, the 
inverse relationship with communication with providers was unexpected. This may reflect a 
tendency for those who have strong communication with their providers to view providers as 
their most trusted source of health information and therefore reduce their need to actively seek 
outside sources of health information. 
Several outcomes were associated with “Being an Informed Decision Maker” and 
“Communicating with My Health Care Provider.” The higher a woman’s score on these self-
advocacy subscales, the less likely her symptoms were to interfere with her life. A woman who 
discusses her symptoms with her health care provider may be more likely to receive effective 
recommendations on how to treat them. Surprisingly, higher self-advocacy scores on these same 
two dimensions were positively correlated with hospitalizations and emergency department 
visits. This unexpected finding could be because a woman (a) is engaged in making health 
decisions and communicates openly so refers herself or receives a referral from her healthcare 
providers to go to a hospital or emergency department or (b) has several medical problems that 
cause her to have hospital admissions and emergency department visits which then necessitate 
decision-making and communication with her healthcare providers. Unfortunately, there is no 
way to determine whether the healthcare utilization by women in this study were appropriate. 
Therefore, it remains unclear whether self-advocacy is associated with women’s ability to seek 
and obtain medical attention when in need.  
Compared to the previous measure of self-advocacy among individuals with HIV/AIDS 
(PSAS), the FSACS subscale of “Communicating with My Health Care Providers” was not 
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associated with “Mindful Non-Adherence” as hypothesized. In fact, many of the items derived 
from the PSAS measure were eliminated during the factor analysis including items about 
adjusting provider recommendations, deciding not to follow provider’s advice, and 
acknowledging that health care providers did not know more about the woman’s health than she 
did. Given this discrepancy along with the weak to moderate correlations among other subscales 
and mostly insignificant correlations with symptom distress and healthcare utilization, the 
FSACS subscale seems to be tapping into a type of self-advocacy distinct from that of the PSAS 
and one that relates to important health outcomes.  
The poor correlation between the FSACS communication subscale and the PSAS mindful 
non-adherence subscale may reflect the significant changes made to this dimension throughout 
psychometric testing and therefore represent a drift from the original concept. For this reason 
along with concerns about the three cross-loading items on this subscale, future testing will 
explore whether these communication items adequately detect a woman’s ability to drive her 
own care and work with her health care team or if there are additional behaviors needed to more 
completely represent this concept.  
As the first psychometric analysis of a measure of self-advocacy particular to cancer and 
females, additional testing of the FSACS Scale will continue to refine the model and find targets 
for intervention. Specifically, research will focus on find predictors of low self-advocacy and 
identifying sub-groups of female cancer survivors at risk for poor self-advocacy. In this way, 
self-advocacy interventions can be tailored to fit the distinct needs of women struggling in 
specific dimensions of self-advocacy. 
In accordance with principles of instrument development, the sample in this study was 
purposefully broad in order to capture the full breadth of self-advocacy among and be 
  136 
generalizable to all adult female cancer survivors. Future research explicitly will explore 
variations in self-advocacy among women who are likely to face greater challenges during their 
cancer experience including women with advanced cancers, recurrences, lower levels of 
education, financial difficulties, etc. Likewise, more precise measures of healthcare utilization 
appropriateness will be used. 
Limitations to this study are consistent with those of survey studies. Self-reported disease 
and treatment information were not able to be verified. The cross-sectional design limits 
statistical testing to associations rather than using self-advocacy as a predictor or outcome as 
proposed in the measurement model. Low response rates and significant differences between 
non-responders and responders in the Pennsylvania Tumor Registry along with unknown non-
response rates with the advocacy organizations risks bias in the sample and therefore limits the 
generalizability of data to all adult female cancer survivors. 
3.4.6 Conclusions 
The FSACS Scale is a psychometrically-sound, parsimonious measure self-advocacy among 
female cancer survivors. Evidence in support of the tool’s construct validity supported the 
theoretical dimensions of the overall construct, and the final 20-item measure performed mostly 
as expected compared to proposed predictors, outcomes, and related measures of self-advocacy. 
Future work to explore the use of the tool in detecting women with low self-advocacy 
will assist clinicians and researchers in being able to support women ill-equipped to address their 
problems, needs, and wants throughout their cancer experience. Partnering with key health care 
providers and patient navigators in the clinical setting will be critical next steps to ensuring the 
application of this new tool and theory of self-advocacy in the most appropriate settings. 
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4.0  INCIDENTAL FINDINGS 
4.1 DIMENSIONALITY 
Surprisingly, many of the items conceptually derived from the Patient Self-Advocacy Scale 
(PSAS) did not have strong reliability and validity results in the current study. In fact, the 
FSACS subscale “Communicating with My Health Care Providers” had an extremely weak, non-
significant correlation (r = -0.042) with the PSAS subscale “Mindful Non-adherence” subscale. 
The lack of significant association between these two dimensions suggests that they are unique 
and distinct despite originally being intended to tap into a similar concept. The “Mindful Non-
adherence” questions regarding whether or not survivors adjusted their providers’ 
recommendations did not perform well during cognitive interviews, content validity and 
reliability testing. Despite being conceptually congruent with the PSAS (2 of the three items 
were directly derived from the PSAS), these items were below the acceptable cut-off for at least 
two of these three psychometric evaluations. In short, these large discrepancies in this one 
subscale along with weak correlations in the other two subscales confirm that the FSACS Scale 
is tapping into a type of self-advocacy among women with cancer that is conceptually distinct 
from self-advocacy among individuals with HIV/AIDS. 
  139 
4.2 SUB-GROUP DIFFERENCES IN FSACS SCORES 
Subsets of participants were compared on the FSACS subscales, predictors (IPIP, ISEL, and 
HIOS), outcomes (symptom severity and interference; healthcare utilization), and related 
measures (PSAS and PAM) to explore if there were significant differences among women with 
varying health and sociodemographic backgrounds. While exploratory in nature, these 
demographic distinctions will be essential in designing future study’s sampling procedures and 
interventions in order to ensure that women who struggle to self-advocate are both being 
identified and served according to their unique needs. 
4.2.1 Cancer Type Differences 
The two largest subgroups of cancer types were breast (n = 122) and ovarian cancer (n = 65). 
Comparing women with breast and ovarian cancer diagnoses only the “Connected Strength” 
subscale significantly varied between groups with women with ovarian cancer reporting higher 
scores (M = 35.17) than women with breast cancer (M = 32.49), t(185) = -3.13, p = 0.002). 
Because most ovarian cancer survivors were recruited through the National Ovarian Cancer 
Coalition (NOCC) which is an advocacy group with no breast cancer advocacy group 
counterpart, this result may reflect the sampling bias. For example, when FSASCS subscale 
scores of women recruited from the NOCC were compared to women recruited from the 
Pennsylvania Tumor Registry (which used a random sampling procedure), “Connected Strength” 
was the only subscale that significantly differed between groups with women with NOCC 
members having higher scores ) (t(147) = -2.67, p = 0.008). Conversely, this difference between 
women with breast vs. ovarian cancer diagnoses may reflect true differences in the extent to 
which ovarian cancer seek out and support others with their same diagnosis. 
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4.2.2 Time Since Diagnosis Differences 
Compared to women within a year of diagnosis, women with more than 5 years since their 
cancer diagnosis did not have significantly different scores on any FSACS subscale. However, 
when compared to women between 1 and 5 years of diagnosis, women within a year of diagnosis 
had significantly lower scores on the “Being an Informed Decision Maker” subscale (t(170) = -
2.43, p = 0.016). Although symptom severity did not differ between women who were newly 
diagnosed compared to long-term survivors, symptom interference was significantly higher 
among women within a year of diagnosis (t(196) = 2.15, p = 0.032). Surprisingly, long-term 
survivors were more likely to have been admitted to a hospital in the past three months (t(196) = 
-4.72, p < 0.001), less likely to have a PCP (t(200) = 2.11, p = 0.036), and have a visiting nurse 
(t(199) = -1.99, p = 0.048) than women who were newly diagnosed. These two groups did not 
significantly differ in any of the predictor or related measures. 
4.2.3 Stage of Cancer Diagnosis Differences 
FSACS subscale scores did not significantly differ between women diagnosed at Stage I 
compared to Stage IV. These groups did not differ on any predictor, outcome, or related measure 
save for the PAM on which women diagnosed at Stage IV scored higher (t(110) = -2.30, p = 
0.023). Interestingly, women diagnosed at Stage III reported higher “Connected Strength” 
subscale scores than women diagnosed at Stage I (t(141) = -2.28, p = 0.024). Beyond symptom 
distress (which women diagnosed at Stage III understandably reported significantly higher scores 
than women diagnosed at Stage I), no other significantly different scale scores existed between 
these two groups. No significant differences existed between women diagnosed at Stage III 
compared to women diagnosed at Stage IV. 
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4.2.4 Racial Differences 
FSACS subscale scores did not significantly differ between white (n = 280) and African 
American (n = 24) women, nor did any of the scores of any of the predictors, outcomes, or 
related measures. Given the uneven sample sizes, this variable will continue to be examined in 
the future in order to detect if race impacts self-advocacy scores. 
4.2.5 Age Differences 
In order to compare women based on their age, six groups were created based on the median age 
and quartile ranges. Only scores on the “Connected Strength” subscale significantly differed 
between young women (age 25 – 42) and older women (age 76 and above), with younger women 
reporting higher scores on this subscale (t(67) = 2.76, p = 0.007). Furthermore, these two groups 
had significantly different scores on many of the predictor, outcome, and related measures. 
Compared to older women, younger women reported significantly higher symptom interference, 
patient self-advocacy with individuals with HIV/AIDS (PSAS), health information orientation 
(HIOS), and openness and conscientiousness (IPIP) scores. Healthcare utilization did not 
significantly differ between the youngest and oldest participants, nor did perceived availability of 
social support (ISEL) or patient activation (PAM). 
Interestingly, when women age 25-42 (youngest) were compared to women age 68-75 
(second oldest), the older age group scored significantly higher on the “Being an Informed 
Decision Maker” (t(87) =-2.74, p = 0.007) and “Communicating with my Health Care Providers” 
(t(87) = -2.41, p = 0.018) subscales. Yet, this youngest group of women scored significantly 
higher than women age 68-75 on the health information orientation (HIOS) measure. These 
findings may reflect more healthcare experience among older women and a better ability to 
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prepare and communicate their needs, and younger women’s skills at obtaining and gathering 
health information. 
4.2.6 Educational Differences 
Comparing women with a high school degree or less with women with at least some graduate 
school, both the “Being an Informed Decision Maker” (t(153) = -4.25, p < 0.001) and 
“Communicating with My Health Care Providers” (t(153) = -4.39, p < 0.001) subscales 
significantly varied with more educated women having higher FSACS subscale scores. 
“Connected Strength” subscale scores did not significantly vary between these groups. The same 
statistically significant differences in FSACS subscale scores existed among women with a 
vocational degree or 2-year degree compared to women with at least some graduate school, but 
not between women with a vocation degree or 2-year degree and women with a bachelor’s 
degree. 
Symptom severity (t(149) = 3.63, p < 0.001) and symptom interference (t(149) = 1.97, p 
= 0.05) were also significantly higher among women with less than a high school education 
compared to those with at least some graduate school. Women with a vocational degree or 2-year 
degree also had significantly higher symptom severity and symptom interference than women 
with a graduate degree.  
Women with less than a high school education scored significantly lower on the PSAS, 
PAM, and IPIP compared to women with at least some graduate school but on no other 
measures. 
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4.2.7 Income Differences 
Women with a household income less than $20,000 a year reported strong differences than 
women with household incomes over $150,000 a year. Women with higher household incomes 
had significantly higher scores on the “Being an Informed Decision Maker” (t(44) = -3.56, p = 
0.001) and “Communicating with My Health Care Providers” (t(44) = -3.79, p < 0.001) 
subscales of the FSACS compared  to poorer women, but not the “Connected Strength” subscale. 
This wealthiest group also reported statistically higher PSAS, PAM, IPIP, and ISEL total scores. 
There were no group differences in either symptom distress or healthcare utilization. Similar 
results were found among the subset (n = 41) women who responded “No” to the 
sociodemographic question asking if their current household income met their basic needs. 
Women’s reported household income was combined with their total number of adult and 
children living their house. These household incomes by total household number were compared 
to the 2015 federal poverty thresholds in order to categorize all participants as either below or 
above the poverty line. Only 15 women were below the poverty line. While this was not a large 
enough sample size for comparisons, exploratory analyses were conducted to evaluate whether 
women below the federal poverty line scored differently on the three FSACS dimensions 
compared to women above the federal poverty line. Across all three dimensions, women below 
the poverty line had significantly lower FSACS scores than women above the federal poverty 
line. 
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4.2.8 Summary of Differences 
Strong differences in FSACS subscales and other measures by age, educational status, and 
income warrant further investigation. Of note, the 18 women who were over age 80 all had 
household incomes below $50,000 a year and 12 (66.7%) had less than a high school education. 
Lack of differences between newly diagnosed women and long-term survivors needs to 
be further investigated. It is not clear if women further from diagnosis are not making decisions 
regarding their health, interacting with their health care team and not in need of getting/giving 
support from others and therefore scoring lower. Or, self-advocacy may be behaving more like a 
trait rather than a state, in which case efforts to build self-advocacy as a skill might be difficult. 
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5.0  APPENDICES 
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 APPENDIX A
VALIDITY INSTRUMENTS 
Self-Advocacy in Cancer Survivorship 
Questionnaires 
Thank you for being a part of this study! 
ID: _________________ 
  
 
 
Screening 
Questionnaire 
 
 
 
 
 
 
1. Are you female? 
_____ Yes 
_____ No 
 
2. Can you read and write in English? 
_____ Yes 
_____ No 
 
3. Have you been diagnosed with cancer AFTER the age of 18? 
_____ Yes 
_____ No 
 
4. Have you been diagnosed with a cancer OTHER THAN basal cell 
carcinoma, squamous cell carcinoma, or cervical intraepithelial 
neoplasia? 
_____ Yes 
_____ No 
 
 
 
 
 Study ID:
CRE - 1159SAC, V1.1
June 27, 2014
1 8 5
Page 1 of 4
  Instrument Number:
1 1 5 9
Female Self-Advocacy Measure - Oncology
Please use BLACK Pen Only!
/ /  ID Number: Administration Date:
 ( FOR STAFF USE ONLY )
 (month)  (day) (year)
1 2
 Baseline  2 Weeks
  Visit Number:
I seek out information to help me improve my
life as a cancer survivor.
   1.
The following statements reflect "self-advocacy" among female cancer survivors.  A cancer survivor is anyone who
has ever been diagnosed with cancer.
   2. I make sure the health information I get is
trustworthy.
These questions are purposefully redundant.  We are trying to find the best statements to reflect "self-advocacy."
Your responses will help us figure out which statements are best.
Please read each of the following statements carefully.  Think about your experiences having cancer and, if you
currently do not have cancer, think about your experiences since you had cancer.
Then, for each statement, fill in the circle that corresponds to the response that best reflects how much you agree
or disagree with each statement.
   3. I can tell the difference between health informa-
tion that does and does not apply to me.
   4. Health information gives me more control as a
cancer survivor.
   5. I ignore questionable health information.
   6. I try new things to improve my life as a cancer
survivor.
   7. I don't know enough to help make decisions
about my cancer care.
I use my skills to solve the problems I face as
a cancer survivor.
   8.
Continued on next page . . .
1 2 3 4 5 6
     Strongly
    Disagree
 
    Disagree
  Somewhat
   Disagree
  Somewhat
      Agree
 
      Agree
    Strongly
       Agree
   9. I gather information before making decisions
about my cancer care.
 10. If I had problems with my job or other respon-
sibilities, I would know where to look for help.
INSTRUCTIONS:
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June 27, 2014
ID Number:
(for internal use only) (for internal use only)
/ /Date:
Page 2 of 4
 11. I weigh my options carefully before making
important decisions about my cancer care.
 12. I prepare myself to make decisions about my
cancer care.
 13. When it comes to making decisions about my
cancer care, I know what my priorities are.
 14. Having information helps me to make decisions
about my cancer care.
 15. If a health problem doesn't go away, I look for
different ways to manage it.
 16. If I had problems covering the costs of my
cancer care, I would know where to look for
help.
 17. Sometimes I adjust my provider's
recommendations to better fit with my life.
 18. If a treatment is not working, I wait for my
provider to make a change.
 19. I ask questions when I don't understand what
my provider is telling me.
 20. My provider knows what is best for me.
 21. Sometimes I decide not to follow the advice of
my provider.
 22. I don't want my provider to think I am a difficult
patient.
 23. If I don't do what my provider asks me to do, I
have a good reason.
 24. I feel like I can disagree with my provider.
 25. If a medication is not working, I tell my provider.
Continued on next page . . .
     Strongly
    Disagree
 
    Disagree
  Somewhat
   Disagree
  Somewhat
      Agree
 
      Agree
    Strongly
       Agree
1 2 3 4 5 6
 26. I question my provider if I don't agree with his
or her recommendations.
 27. I don't talk about a health concern with my
provider unless I think there is a solution.
 28. I rarely tell my provider about problems I am
having related to cancer.
 29. I know where to get an answer if my provider
can't give me one.
1 8 5
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 31. I am not sure where I would go if my provider
is not able to answer the questions I have.
 32. I am comfortable asking for a second opinion.
 33. Not following the advice of my provider bothers
me.
 34. I know what's best for me medically.
 35. I seek other help for my needs that are not
being met by my provider.
 36. I worry that asking for a second opinion would
hurt my relationship with my provider.
 37. I have a hard time voicing my preferences to
my provider.
 38. I seek out support from other cancer survivors.
 39. I seek out support from friends and family.
 40. Helping other cancer survivors also helps me.
 41. I don't like asking my friends and family for
help.
 42. Many of my decisions are based on what's best
for my family.
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(for internal use only) (for internal use only)
/ /Date:
 30. I ask my provider to explain his or her
recommendations.
 45.
 44.
 43. Being there for other cancer survivors is an
important part of being a cancer survivor.
When I hear that someone has cancer, I try to
reach out to them.
It helps me to know that other cancer survivors
have gone through what I am going through.
Continued on next page . . .
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    Disagree
 
    Disagree
  Somewhat
   Disagree
  Somewhat
      Agree
 
      Agree
    Strongly
       Agree
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 46. My friends and family motivate me to get better.
 47. I can balance my needs with the needs of others
who depend on me.
 48. I am comfortable telling my friends and family
what I need.
 49. I protect my family and friends from my health
problems.
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        T. Hagan & H. Donovan
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(for internal use only) (for internal use only)
/ /Date:
 50. Sometimes I have to put myself first.
 51. I feel connected to other cancer survivors.
 52. I support other cancer survivors.
 53. Telling other people my story makes me feel
good.
 54. I prefer to deal with my cancer on my own.
 55. I want to give back by helping other cancer
survivors.
 56. I try to raise awareness about cancer.
 57. I am comfortable sharing my cancer experience
with others.
     Strongly
    Disagree
 
    Disagree
  Somewhat
   Disagree
  Somewhat
      Agree
 
      Agree
    Strongly
       Agree
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  Instrument Number:
1 1 6 0
 Study ID:
/ /  ID Number: Administration Date:
 ( FOR STAFF USE ONLY )
CRE - 1160PSA, V1.0
June 24, 2013
 (month)  (day) (year)
Patient Self-Advocacy Scale (PSAS)
Please use BLACK Pen Only!
Please read each of the following statements carefully.  Think about what you experienced while having cancer
and, if you currently do not have cancer, think about your experiences since you had cancer.
I believe it is important for people with cancer
to learn as much as they can about their illnesses
and treatments.
  1.
  2. I actively seek out information on my illnesses.
  3. I am more educated about my health than most
US citizens.
Then, for each statement, fill in the circle that corresponds to the response that best reflects how much you agree
or disagree with each statement.
  4. I have full knowledge of the health problems of
people like myself (people with cancer).
  5. I don't get what I need from my physician because
I am not assertive enough.
  6. I am more assertive about my health care needs
than most U.S. citizens.
  7. I frequently make suggestions to my physicians
about my health care needs.
  8. If my physician prescribes something I don't
understand or agree with, I question it.
  9. Sometimes there are good reasons not to follow
the advice of a physician.
10. Sometimes I think I have a better grasp of what I
need medically than my doctor does.
11. If I am given a treatment by my physician that I
don't agree with, I am likely not to take it.
12. I don't always do what my physician or health
care worker has asked me to do.
54321
    Strongly
    Disagree
 
     Disagree
 
      Neutral       Agree
    Strongly
      Agree
  Visit Number: 1 2
 Baseline  2 Weeks
Brashers, D.E., Haas, S.M., & Neidig, J.L. (1999). The patient self-advocacy scale: Measuring patient
involvement in health care decision-making interactions.  Health Communication, 11(2), 97-121.
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  Instrument Number:
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 Study ID:
CRE - 1161HIO, V1.0
June 24, 2013
Health Information Orientation  Scale (HIOS)
Please use BLACK Pen Only!
/ /  ID Number: Administration Date:
 ( FOR STAFF USE ONLY )
 (month)  (day) (year)
Think about the following statements in terms of how you react when you are dealing with health concerns.
I like to gather as much information as I can before I
make a decision.
  1.
Then, for each statement, fill in the circle that corresponds to how true each statement is for you, choosing only
ONE response per line.
  Visit Number: 1 2
    Not at all
        true
    A little bit
        true
   Somewhat
         true
    Quite a bit
         true
  Very much
        true
0 1 2 3 4
I have difficulty making sense of information from
multiple sources.
  2.
I fear that I might find out something I don't want to
know.
  3.
I like to review information multiple times before
making a decision.
  4.
I like to make decisions quickly.  5.
  6. After I've made a decision, I continue to look for
related information.
  7. I think it's the doctor's job to deal with information,
not mine.
  8. I feel overwhelmed by the amount of information
available.
 Baseline  2 Weeks
DuBenske, L. L., Burke-Beckjord, E., Hawkins, R. P., & Gustafson, D. H. (2009).  Psychometric
evaluation of the Health Information Orientation Scale: a brief measure for assessing health
information engagement and apprehension. Journal of Health Psychology, 14(6), 721-730.
INSTRUCTIONS:
22235
1 8 5
Page 1 of 1
  Instrument Number:
1 1 6 2
 Study ID:
/ /  ID Number: Administration Date:
 ( FOR STAFF USE ONLY )
CRE - 1162IPI, V1.0
August 6, 2013
 (month)  (day) (year)
International Personality Inventory Pool (IPIP)
Please use BLACK Pen Only!
1 2
 Baseline  2 Weeks
  Visit Number:
This questionnaire contains phrases that describe people's behaviors.  Please use the rating scale below to indicate
how accurately each statement describes you.  Describe yourself as you generally are now, not as you wish to be in
the future.
I believe in the importance of art.  1.
  2. I am not interested in abstract ideas.
  3. I have a vivid imagination.
Describe yourself as you honestly see yourself, in relation to other people you know of the same sex as you, and
roughly your same age.  So that you can describe yourself in an honest manner, your responses will be kept in
absolute confidence.
Please read each statement carefully, and then fill in the circle that corresponds to your response.
        Very
   inaccurate
  Moderately
   inaccurate
     Neither
  inaccurate
 nor accurate
   Moderately
     accurate
       Very
    accurate
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  4. I tend to vote for liberal political candidates.
  5. I carry the conversation to a higher level.
  6. I avoid philosophical discussions.
  7. I enjoy hearing new ideas.
  8. I do not like art.
  9. I do not enjoy going to art museums.
 10. I tend to vote for conservative political candidates.
 11. I am always prepared.
 12. I make plans and stick to them.
 13. I shirk my duties.
 14.
 15.
 16.
 17.
I don't see things through.
I pay attention to details.
I get chores done right away.
I carry out my plans.
 18.
 19.
I waste my time.
I find it difficult to get down to work.
 20. I do just enough work to get by.
Goldberg, L. R. (1999).  A broad-bandwidth, public domain, personality inventory measuring the lower-level facets of several five-factor models,
Personality Psychology in Europe.  I. D. Mervielde, I., De Fruyt, F. & Ostendorf, F. Tilburg (Eds.), The Netherlands, Tilburg University Press, 7: 7-28.
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M.D. Anderson Symptom Inventory (MDASI)
Please use BLACK Pen Only!
/ /  ID Number: Administration Date:
 ( FOR STAFF USE ONLY )
 (month)  (day) (year)
1 2
 Baseline  2 Weeks
  Visit Number:
People with cancer frequently have symptoms that are caused by their disease or by their treatment.  We ask you
to rate how severe the following symptoms have been in the last 24 hours.
For each symptom listed below, fill in one circle that corresponds to its severity in the last 24 hours, using a scale
from "0" (the symptom was "Not present") to "10" (the symptom was "As bad as you can imagine").
Your pain at its WORST?   a.
Your fatigue (tiredness) at its WORST?   b.
   c. Your nausea at its WORST?
   d. Your disturbed sleep at its WORST?
   e.
   f.
   g.
   h.
Your feelings of being depressed (upset) at its WORST?
Your shortness of breath at its WORST?
Your problem with remembering things at its WORST?
Your problem with lack of appetite at its WORST?
   i.
   j.
   k.
Your feeling drowsy (sleepy) at its WORST?
Your having a dry mouth at its WORST?
Your feeling sad at its WORST?
   l. Your vomiting at its WORST?
  m. Your numbness or tingling at its WORST?
0 1 2 3 4 5 6 7 8 9 10
As bad as you
 can imagine
     Not
  present
INSTRUCTIONS:
  1. How severe are your symptoms in the last 24 hours?
22881
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/ /Date:
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Cleeland, C. S., T. R. Mendoza, Wang, X. S., Chou, C., Harle, M. T., Morrissey, M., &
Engstrom, M. C. (2000).  Assessing symptom distress in cancer patients: The M. D.
Anderson Symptom Inventory. Cancer, 89(7), 1634-1646.
General activity?   a.
Mood?   b.
   c. Work (including around the house)?
0 1 2 3 4 5 6 7 8 9 10
Interfered
completely
 Did not
interfere
   d. Relations with other people?
   e. Walking?
   f. Enjoyment of life?
Now, we are asking you to rate how your symptoms possibly interfered with your life in the last 24 hours.
For each symptom listed below, fill in one circle that corresponds to its interference in your life in the last 24 hours,
using a scale from "0" (the symptom "Did not interfere") to "10" (the symptom "Interfered completely").
  2. How have your symptoms interfered with your life in the last 24 hours?
INSTRUCTIONS:
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Healthcare Utilization
Please use BLACK Pen Only!
/ /  ID Number: Administration Date:
 ( FOR STAFF USE ONLY )
 (month)  (day) (year)1 2
 Baseline  2 Weeks
  Visit Number:
Please indicate the number of times you have used health care services in the past 3 months.
 1. How many nights did you
spend in the hospital?
How many times:
Was the admission related to
your cancer or its treatment?
 2.
1  Yes 2  No 3  Not sure
 3. Were you admitted to the ICU?
1  Yes --->
2  No
For how many
(nights)
1. Were you admitted to a hospital in the past 3 months?
  a.  First time:
1 Yes 2 No ----> SKIP to Question 2 on the next page
 4. Name of the hospital:
 5. In what city is it located:
   b. Second time:
nights:
 a.
(nights)
If not hospitalized a second time,
V
N/A (-2)fill in this circle:
 1. How many nights did you
spend in the hospital?
(nights)
4.
 2. Was the admission related to
your cancer or its treatment?
 3. Were you admitted to the ICU?
1  Yes --->
2  No
 4. Name of the hospital:
 5. In what city is it located:
 a. For how many
(nights)
 1. How many nights did you
spend in the hospital?
(nights)
 2. Was the admission related to
your cancer or its treatment?
 3. Were you admitted to the ICU?
1  Yes --->
2  No
 4. Name of the hospital:
 5. In what city is it located:
 a. For how many
(nights)
nights: nights:
VV
  c. Third time:
If not hospitalized a third time,
N/A (-2)
SKIP to Question 2 on the next page
fill in this circle:
V
then,
5.
1  Yes 2  No 3  Not sure 1  Yes 2  No 3  Not sure
OFFICE
USE
ONLY
FOR 4.
5.
OFFICE
USE
ONLY
FOR 4.
5.
OFFICE
USE
ONLY
FOR
INSTRUCTIONS:
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 1. What were the approximate
dates for the first ER visit?
How many times:
Was the admission related to
your cancer or its treatment?
 2.
2. Have you visited an Emergency Department in the past 3 months?
  a. First time:
1 Yes 2 No ----> SKIP to Question 3 on the next page
 3. Name of the hospital:
 4.
  b. Second time:
If not applicable,
V
N/A (-2)fill in this circle:
 3. Name of the hospital:
 4.
 3. Name of the hospital:
 4.
VV
 c. Third time:
N/A (-2)
SKIP to Question 3 on the next page
fill in this circle:
V
then,
/ /
through
a.
b.
1  Yes 2  No 3  Not sure
(month)   (day) (year)
(month)   (day) (year)
a.
(month)   (day) (year)
through
b.
(month)   (day) (year)
 2. Was the admission related to
your cancer or its treatment?
a.
(month)   (day) (year)
through
b.
(month)   (day) (year)
 2. Was the admission related to
your cancer or its treatment?
3.
4.
OFFICE
USE
ONLY
FOR
 1. What were the approximate
dates for the second ER visit?
 1. What were the approximate
dates for the third ER visit?
If not applicable,
/ /
/ /
/ /
1  Yes 2  No 3  Not sure
/ /
/ /
1  Yes 2  No 3  Not sure
3.
4.
OFFICE
USE
ONLY
FOR 3.
4.
OFFICE
USE
ONLY
FOR
In what city is it located: In what city is it located: In what city is it located:
1 8 5
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3. Do you have a Primary Care physician?
1 Yes 2 No ----> SKIP to Question 4 below
V
 a. What is your Primary Care physician's name?
(First Name) (Last Name)
OFFICE
USE
ONLY
FOR
 b. In what city is he/she located:
 c. Have you visited your Primary Care physician in the past 3 months?
1  Yes --->
2  No
How many times? 1.
 2. Were the visits related to your cancer or its treatment?
1  Yes ------>  3.
2  No
3  Not sure
How many of the visits were related
to your cancer or its treatment?
a.
b.
4. Has a nurse from a home care service (Visiting Nurse) provided care to you in your home in the past 3
months?
1 Yes 2 No
V
 a. How many times:
Were the visits related to your cancer or its treatment?
1  Yes ------>  c.
2  No
3  Not sure
 b.
How many of the visits were related to your cancer or
its treatment?
                  B. Given & W. Given
Michigan State University School of Nursing
                             2013
1 8 5
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Patient Activation Measure (PAM)
Please use BLACK Pen Only!
/ /  ID Number: Administration Date:
 ( FOR STAFF USE ONLY )
 (month)  (day) (year)
When all is said and done, I am the person who is
responsible for taking care of my health.
  1.
  Visit Number: 1 2
 Baseline  2 Weeks
1 2 3 4 (-2)
       Not
  Applicable
     Strongly
       Agree
 
       Agree
 
    Disagree
    Strongly
    Disagree
Taking an active role in my own health care is the
most important thing that affects my health.
  2.
I am confident I can help prevent or reduce problems
associated with my health.
  3.
I know what each of my prescribed medications
does.
  4.
I am confident that I can tell whether I need to go to
the doctor or whether I can take care of a health
problem myself.
  5.
I am confident that I can tell a doctor concerns I
have even when he or she does not ask.
  6.
I am confident that I can follow through on medical
treatments I may need to do at home.
  7.
I understand my health problems and what causes
them.
  8.
I know what treatments are available for my health
problems.
  9.
I have been able to maintain (keep up with) lifestyle
changes, like eating right or exercising.
10.
11. I know how to prevent problems with my health.
12. I am confident I can figure out solutions when new
problems arise with my health.
13. I am confident that I can maintain lifestyle changes,
like eating right and exercising, even during times
of stress.
For each statement, fill in the circle that indicates how much you agree or disagree with the statement.
INSTRUCTIONS:
Hibbard, J.H., Stockard, J., Mahoney, E.R., & Tusler, M. (2004).  Development of the
Patient Activation Measure (PAM): Conceptualizing and measuring activation in
patients and consumers.  Health Service Research, 39(4 Pt 1), 1005-1026.
23358
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Interpersonal Support Evaluation List
Please use BLACK Pen Only!
/ /  ID Number: Administration Date:
 ( FOR STAFF USE ONLY )
 (month)  (day) (year)  Visit Number: 1 2
 Baseline  2 Weeks
This scale is made up of a list of statements each of which may or may not be true about you.
If you are absolutely certain a statement is true about you, choose "Definitely True."  If you think it is true but you
are not absolutely certain, choose "Probably True."
Similarly, if you are absolutely certain a statement is false, choose "Definitely False."  If you think it is false but you
are not absolutely certain, choose "Probably False."
If I wanted to go on a trip for a day (for example, to the country or
mountains), I would have a hard time finding someone to go with me.
  1.
I feel that there is no one I can share my most private worries and fears
with.
  2.
  3.
   Definitely
      False
   Probably
      False
   Probably
      True
   Definitely
       True
4321
If I were sick, I could easily find someone to help me with my daily
chores.
  4. There is someone I can turn to for advice about handling problems with
my family.
  5. If I decide one afternoon that I would like to go to a movie that evening,
I could easily find someone to go with me.
  6. When I need suggestions on how to deal with a personal problem, I
know someone I can turn to.
  7. I don't often get invited to do things with others.
  8. If I had to go out of town for a few weeks, it would be difficult to find
someone who would look after my house or apartment (the plants, pets,
garden, etc.).
  9. If I wanted to have lunch with someone, I could easily find someone to
join me.
 10. If I was stranded 10 miles from home, there is someone I could call who
could come and get me.
 11. If a family crisis arose, it would be difficult to find someone who could
give me good advice about how to handle it.
 12. If I needed some help in moving to a new house or apartment, I would
have a hard time finding someone to help me.
INSTRUCTIONS:
Cohen, S., Mermelstein, R., Kamarck, T., & Hoberman, H. (1985).  Measuring the
functional components of social support.  Social support: Theory, research, and
application. I.G.S.B.R  Sarason (Eds.)  The Hague, Holland, Martinus, Nijhoff.
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  Instrument Number:
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/ /  ID Number: Administration Date:
 ( FOR STAFF USE ONLY )
The following information requested is important in helping us understand more about you and your health.
The information that you provide will be used for research purposes ONLY and will be held in confidence.
Please do not skip any questions.  Thank you!
1   Male
2   Female
What is your sex?
 (years)
/ /    
  1.
  2. What is your date of birth?
  3. What was your age at your last birthday?
SOCIODEMOGRAPHIC QUESTIONNAIRE
(Short Form)
Center for Research and Evaluation
University of Pittsburgh School of Nursing
 (month)  (day) (year)
Please use BLACK Pen Only!
 (year)(day)  (month)
Place only one letter or one number in each box as shown . . .
without touching the sides of the blocks, such as in the following example.
For optimum accuracy, it is recommended that characters be written block style
  Visit Number:
 Baseline
2 310
36132
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  4.
1   Never married
2   Currently married
3   Living with partner/significant other
4   Widowed
5   Separated
6   Divorced
7   Other; specify ---->
Which one of the following best describes your current relationship status?
 (for office use only)
How many years have you been in your current relationship:
( If less than one year, write in "00" )
  5.
Given the ever-increasing ethnic diversity of the population in the United States of America, the following
questions are being asked to gather information on your racial/ethnic background . . .
  6.
       I am not currently
        in a relationship
N/A;
  (-2)
Please choose the one category that best applies to you . . . .
  (years)
What is your race:
   a. Do you consider yourself to be Hispanic or Latino, that is, of Mexican, Puerto Rican, Cuban, or of Latin
American descent?
1  Yes
2  No
3  Unknown
 1   White
 2   Black or African American
 3   American Indian; please specify:
 4   Alaska Native
 5   Native Hawaiian or other Pacific Islander
 6   Asian
 7   Other; specify:
 8   Unknown
   b.
Are you of more than one racial/ethnic background?
 1   White
  (1)
 2   Black or African American
 3   American Indian
 4   Alaska Native
 5   Native Hawaiian or other Pacific Islander
 6   Asian
   c.
1  Yes -----------> 
2  No
3  Unknown
 Please specify all categories that apply to you . . . .
 7   Other
ID Number:
(for internal use only) (for internal use only)
/ /Date:
1 8 5
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In what type of area did you live most
of your childhood?
1   Urban, large city
2   Urban, small city
3   Suburb of large city
4   Suburb of small city
5   Rural, farm
6   Rural, non-farm
7   Other; specify -->
  (for office use only)
  8.
  9.
What is your current employment status?
1   Full time (working at least 35 hours a week)
2   Part time (working less than 35 hours a week)
3   Laid off or unemployed, but looking for work
4   Laid off or unemployed, but not looking for work
5   Retired, not working at all
6   Retired, but working part or full time
7   Disabled, unable to work
8   Full time homemaker
9   Other; specify:
12.
 (for office use only)
1  Yes ---->
2  No
1  Part time
2  Full time
Are you currently a student?13.
Is English your first language?
1   Yes
2   No ---->
  (for office use only)
  7. 11. Select the highest diploma or degree you have
completed:
 1)   Grade school  [grades 1-8]
 2)   High school  [grades 9-12]
 3)   Earned G.E.D.  [Graduate Equivalent Diploma]
 4)   Vocational/Technical school certificate
 5)   2-year college  [Associate's level]
 6)   4-year college  [Bachelor's level]
 7)   Graduate school  [Master's level]
 8)   Professional school  [i.e., MD; D.V.M.; JD]
 9)   Graduate school  [Doctoral level, i.e., PhD; Ed.D.]
10)  Unknown
We'd like to know where you live.
Please enter the 5-digit ZIPCODE of
your PRIMARY RESIDENCE:
(where you live most of the time)
 (years)
(For example, if you completed high school
in the USA, you would have had 12 years of
How many years of formal education
have you completed?
10.
language:
What was your first a.
education.)
What is your student status?
ID Number:
(for internal use only) (for internal use only)
/ /Date:
1 8 5
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1  Yes 2  No
 Are you currently employed?
What is your primary occupation?  (the one
where you work the most hours per week):
(for office use only)
Job title:
 a.
Has this been your primary occupation for
most of your working life?
1  Yes
2  No  --->
 b.
 c. What was your primary
occupation?
Job title:
 (for office use only)
 d. Did you change occupations
because of health reasons?
1  Yes 2  No
 Please select all reasons
 that  apply to you . . . .
 (1)
14. Have you ever been employed?
1  Yes ---->
2  No
 a.
Job title:
(for office use only)
 b. When was the last year that you were
employed:
 c. Did you stop working because of health
reasons?
1  Yes 2  No
 1.
 2.
 3.
I changed because of
the physical demands
of my job.
I changed because of
the mental demands
of my job.
When you were employed, what was your
primary occupation? (the one where you
worked the most hours per week):
(for office use only)
V V
V
V
 1.
 2.
 3.
I changed because of
the physical demands
of my job.
I changed because of
the mental demands
of my job.
 (for office use only)
 (1)
 Please select all reasons that
 apply to you . . . .
   SKIP
     to
Question
     15
V
Other; specify:
Other; specify:
ID Number:
(for internal use only) (for internal use only)
/ /Date:
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Do you have any children?
1  Yes ---->
2  No
Including yourself, how many people currently live in your household? 16.
Do you have a religious preference?
How important is religion in your life?
1  Not at all 2  Somewhat 3  Extremely
a.)
b.)
 17
How many: a.
15.
(adults) (children under age 18) a.  b.
If NONE, enter 00.
1  Yes ---->
2  No
To what extent do you follow the customs and practices of your
religion?
1   Christianity
2   Judaism
3   Islam
4   Hinduism
5   Buddhism
6   Other; specify:
 1. Please specify:
 (for office use only)
 (Choose ONE response only.)
1   Never
2   Sometimes
3   Frequently
4   Always
 2.
ID Number:
(for internal use only) (for internal use only)
/ /Date:
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18. Do you have health care insurance?
1   Yes, all
2   Yes, some of the cost -----> Please specify in what way:
3   No
4   Unknown
1  Yes ---->
2  No
What type(s) of insurance do you have? a.
(Please choose ALL that apply.)
 1   Medicare
  (1)
 2   Medicaid
 3   Supplemental Security Income (SSI)
 4   Veterans Administration
 5   Disability income
 6   Private health insurance
 7   Other; specify:
 b. Does your insurance cover the cost of medication?
1   Yes, all
2   Yes, some of the cost -----> Please specify in what way:
3   No
4   Unknown
 c. Does your insurance cover the cost of health care?
 (for office use only)
Page 6 of 7
   SKIP
     to
Question
     19
V
ID Number:
(for internal use only) (for internal use only)
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19. What are all the sources of your own total gross annual income (before taxes and deductions):
 a.   Wages, salaries, commisions, bonuses, or tips from all jobs
  (1)
 b.   Self-employment income from tax or non-farm business
 c.   Interest, dividend, net rental income, royalty income, or income from estates or trusts
 d.   Social security or railroad retirement
 e.   Supplemental Security Income or other public assistance income
 f.    Retirement, survivor, or disability pensions
 h.   Other; specify:
 g.   Workers Compensation
The following questions concern family and individual income.  We recognize the sensitive nature of these
questions.  This information is important in order to understand the economic impact of the chronic illness on
the family and individual.  Your answers will be held in strict confidence.
If you are currently employed, please select your own gross annual income from wages only (before
taxes and deductions):
( not employed )
N/A
(1)   Under $10,000
(2)   $10,000 to $14,999
(3)   $15,000 to $19,999
(4)   $20,000 to $29,999
(5)   $30,000 to $39,999
(6)   $40,000 to $49,999
(7)   $50,000 to $59,999
 (8)   $60,000 to $69,999
 (9)   $70,000 to $79,999
(10)  $80,000 to $99,999
(11)  $100,000 to $150,000
(12)  Over $150,000
(13)  Unknown
(14)  Refused
20.
  (-2)
What is the total gross annual income for your household from all sources (before taxes and
deductions):
(1)   Under $10,000
(2)   $10,000 to $14,999
(3)   $15,000 to $19,999
(4)   $20,000 to $29,999
(5)   $30,000 to $39,999
(6)   $40,000 to $49,999
(7)   $50,000 to $59,999
 (8)   $60,000 to $69,999
 (9)   $70,000 to $79,999
(10)  $80,000 to $99,999
(11)  $100,000 to $150,000
(12)  Over $150,000
(13)  Unknown
(14)  Refused
21.
1  Yes
2  No
 (for office use only)
Page 7 of 7
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(for internal use only) (for internal use only)
/ /Date:
                         Copyright  2009
       by the Center for Research and Evaluation
  The University of Pittsburgh School of Nursing
Does your current household income meet your basic needs (such as food, housing, utilities, and
health care)?
22.
1 8 5
36132
1 
 
Health History 
Questionnaire 
 
 
(1) With what type of cancer(s) have you been diagnosed?  
      ______________________________________________ 
If you have had multiple types of cancer, please fill out the 
remaining questionnaires about your first cancer diagnosis. 
 
(2) What stage was your cancer when it was diagnosed?  
__ DCIS or pre-cancer  
__ Stage I  
__ Stage II 
__ Stage III 
__ Stage IV 
__ Unknown 
__ Not sure 
 
(3) When were you diagnosed with cancer? (MM/DD/YYYY)  
_________________________________ 
 
(4) Have you had any recurrences?  
__ Yes 
 If YES, how many recurrences have you had? _________________ 
__ No 
(5) Are you currently receiving treatment?  
__ Yes 
2 
 
__ No 
If YES, what kind of treatments are you currently receiving? (Select all that apply.) 
__ Chemotherapy 
__ Radiation therapy 
__ Surgery  
__ Adjuvant therapy 
__ Maintenance therapy 
__ Other __________________________ 
 
(6) What past treatments have you had for your cancer (if different from what you are 
currently receiving)?  
Select all that apply.  Please type in the approximate dates that you received this/these 
treatment(s).) 
__ Chemotherapy  Dates (approximate):______________________________________ 
__ Radiation therapy  Dates (approximate):______________________________________ 
__ Surgery  Dates (approximate):______________________________________ 
__ Adjuvant therapy  Dates (approximate):______________________________________ 
__ Maintenance therapy  Dates (approximate):______________________________________ 
__ Other __________________________  Dates (approximate):_________________________ 
 
(7) Were you diagnosed with more than one type of cancer? 
__ Yes 
__ No 
If yes, when were you diagnosed with the other types of cancer you have had?  What 
types of treatment did you receive?  
(Any details you give us are welcome!) 
________________________________________________________________________
________________________________________________________________________ 
 
  
 
 
Some Final Questions… 
 
 
 
 
 
 
1. Where did you hear about this study? 
_____ CTSI Research Participant Registry (University of Pittsburgh) 
_____ Pennsylvania Tumor Registry 
_____ National Ovarian Cancer Coalition 
_____ American Cancer Society (Cancer Survivors Network) 
_____ Cancer Caring Center 
_____ Urban League of Greater Pittsburgh 
_____ African American Women's Speakers Bureau 
_____ Our Clubhouse (formerly Gilda's Club of Western Pennsylvania) 
_____ Other: (Please describe) __________________________________________________ 
 
2. Would you like to see the results of this study?   
_____ Yes 
_____ No 
 
3. How much experience do you have managing a complex illness (your own or someone 
else’s) in addition to your own cancer?  Please describe. 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
4. Would you be open to being contacted in the future for other research studies regarding 
self-advocacy and cancer? 
_____ Yes 
_____ No 
 
 
5. Is there anything else that you would like us to know about yourself or your answers to 
this survey? 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
  
 
 
You have completed all questionnaires. 
 
Thank you for your time and thought! 
 
 
If you have any additional thoughts you want us 
to know, please add them here: 
 
 
 
 
 
 
 
If you have any questions or concerns,  
please contact the study’s principle investigator,  
Teresa Hagan at 412-624-4101or selfadvocacystudy@gmail.com. 
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FINAL FSACS SCALE 
FSACS Scale – 20 item 
© 2015 University of Pittsburgh (Hagan, Cohen, Rosenzweig, Stone, & Donovan) 1 
Female Self-Advocacy in Cancer Survivorship Scale 
Please read each of the following statements carefully.  Think about your experiences having 
cancer and (if you do not currently have cancer) your time since cancer. 
Circle the number the best reflects how much you agree or disagree with each statement.  
1. I use my skills to solve the problems I face as a cancer survivor.
1 2 3 4 5 6 
Strongly 
disagree 
Disagree Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
2. I gather information before making decisions about my cancer care.
1 2 3 4 5 6 
Strongly 
disagree 
Disagree Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
3. I weigh my options carefully before making important decisions about my cancer care.
1 2 3 4 5 6 
Strongly 
disagree 
Disagree Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
4. I prepare myself to make decisions about my cancer care.
1 2 3 4 5 6 
Strongly 
disagree 
Disagree Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
5. When it comes to making decisions about my cancer care, I know what my priorities are.
1 2 3 4 5 6 
Strongly 
disagree 
Disagree Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
6. I am comfortable asking for a second opinion.
1 2 3 4 5 6 
Strongly 
disagree 
Disagree Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
7. I ask questions when I don’t understand what my provider is telling me.
1 2 3 4 5 6 
Strongly 
disagree 
Disagree Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
START 
HERE 
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8. I question my provider if I don’t agree with his or her recommendations. 
1 2 3 4 5 6 
Strongly 
disagree 
Disagree 
 
Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
 
9. I don’t talk about a health concern with my provider unless I think there is a solution.* 
1 2 3 4 5 6 
Strongly 
disagree 
Disagree 
 
Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
 
10. I rarely tell my provider about the problems I am having.* 
1 2 3 4 5 6 
Strongly 
disagree 
Disagree 
 
Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
 
11. I know where to get an answer if my provider can’t give me one. 
1 2 3 4 5 6 
Strongly 
disagree 
Disagree 
 
Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
 
12. I ask my provider to explain his or her recommendations. 
1 2 3 4 5 6 
Strongly 
disagree 
Disagree 
 
Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
 
13. I seek out support from other cancer survivors. 
1 2 3 4 5 6 
Strongly 
disagree 
Disagree 
 
Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
 
14. I seek out support from friends and family. 
1 2 3 4 5 6 
Strongly 
disagree 
Disagree 
 
Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
 
15. Helping other cancer survivors also helps me. 
1 2 3 4 5 6 
Strongly 
disagree 
Disagree 
 
Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
 
16. When I hear someone has cancer, I try to reach out to them. 
1 2 3 4 5 6 
Strongly Disagree Somewhat Somewhat Agree Strongly 
FSACS Scale – 20 item 
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disagree  disagree agree agree 
 
17. It helps me to know that other cancer survivors have gone through what I am going through. 
1 2 3 4 5 6 
Strongly 
disagree 
Disagree 
 
Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
 
18. Telling other people my story makes me feel good. 
1 2 3 4 5 6 
Strongly 
disagree 
Disagree 
 
Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
 
19. I try to raise awareness about cancer. 
1 2 3 4 5 6 
Strongly 
disagree 
Disagree 
 
Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
 
20. I am comfortable sharing my cancer experience with others. 
1 2 3 4 5 6 
Strongly 
disagree 
Disagree 
 
Somewhat 
disagree 
Somewhat 
agree 
Agree 
Strongly 
agree 
 
* Reverse=scored item 
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 APPENDIX C
HUMAN SUBJECTS APPROVALS AND CONSENTS 
Informational Script 
Title: Content Validity of the Self-Advocacy in Cancer Survivorship (SACS) Scale 
PI: Teresa Hagan 
The purpose of this research study is to assess the validity of a questionnaire of self-advocacy 
among women with a history of cancer (the Self-Advocacy in Cancer Survivorship (SACS) 
Scale).  Validity means that this questionnaire is measuring what it is supposed to measure.  We 
are asking 8 individuals who are experts in self-advocacy, oncology, and/or women’s health to 
review our proposed measure of self-advocacy.  You are being asked to participate in this study 
because your expertise fits in these categories and allows you to give expert opinion concerning 
this measure of self-advocacy.  If you chose to participate, we will send you three documents: 
1. A brief introduction to the SACS Scale
2. A copy of the SACS Scale
3. A survey about your opinion the SACS Scale
You will review our proposed measure.  Then you will complete the survey about the proposed 
measure.  Finally, you will return the survey to Teresa in a pre-stamped, pre-addressed envelope.  
This study should take a total of approximately 90 minutes.  Reading the introduction will take 
about 15 minutes.  Reading the scale will take about 30 minutes.  Responding to the survey will 
take about 45 minutes.  These times may vary depending on how much time you take in 
reviewing the measure and preparing your response. 
There are no risks or benefits to participating in this study.  No personal or sensitive information 
will be collected.  Your responses to the survey are confidential and will not be kept in a locked 
file cabinet at the School of Nursing.  To ensure confidentiality, the survey will be completely 
anonymously.  You will not receive any payment for participation. Your participation in this 
research study is completely voluntary.  You may withdraw at any time.  This study is being 
conducted by Teresa Hagan.  She can be reached at 412-334-6457 if you have any questions or 
concerns. 
Page 1 of 5 Participant’s Initials __________________            
   University Of Pittsburgh    
     Institutional Review Board   
Approval Date: 12/12/2012 
Renewal Date:  «Renewal Date» 
IRB #:  PRO12100617 
    School of Nursing 
   Acute/Tertiary Care Department 
CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY 
TITLE:  Establishment of the Reliability of the Self-Advocacy in Cancer Survivorship Scale 
PRINCIPAL INVESTIGATOR: Teresa Hagan, BSN, RN 
Graduate Student 
University of Pittsburgh School of Nursing 
336 Victoria Building, 3500 Victoria Street 
Telephone: 412-334-6457 
CO-INVESTIGATORS: Heidi Donovan, PhD, RN 
Associate Professor, Department of Acute and Tertiary Care 
University of Pittsburgh School of Nursing 
336 Victoria Building,  3500 Victoria Street 
Telephone: 412-624-2699 
Susan Cohen, DSN, APRN, FAAN 
Associate Professor, Department of Health Promotion and Development 
University of Pittsburgh School of Nursing 
440 Victoria Building, 3500 Victoria Street 
Telephone: 412-624-5345 
CONSULTANTS: Margaret Rosenzweig, PhD, CRNP-C, AOCN 
Associate Professor, Department of Acute and Tertiary Care 
University of Pittsburgh School of Nursing 
336 Victoria Building, 3500 Victoria Street 
Telephone: 412-383-8839 
Clement Stone, PhD 
Professor, Department of Education  
University of Pittsburgh School of Education 
5920 Wesley W. Posvar Hall, 230 South Bouquet Street 
Telephone: 412-624-9359 
SOURCE OF SUPPORT: NINR F31 NR01466-01A1 
Sigma Theta Tau International/Rosemary Crisp Berkel Research Award 
Nightingale Awards of Pennsylvania PhD Award 
Why is this research being done? 
You are being asked to participate in a research study.  We are studying a measurement tool to assess self-
advocacy among female cancer survivors.  Self-advocacy is a term that describes how well someone is able to stand 
up for their values, priorities, and beliefs.  Right now, there is no measurement tool for self-advocacy for female 
cancer survivors.  This study will measure the reliability (or consistency) of a questionnaire that can measure self-
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advocacy among female cancer survivors. 
 
Who is being asked to take part in this research study? 
 
You are being invited to take part in this research study because you are a female with a history of cancer.  
 
People invited to participate in this study must be at least 18 years old, female, have a history of cancer (that has 
been diagnosed after the age of 18), and be able to complete the questionnaires in English.  You can not have a 
diagnosis of basal cell carcinoma or cervical intraepithelial neoplasia stage 1. The study is being performed on a total 
of 40 individuals in three different medical centers and four cancer and advocacy organizations in Pittsburgh.   
 
What procedures will be performed for research purposes? 
 
If you decide to take part in this research study, you will undergo the following procedures that are not part of your 
standard medical care: 
 
Screening Procedures: 
 
You have already undergone screening to participant in this research study.  You have indicated that you 
meet the following inclusion and exclusion criteria (listed above in “Who is being asked to take part in this 
research study” section).  
 
Research Study Procedures: 
 
If you qualify to take part in this research study, you will undergo the procedures listed below.  These 
procedures will take place in a private area in the clinic or organization.  
 
You will be asked to complete a set of questionnaires today and 2 weeks from today.  
Questionnaires include a demographic questionnaire, basic health information, and self-advocacy among 
people with cancer.   
 
i. Today: You will complete the first set of questionnaires the same day as you sign this 
consent form (today): 
1. After you complete the first set of questionnaires, you will be asked five short 
questions about how you answered one of the questionnaires and if you had 
problems completing this questionnaire. 
ii. Two Weeks from Today: You will complete the second set of questionnaires 2 weeks 
from today.  It is the same set of questionnaires as before.   
1. After you finish completing the first set of questionnaires today, the Principal 
Investigator (Ms. Hagan) will provide you a copy of the second questionnaire and 
instructions of when and how to complete the questionnaires.  You will also be 
given instructions of how to return the completed questionnaires, along with a 
pre-stamped, pre-addressed envelope.  
2. Ms. Hagan will call you to remind to complete and return the second 
questionnaires 2 days before the due date. 
3. Ms. Hagan will send reminder postcards to you to complete and return the 
questionnaires 3 and 5 days after the due date if the questionnaires are not 
received. 
 
What are the possible risks, side effects, and discomforts of this research study? 
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This is a very low risk study, but you should be aware of risks.   
 
1. The major potential risk is a breach of confidentiality, but we will do everything possible to protect your privacy.  To 
reduce the likelihood of a breach of confidentiality 
 
To protect your privacy, only Ms. Hagan and members of the research team will be aware of your participation in this 
research study. All information will be identified only by a code or case number.  The information linking these case 
numbers with your identity will be kept separate from the research records.  All researchers involved in this study 
have been thoroughly trained to maintain your privacy.  All information you provide will be kept by the Principle 
Investigator in a locked file cabinet within a locked office at the School of Nursing.  Your identity will not be revealed 
in any description or publications of this research. 
 
Although we will do everything in our power to protect your privacy and the confidentiality of your records, just as with 
the use of your medical information for health care purposes, we cannot guarantee the privacy of your research 
records.  Authorized representatives from the University of Pittsburgh Research Conduct and Compliance Office may 
review your data for the purpose of monitoring the conduct of this study 
 
2. Another possible risk of this research study may include stress from having to complete the questionnaires.  It is 
expected to take between 40 and 60 minutes total for each set of questionnaires.  (The questionnaires will take 30 to 
45 minutes to complete.  The interview will take between 10 and 15 minutes.)  To reduce the stress, you will be 
allowed to take breaks during this time as often as needed.  You may stop participating at any time.    
 
What are possible benefits from taking part in this study? 
 
You will receive no direct benefit from taking part in this research study.  The creation and use of this measurement 
tool may benefit female cancer survivors in the future, but will have no direct benefit to you. 
 
Will I be paid if I take part in this research study? 
 
You will receive a $20 gift card for your time and effort in taking part in this research study. You will receive this gift card after 
completing and returning both sets of questionnaires to Ms. Hagan.   
 
Who will know about my participation in this research study? 
 
Any information about you obtained from this research will be kept strictly confidential.  All records related to your 
involvement in this research study will be stored in a locked file cabinet in a locked room at the School of Nursing.  .  
Your identity on these records will be indicated by a case number rather than by your name, and the information 
linking these case numbers with your identity will be kept separate from the research records.  You will not be 
identified by name in any publication of the research. All records will be retained by us for a minimum of seven years. 
 
It is possible that we may use the information obtained from this study in other research studies examining the 
validity of this questionnaire.  This information may also be shared with other researchers here, and at other research 
centers, but those researchers will never be provided with any personal identifiers that would allow them to learn who 
you are.   
 
Will this research study involve the use or disclosure of my identifiable medical information? 
 
No. 
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Is my participation in this research study voluntary? 
 
Your participation in this research study is completely voluntary.  Whether or not you provide your consent for 
participation in this research study will have no effect on your current or future relationship with the University of 
Pittsburgh.  Whether or not you provide your consent for participation in this research study will have no effect on 
your current or future medical care at a UPMC hospital or affiliated health care provider or your current or future 
relationship with a health care insurance provider. 
 
May I withdraw, at a future date, my consent for participation in this research study? 
 
You may withdraw, at any time, your consent for participation in this research study.  Any information recorded for, or 
resulting from, your participation in this research study prior to the date that you formally withdrew your consent may 
continue to be used and disclosed by the investigators for the purposes described above. 
        
Your decision to withdraw your consent for participation in this research study will have no effect on your current or 
future relationship with the University of Pittsburgh.  Your decision to withdraw your consent for participation in this 
research study will have no effect on your current or future medical care at a UPMC hospital or affiliated health care 
provider or your current or future relationship with a health care insurance provider. 
 
If you decide you no longer wish to participate after you have signed the consent form, you should contact Ms. Hagan 
(412-334-6457). Your decision to withdraw from this study will have no effect on your current or future relationship 
with the University of Pittsburgh.  If you or would like additional information, you may contact the Research Office at 
412-692-5551. Questions about your rights as a research participant can be answered by the Human Subject 
Protection Advocate at the University of Pittsburgh IRB Office- 866-212-2668. 
 
If I agree to take part in this research study, can I be removed from the study without my consent? 
 
You will not be removed from this study without your consent. 
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************************************************************************ 
VOLUNTARY CONSENT 
 
The above information has been explained to me and all of my current questions have been answered.  I understand 
that I am encouraged to ask questions about any aspect of this research study during the course of this study, and 
that such future questions will be answered by a qualified individual or by the investigator(s) listed on the first page of 
this consent document at the telephone number(s) given. I understand that I may always request that my questions, 
concerns or complaints be addressed by a listed investigator.   
 
I understand that I may contact the Human Subjects Protection Advocate of the IRB Office, University of Pittsburgh 
(1-866-212-2668) to discuss problems, concerns, and questions; obtain information; offer input; or discuss situations 
that have occurred during my participation.   
 
By signing this form, I agree to participate in this research study.  A copy of this consent form will be given to me. 
 
____________________________  ____________________________  ____________ 
Participant’s Signature   Printed Name of Participant  Date 
 
 
 
************************************************************************ 
CERTIFICATION of INFORMED CONSENT 
 
I certify that I have explained the nature and purpose of this research study to the above-named individual(s), and I 
have discussed the potential benefits and possible risks of study participation.  Any questions the individual(s) have 
about this study have been answered, and we will always be available to address future questions as they arise.”  
 
___________________________________  ________________________ 
Printed Name of Person Obtaining Consent  Role in Research Study 
 
_________________________________  ____________ 
Signature of Person Obtaining Consent  Date 
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 CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY 
 
TITLE:  Establishment of the Validity of the Female Self-Advocacy in Cancer Survivorship Scale 
 
PRINCIPAL INVESTIGATOR:  Teresa Hagan, BSN, RN 
Graduate Student 
University of Pittsburgh School of Nursing 
336 Victoria Building, 3500 Victoria Street 
     Telephone: 412-624-4101 
 
CO-INVESTIGATORS:   Heidi Donovan, PhD, RN 
Associate Professor, Department of Acute and Tertiary Care 
University of Pittsburgh School of Nursing 
336 Victoria Building, 3500 Victoria Street 
Telephone: 412-624-2699 
 
     Susan Cohen, DSN, APRN, FAAN 
Associate Professor, Department of Health Promotion and Development 
University of Pittsburgh School of Nursing 
440 Victoria Building, 3500 Victoria Street 
Telephone: 412-624-5345 
 
CONSULTANTS:    Margaret Rosenzweig, PhD, CRNP-C, AOCN 
Associate Professor, Department of Acute and Tertiary Care 
University of Pittsburgh School of Nursing 
336 Victoria Building, 3500 Victoria Street 
Telephone: 412-383-8839 
 
Clement Stone, PhD 
Professor, Department of Education  
University of Pittsburgh School of Education 
5920 Wesley W. Posvar Hall, 230 South Bouquet Street 
Telephone: 412-624-9359 
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Why is this research being done? 
 
You are being asked to participate in a research study.  We are developing a questionnaire to measure how well 
female cancer survivors are able to stand up for themselves. We call a person’s ability to stand up for her own values 
and beliefs “self-advocacy”.   We want to see whether our questionnaire accurately measures self-advocacy among 
female cancer survivors. 
 
Who is being asked to take part in this research study? 
 
You are being invited to take part in this research study because you are an adult female with a history of cancer 
diagnosed after age 18.  
 
What procedures will be performed for research purposes? 
 
 
The study procedures consist of 2 mailed questionnaires. We will send you paper copies of both questionnaires with 
a pre-stamped, pre-addressed return envelope. 
 
1. The first questionnaire is a screening questionnaire.   
You will answer 4 questions to make sure you are eligible to participate. If you are not eligible, you will not complete 
the second questionnaire.  Instead, you will be asked to complete 4 additional questions to help us understand what 
women are not participating in this study.  Answering these 4 additional questions is voluntary. 
 
We estimate that this screening questionnaire will take 1 minute to complete. 
 
2. The second questionnaire will be completed online or by mail.  
You will complete a set of questionnaires including demographic information, basic health information, and questions 
about your health and experience with cancer.  You will then return the completed questionnaires in the return 
envelope provided to you. 
 
We estimate that both questionnaires will take 60 minutes to complete. 
 
If we do not receive these questionnaires, we will send you a reminder postcard 2 weeks after the initial letter and a 
reminder letter and replacement questionnaire 3 weeks after the initial letter. 
 
What are the possible risks, side effects, and discomforts of this research study? 
 
This is a very low risk study, but you should be aware of risks.   
 
1. The major potential risk is a breach of confidentiality, but we will do everything possible to protect your privacy.  To 
protect your privacy, only Ms. Hagan and members of the research team will be aware of your participation in this 
research study. Mailed questionnaires will be kept in secure, locked file cabinets at the School of Nursing.  All 
information will be identified only by a case number.  The information linking these case numbers with your identity 
will be kept separate from the research records.  All researchers involved in this study have been thoroughly trained 
to maintain your privacy.  All information you provide will be kept by the Principle Investigator in a locked file cabinet 
within a locked office at the School of Nursing.  Your identity will not be revealed in any description or publications of 
this research. 
 
Although we will do everything in our power to protect your privacy and the confidentiality of your records, just as with 
the use of your medical information for health care purposes, we cannot guarantee the privacy of your research 
records.  Authorized representatives from the University of Pittsburgh Research Conduct and Compliance Office may 
review your data for the purpose of monitoring the conduct of this study. 
 
2. Another possible risk of this research study may include stress from having to complete the questionnaires.  In 
case any questions cause you stress or discomfort, you can take a break from completing the questionnaires.   
 
What are possible benefits from taking part in this study? 
 
You will receive no direct benefit from taking part in this research study.  The creation and use of this measurement 
tool may benefit female cancer survivors in the future, but will have no direct benefit to you. 
 
Will I be paid if I take part in this research study? 
 
Participants will be paid a $10  Amazon.com gift card after completing and returning the questionnaires to Ms. Hagan. 
 
Who will know about my participation in this research study? 
 
Any information about you obtained from this research will be kept strictly confidential.  All records related to your 
involvement in this research study will be stored in a locked file cabinet in a locked room at the School of Nursing.  
Your identity on these records will be indicated by a case number rather than by your name, and the information 
linking these case numbers with your identity will be kept separate from the research records.  You will not be 
identified by name in any publication of the research. All records will be retained by us for a minimum of seven years. 
 
It is possible that we may use the information obtained from this study in other research studies examining the 
validity of this questionnaire.  This information may also be shared with other researchers here, and at other research 
centers, but those researchers will never be provided with any personal identifiers that would allow them to learn who 
you are.   
 
Will this research study involve the use or disclosure of my identifiable medical information? 
 
No. 
 
Is my participation in this research study voluntary? 
 
Your participation in this research study is completely voluntary.  Whether or not you provide your consent for 
participation in this research study will have no effect on your current or future relationship with the University of 
Pittsburgh.  Whether or not you provide your consent for participation in this research study will have no effect on 
your current or future medical care at a UPMC hospital or affiliated health care provider or your current or future 
relationship with a health care insurance provider. 
 
May I withdraw, at a future date, my consent for participation in this research study? 
 
You may withdraw, at any time, your consent for participation in this research study.  Any information recorded for, or 
resulting from, your participation in this research study prior to the date that you formally withdrew your consent may 
continue to be used and disclosed by the investigators for the purposes described above. 
 
Your decision to withdraw your consent for participation in this research study will have no effect on your current or 
future relationship with the University of Pittsburgh.  Your decision to withdraw your consent for participation in this 
research study will have no effect on your current or future medical care at a UPMC hospital or affiliated health care 
provider or your current or future relationship with a health care insurance provider. 
 
If you decide you no longer wish to participate after you have signed the consent form, you should contact Ms. Hagan 
(412-624-4101). Your decision to withdraw from this study will have no effect on your current or future relationship 
with the University of Pittsburgh.  If you or would like additional information, you may contact the Research Office at 
412-692-5551. Questions about your rights as a research participant can be answered by the Human Subject 
Protection Advocate at the University of Pittsburgh IRB Office- 866-212-2668. 
 
If I agree to take part in this research study, can I be removed from the study without my consent? 
 
If you are ineligible to participate, you will be removed from the study. Your screening data may be kept to track who 
was not participating.  If you are eligible to participate, you will not be removed from this study without your consent. 
 
 
Agreement to Participate 
By completing and returning the completed questionnaire you agree to 
participate in this research study. 
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WHY IS THIS RESEARCH BEING DONE? 
 
You are being asked to participate in a research study. We are developing a questionnaire to measure how well 
female cancer survivors are able to stand up for themselves. We call a person's ability to stand up for her own values 
and beliefs "self-advocacy". We want to see whether our questionnaire accurately measures self-advocacy among 
female cancer survivors. 
 
 
WHO IS BEING ASKED TO TAKE PART IN THIS RESEARCH STUDY? 
 
You are being invited to take part in this research study because you are an adult female with a history of cancer 
diagnosed after age 18. 
 
 
 
WHAT PROCEDURES WILL BE PERFORMED FOR RESEARCH PURPOSES? 
 
The study procedures consist of 2 questionnaires on a secure website. We will send you the web address of the 
website. 
 
1) The first questionnaire is a screening questionnaire (you just completed this). 
 
You previously answered 4 questions to make sure you are eligible to participate. If you are not eligible, you will not 
complete the second questionnaire. Instead, you will be asked to respond to 4 additional questions to help us 
understand a little more about women who are not participating in the study. 
 
We estimate that this screening questionnaire will take 1 minute to complete. 
 
2) The second questionnaire will be completed on-line.  You will also be asked if you want to be mailed the 
questionnaires to do on paper. 
 
You will complete a set of questionnaires including demographic information, basic health information, and questions 
about your health and experience with cancer. 
 
We estimate that the second questionnaire will take 60 minutes to complete. 
 
If we do not receive your questionnaires, we will send you reminder emails 5, 10, and 21 days after the first email we 
sent you. 
 
 
WHAT ARE THE POSSIBLE RISKS, SIDE EFFECTS, AND DISCOMFORTS OF THIS RESEARCH STUDY? 
 
This is a very low risk study, but you should be aware of risks. 
 
1) The major potential risk is a breach of confidentiality, but we will do everything possible to protect your privacy. To 
protect your privacy, only Teresa Hagan (the principle investigator) and members of the research team will be aware 
of your participation in this research study. The website where you complete the questionnaires is secure, and your 
data will be safely stored and only be accessed by Ms. Hagan. Any records will be kept in secure, locked file cabinets 
at the School of Nursing. All information will be identified only by a case number. The information linking these case 
numbers with your identity will be kept separate from the research records. All researchers involved in this study 
have been thoroughly trained to maintain your privacy. All information you provide will be kept by the Principle 
Investigator in a locked file cabinet within a locked office at the School of Nursing. Your identity will not be revealed in 
any description or publications of this research. 
 
Although we will do everything in our power to protect your privacy and the confidentiality of your records, just as with 
the use of your medical information for health care purposes, we cannot guarantee the privacy of your research 
records. Authorized representatives from the University of Pittsburgh Research Conduct and Compliance Office may 
review your data for the purpose of monitoring the conduct of this study. 
 
2) Another possible risk of this research study may include stress from having to complete the questionnaires. In 
case any questions cause you stress or discomfort, you can take a break from completing the questionnaires and 
return at any time without any of your data being lost. 
 
 
WHAT ARE POSSIBLE BENEFITS FROM TAKING PART IN THIS STUDY? 
 
You will receive no direct benefit from taking part in this research study. The creation and use of this measurement 
tool may benefit female cancer survivors in the future, but will have no direct benefit to you. 
 
 
WILL I BE PAID IF I TAKE PART IN THIS RESEARCH STUDY? 
 
Participants will be given a $10 Amazon.com gift code after returning the completed on-line survey to Ms. Hagan. 
  
Note: If you want to complete the questionnaires through mail rather than on-line, you will receive a $10 Amazon.com 
gift code when you return the completed questionnaires to Ms. Hagan. 
 
 
WHO WILL KNOW ABOUT MY PARTICIPATION IN THIS RESEARCH STUDY? 
 
Any information about you obtained from this research will be kept strictly confidential. All records related to your 
involvement in this research study will be stored in a locked file cabinet in a locked room at the School of Nursing. 
Your identity on these records will be indicated by a case number rather than by your name, and the information 
linking these case numbers with your identity will be kept separate from the research records. You will not be 
identified by name in any publication of the research. All records will be retained by us for a minimum of seven years. 
 
It is possible that we may use the information obtained from this study in other research studies examining the 
validity of this questionnaire. This information may also be shared with other researchers here, and at other research 
centers, but those researchers will never be provided with any personal identifiers that would allow them to learn who 
you are. 
 
 
WILL THIS RESEARCH STUDY INVOLVE THE USE OR DISCLOSURE OF MY IDENTIFIABLE MEDICAL 
INFORMATION? 
 
No. 
 
 
IS MY PARTICIPATION IN THIS RESEARCH STUDY VOLUNTARY? 
 
Your participation in this research study is completely voluntary. Whether or not you provide your consent for 
participation in this research study will have no effect on your current or future relationship with the University of 
Pittsburgh. Whether or not you provide your consent for participation in this research study will have no effect on your 
current or future medical care at a UPMC hospital or affiliated health care provider or your current or future 
relationship with a health care insurance provider. 
 
 
MAY I WITHDRAW, AT A FUTURE DATE, MY CONSENT FOR PARTICIPATION IN THIS RESEARCH STUDY? 
 
You may withdraw, at any time, your consent for participation in this research study. Any information recorded for, or 
resulting from, your participation in this research study prior to the date that you formally withdrew your consent may 
continue to be used and disclosed by the investigators for the purposes described above. 
 
Your decision to withdraw your consent for participation in this research study will have no effect on your current or 
future relationship with the University of Pittsburgh. Your decision to withdraw your consent for participation in this 
research study will have no effect on your current or future medical care at a UPMC hospital or affiliated health care 
provider or your current or future relationship with a health care insurance provider. 
 
If you decide you no longer wish to participate after you have signed the consent form, you should contact Teresa 
Hagan (412-624-4101). Your decision to withdraw from this study will have no effect on your current or future 
relationship with the University of Pittsburgh. If you or would like additional information, you may contact the 
Research Office at 412-692-5551. Questions about your rights as a research participant can be answered by the 
Human Subject Protection Advocate at the University of Pittsburgh IRB Office- 866-212-2668. 
 
 
IF I AGREE TO TAKE PART IN THIS RESEARCH STUDY, CAN I BE REMOVED FROM THE STUDY WITHOUT 
MY CONSENT? 
 
If you are ineligible to participate, you will be removed from the study. Your screening data may be kept to track who 
was not participating. If you are eligible to participate, you will not be removed from this study without your consent. 
 
Agreement to Participate 
By clicking “yes” to the following question asking if you consent to participate in 
this research study, you are providing your consent to participate. 
 
 University of Pittsburgh 
Institutional Review Board 
3500 Fifth Avenue 
Pittsburgh, PA 15213 
(412) 383-1480 
(412) 383-1508 (fax) 
http://www.irb.pitt.edu 
 
Memorandum 
    
To: Teresa Hagan, RN, BSN, BA  
From: Sue Beers, PhD,  Vice Chair 
Date: 9/12/2012 
IRB#:  PRO12090171  
Subject: Content Validity of the Self-Advocacy in Cancer Survivorship (SACS) Scale 
 
The above-referenced protocol has been reviewed by the University of Pittsburgh Institutional Review 
Board. Based on the information provided to the IRB, this project includes no involvement of human 
subjects, according to the federal regulations [§45 CFR 46.102(f)]. That is, the investigator conducting 
research will not obtain information about research subjects via an interaction with them, nor will the 
investigator obtain identifiable private information. Should that situation change, the investigator must 
notify the IRB immediately.  
 
Given this determination, you may now begin your project.  
Please note the following information:  
 If any modifications are made to this project, use the "Send Comments to IRB Staff" process 
from the project workspace to request a review to ensure it continues to meet the determination.  
 Upon completion of your project, be sure to finalize the project by submitting a "Study 
Completed" report from the project workspace.  
Please be advised that your research study may be audited periodically by the University of Pittsburgh Research 
Conduct and Compliance Office.  
 
 University of Pittsburgh 
Institutional Review Board 
3500 Fifth Avenue 
Pittsburgh, PA 15213 
(412) 383-1480 
(412) 383-1508 (fax) 
http://www.irb.pitt.edu 
 
Memorandum 
    
To: Teresa Hagan BSN RN 
From: Sue Beers PHD, Vice Chair 
Date: 12/12/2012  
IRB#: PRO12100617  
Subject: Establishment of the Reliability of the Self-Advocacy in Cancer Survivorship Scale  
 
The University of Pittsburgh Institutional Review Board reviewed and approved the above referenced 
study by the expedited review procedure authorized under 45 CFR 46.110 and 21 CFR 56.110.  Your 
research study was approved under:  
45 CFR 46.110.(7)  
 
 
The risk level designation is Minimal Risk. 
Approval Date: 12/12/2012 
Expiration Date: 12/11/2013  
The following documents were approved by the IRB: 
We, the University of Pittsburgh Institutional Review Board, approve the protocol for this research 
study, "Establishment of the Reliability of the Self-Advocacy in Cancer Survivorship Scale" and the 
following documents: -Consent form -Survey questionnaires -Cognitive interview questions  
For studies being conducted in UPMC facilities, no clinical activities can be undertaken by investigators 
until they have received approval from the UPMC Fiscal Review Office.  
Please note that it is the investigator’s responsibility to report to the IRB any unanticipated problems 
involving risks to subjects or others [see 45 CFR 46.103(b)(5) and 21 CFR 56.108(b)]. Refer to the IRB 
Policy and Procedure Manual regarding the reporting requirements for unanticipated problems which 
include, but are not limited to, adverse events.  If you have any questions about this process, please 
contact the Adverse Events Coordinator at 412-383-1480.  
The protocol and consent forms, along with a brief progress report must be resubmitted at least one 
month prior to the renewal date noted above as required by FWA00006790 (University of Pittsburgh), 
FWA00006735 (University of Pittsburgh Medical Center), FWA00000600 (Children’s Hospital of 
Pittsburgh), FWA00003567 (Magee-Womens Health Corporation), FWA00003338 (University of 
Pittsburgh Medical Center Cancer Institute).  
Please be advised that your research study may be audited periodically by the University of 
Pittsburgh Research Conduct and Compliance Office. 
 
 University of Pittsburgh 
Institutional Review Board 
3500 Fifth Avenue 
Pittsburgh, PA 15213 
(412) 383-1480 
(412) 383-1508 (fax) 
http://www.irb.pitt.edu 
 
Memorandum 
    
To: Teresa Hagan  
From: Sue Beers , Vice Chair 
Date: 11/8/2013  
IRB#: PRO12110062  
Subject: Establishment of the Validity of the Self-Advocacy in Cancer Survivorship Scale  
 
The University of Pittsburgh Institutional Review Board reviewed and approved the above 
referenced study by the expedited review procedure authorized under 45 CFR 46.110 and 21 
CFR 56.110.  Your research study was approved under:  
45 CFR 46.110.(7) characteristics/behaviors 
 
The IRB has approved the waiver for the requirement to obtain a written informed consent.  
 
The risk level designation is Minimal Risk.  
Approval Date: 11/7/2013 
Expiration Date: 11/6/2014  
For studies being conducted in UPMC facilities, no clinical activities can be undertaken by 
investigators until they have received approval from the UPMC Fiscal Review Office. 
Please note that it is the investigator’s responsibility to report to the IRB any unanticipated 
problems involving risks to subjects or others [see 45 CFR 46.103(b)(5) and 21 CFR 
56.108(b)]. Refer to the IRB Policy and Procedure Manual regarding the reporting requirements 
for unanticipated problems which include, but are not limited to, adverse events.  If you have any 
questions about this process, please contact the Adverse Events Coordinator at 412-383-1480.  
The protocol and consent forms, along with a brief progress report must be resubmitted at least 
one month prior to the renewal date noted above as required by FWA00006790 (University of 
Pittsburgh), FWA00006735 (University of Pittsburgh Medical Center), FWA00000600 
(Children’s Hospital of Pittsburgh), FWA00003567 (Magee-Womens Health Corporation), 
FWA00003338 (University of Pittsburgh Medical Center Cancer Institute).  
Please be advised that your research study may be audited periodically by the University of 
Pittsburgh Research Conduct and Compliance Office. 
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Institutional Responsibilities as They Affect Investigators (ID:15072) 06/03/15  5/5 (100%) 
Conflicts of Commitment and Conscience (ID:15073) 06/03/15  4/5 (80%) 
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 APPENDIX F
COVER LETTERS FOR UNPUBLISHED MANUSCRIPTS 
 School of Nursing Victoria Building
3500 Victoria St.     
 Pittsburgh, PA 15261 
Fax:  412-624-2401 
Janice L. Hinkle, PhD, RN, CNRN 
The Catholic University of America 
School of Nursing-Gowan Hall 
620 Michigan Avenue NE 
Washington, DC 20064 
June 15, 2015 
Dear Dr. Hinkle, 
It is my pleasure to submit the Letter to the Editor: “Theoretical to Tangible: Creating a Measure 
of Self-Advocacy” to The Journal of Nursing Measurement.  In this manuscript, we describe in 
detail the process of taking an abstract yet relevant concept like self-advocacy (or the ability of 
an individual to stand up for themselves and make their needs known) and operationalize it into a 
reliable measurement tool. 
We believe this manuscript is relevant to your readership because it: 
 Addresses the process of moving a concept into a construct using a systematic and
rigorous process;
 Reports how focus group and literature review findings about a single concept were
synthesized and used to develop sub-dimensions of the construct along with an item list
for a measurement tool;
 Reports the content validity and reliability testing results of the initial tool; and
 Describes the challenges faced by the researchers during the measurement process along
with the researchers’ decisions.
This manuscript has not been submitted elsewhere.  All authors have significantly contributed to 
the design and data analysis of the study as well as the writing of the manuscript. We would 
appreciate any specific instructions or direction to improve this version of the manuscript.   
I look forward to your reply. 
Sincerely, 
Teresa Hagan, BSN, RN, BA 
    School of Nursing 
Fadlo R. Khuri, MD 
Cancer Editorial Office 
American Cancer Society 
250 Williams Street NW 
Atlanta, Georgia 30303 USA 
August 15, 2015 
Dear Dr. Khuri, 
It is our pleasure to submit the manuscript “Validating the Female Self-Advocacy in Cancer 
Survivorship Scale” for your editorial review. This manuscript discusses the development of a 
novel measure self-advocacy but in a novel population – women with a history of cancer.  
We believe that this article addresses the needs of your readership in the following ways: 
 Addresses the absence of a theoretically-based, psychometrically strong measure of
cancer patients’ ability to stand up for herself, or “self-advocate.”
 Reports the multi-phase procedures and empirical evidence supporting the reliability and
validity of a novel measurement of self-advocacy among female cancer survivors.
 Explores the relationship of self-advocacy with health outcomes (e.g. symptom
management and healthcare utilization) and related concepts (e.g. patient activation,
health information orientation, social support, etc.).
All authors have read and approved the manuscript. This manuscript is not under consideration 
elsewhere. 
Thank you for your review of this manuscript.  We look forward to your response. 
Sincerely, 
Teresa Hagan 
University of Pittsburgh School of Nursing 
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